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INTRODUCTION 
CHRONIC KIDNEY DISEASE 
Definition and classification 
In February 2002, the Kidney Disease Outcomes Quality Initiative (K/DOQI) of the National Kidney 
Foundation (NKF) published 15 clinical practice guidelines on chronic kidney disease. The goals of the 
guidelines were to define chronic kidney disease and classify its stages, regardless of underlying cause, 
evaluate laboratory measurements for the clinical assessment of kidney disease, associate the level of 
kidney function with complications of chronic kidney disease, and stratify the risk for loss of kidney function 
and development of cardiovascular disease 1. In 2012, Levey and colleagues presented the definition and 
five-stage classification system of chronic kidney disease and summarized the major recommendations on 
early detection in adults: this paper represented an important shift towards the chronic kidney disease 
recognition as a worldwide public health problem that should be managed in its early stages by general 
internists 2. Improving outcomes for people with chronic kidney disease requires a coordinated world-wide 
approach to prevention of adverse outcomes through defining the disease and its outcomes, estimating 
disease prevalence, identifying earlier stages of disease and antecedent risk factors, and detection and 
treatment for populations at increased risk for adverse outcomes (Figure 1). The definition of chronic 
kidney disease is based on the presence of kidney damage (i.e., albuminuria) or decreased kidney function 
(i.e., glomerular ﬁltration rate [GFR] <60 mL/min per 1.73 m²) for 3 months or more.  
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Figure 1. Conceptual model for chronic kidney disease. Continuum of development, progression and complications of 
chronic kidney disease (CKD) and strategies to improve outcomes. Thick arrows circles represent development, 
progression and remission of CKD. Complication refer to all complication of CKD, including complications of decreased 
glomerular filtration rate (GFR) and cardiovascular disease. Complications might also arise from adverse effects of 
interventions to prevent or treat the disease. Horizontal arrows pointing from left to right represent the progressive 
nature of CKD. Dashed arrowheads mean that remission is less frequent than progression. from Lancet 2012; 379: 
165-80 
 
CKD is classified based on cause, GFR category and albuminuria category (CGA): chronic renal disease is 
divided into five stages on the basis of renal function (Table 1). 
 
Table 1. Classification of CKD 
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Epidemiology 
Chronic kidney disease is a worldwide public health problem 3. In 2015, Mills et al 4 estimated the global 
prevalence and absolute burden of CKD by pooling data from population-based studies. The Global Burden 
of Disease Study 2013 estimated 956,200 deaths worldwide were directly attributable to CKD in 2013, 
representing a 134.6% increase from 1990 5. In addition, CKD was ranked as the 19th highest cause of years 
of life lost in 2013 5.  The global incidence and prevalence of CKD, however, may be underestimated by 
these data; in fact, first of all, in the World Health Report 2002, the item “Disease of Genitourinary System” 
is articulated in only 2 speciﬁc cause groups: “Nephrosis and nephritis” and “Benign prostatic hypertrophy”, 
a classiﬁcation that does not provide any signiﬁcant insight into the contribution of speciﬁc kidney diseases 
to the global burden of disease. Second, patients with CKD are at high risk of cardiovascular diseases (CVD) 
and cerebrovascular diseases, and they are more likely to die of CVD than to develop terminal renal failure. 
Moreover, patients with CVD often develop CKD during the course of their disease 6, 7.  Therefore, an 
unknown proportion of people whose death and disability are attributed to CVD have kidney disease as 
well. The worldwide rise in the number of patients with CKD is reﬂected in the increasing number of people 
with end-stage renal disease (ESRD), treated by renal replacement therapy, dialysis or transplantation 8. 
Two factors are important. The ﬁrst is the ageing of the population: the incidence of ESRD is higher in 
elderly people than in the general population.  The second factor is the global epidemic of type 2 diabetes 
mellitus: diabetes mellitus is responsible for 895.000 deaths every year, according to the GBD project. 
There are currently 170 million patients with diabetes: approximately 30% of them have diabetic 
nephropathy and this proportion is even higher in some ethnic groups. The presence of CKD increases the 
risk of death of CVD in patients with diabetes 3.  
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Diagnosis 
Chronic kidney disease is most frequently diagnosed through blood and urine tests. 
The criteria described for the diagnosis of chronic kidney disease are any of the following 2: 
- Duration >3 months on the basis of documentation: duration is necessary to distinguish chronic 
from acute kidney disease 
- GFR <60 mL/min per 1·73 m²: GFR is the best overall index of kidney function in health and disease 
- Kidney damage as defined by structural abnormalities or functional abnormalities other than 
decreased GFR:  
 pathological abnormalities:  
- glomerular disease (diabetes, autoimmune diseases, systemic infections, drugs, neoplasia) 
- vascular diseases (atherosclerosis, hypertension, ischaemia, vasculitis, thrombotic 
microangiopathy) 
- tubulointerstitial diseases (urinary-tract infections, stones, obstruction, toxic effects of drugs) 
- cystic disease (polycystic kidney disease) 
 history of kidney transplantation - in addition to pathological abnormalities in native kidneys, 
common pathological abnormalities include: 
- chronic allograft nephropathy (non-specific findings of tubular atrophy, interstitial fibrosis, 
vascular and glomerular sclerosis) 
- rejection 
- drug toxic effects (calcineurin inhibitors) 
- BK virus nephropathy 
- recurrent disease (glomerular disease, oxalosis, Fabry’s disease) 
 albuminuria as marker of kidney damage - increased glomerular permeability , urine 
albumin/creatinine ratio (ACR) >30 mg/g: 
- the normal urinary ACR in young adults is < 10 mg/g. Urine ACR categories 10-29, 30-300 and 
> 300 mg are high normal, high and vey high, respectively. Urine ACR > 2000 mg/g is 
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accompanied by signs and symptoms of nephrotic syndrome (low serum albumin, oedema and 
high serum cholesterol) 
- high urinary ACR can be confirmed by urine albumin excretion in a timed urine collection 
 abnormalities in urinary sediment as marker of kidney damage: 
- red-blood-cell casts in proliferative glomerulonephritis 
- white-blood-cell casts in pyelonephritis or interstitial nephritis 
- oval fat bodies or fatty casts in diseases with proteinuria 
- granular casts and renal tubular epithelial cells in many parenchymal diseases (non-specific) 
 imaging abnormalities as markers of kidney damage (ultrasound, CT and MRI with or without 
contrast, isotope scans angiography): 
- polycystic kidneys  
- hydronephrosis due to obstruction 
- cortical scarring due to infarcts, pyelonephritis or vesicoureteral reflux 
- renal masses or enlarged kidneys due to infiltrative diseases 
- renal artery stenosis 
- small and echogenic kidneys (common in late stages of CKD because of many parenchymal 
diseases) 
 Renal tubular acidosis: 
- nephrogenic diabetic insipidus 
- Barrter and Gittelman syndromes 
- Fanconi’s syndrome 
- cystinuria 
- familiar hypomagnesaemia with hypercalciuria and nephrocalcinosis 
Excretion of urinary creatinine varies with age, sex, race, diet and nutritional status, and generally exceeds 
1.0 g per day in healthy adults; therefore, the numeric value for urinary ACR (mg/g) is usually less than the 
rate of urinary albumin excretion (mg/day). Rates of 30–300 mg per day and >300 mg per day correspond 
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to microalbuminuria and macroalbuminuria, respectively. Normal urine contains small amounts of albumin, 
low-molecular-weight serum proteins and proteins that are from renal tubules and the lower urinary tract. 
In most kidney diseases, albumin is the main urine protein, comprising about 60–90% of total urinary 
protein when total protein is very high. Values corresponding to normal, high-normal, high, very high, and 
nephrotic-range total protein are about <50, 50–150, 150–500, >500, and >3500 mg/g, respectively.  
 
 
Symptoms 
Symptoms are usually due to complications of decreased kidney function and when severe, they can be 
treated only by dialysis or transplantation 9. Signs and symptoms of chronic kidney disease develop over 
time if kidney damage progresses slowly. The early symptoms of chronic kidney disease are the same as for 
many other illnesses. These symptoms may be the only sign of a problem in the early stages. 
Symptoms may include: 
 Appetite loss 
 General ill feeling and fatigue 
 Headaches 
 Itching (pruritus) and dry skin 
 Nausea 
 Weight loss without trying to lose weight  
Symptoms that may occur when kidney function has gotten worse include: 
 Abnormally dark or light skin 
 Bone pain 
 Drowsiness or problems concentrating or thinking 
 Numbness or swelling in the hands and feet 
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 Muscle twitching or cramps 
 Breath odor 
 Easy bruising, or blood in the stool 
 Excessive thirst 
 Frequent hiccups 
 Problems with sexual function 
 Menstrual periods stop (amenorrhea) 
 Shortness of breath 
 Sleep problems  
 Vomiting, often in the morning 
 
Causes and risk factors 
Much epidemiological and clinical evidence has shown a link  between  several  factors  and  the  initiation  
and  the progression  of  CKD.  These can  be  classified  into  two 
distinct categories: those proven to be causal (risk factors) and those that are associated with CKD in the 
absence of established causal relations (risk markers) 10. 
Susceptibility factors  
CKD commonly clusters within families, which implies genetic or familial   predisposition 11. Genetic  studies 
have  suggested  links  between  CKD  and  various alterations  or  polymorphisms  of  candidate  genes 
encoding  putative  mediators.  Low birthweight and infant malnutrition in some ethnic minorities might be 
associated with a reduction in  the  number  of  nephrons,  predisposing  to hypertension and renal disease 
in later life 12. Male and elderly  people  might  also  be  more  susceptible  to CKD, which  would  explain  
the  high  proportions  of these  population  groups  in  renal-replacement-therapy programmes 13. 
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Initiation factors  
Many  cohort  studies  have identified  hypertension,  diabetes,  hyperlipidaemia, obesity  and  smoking  as  
risk  factors  or  markers  in  the general population for the development of CKD. Common risk factors and 
markers seem to be linked to both renal and cardiovascular diseases in more developed countries. 
Also, albuminuria itself is a predictor not only of CKD but also of cardiovascular morbidity and mortality 14. 
Impaired kidney function is also a major risk factor for patients with cardiovascular disease 6, 15.  
Consequently, early detection and  prevention could influence both renal and cardiovascular morbidity and 
mortality. Evidence  is  lacking  on  the  etiology  of  ESRD in  many less developed  countries  owing  to  
poor  data  collection and  the  absence  of  renal  registries.  In  addition,  these countries  continue  to  
suffer  from  the  burden  of infectious  diseases  with  infection-related  glomerulonephritis  and  
consequent  renal  insufficiency.  The infections include HIV (40 million infected worldwide), hepatitis  C  
virus  (170  million),  malaria  (300  million cases  per  year),  schistosomiasis  (200  million)  and tuberculosis 
(200 million) [WHO, 2003]. The growth in the number of cases of CKD attributable to these infections is 
likely to parallel the rising number of infected individuals. 
Progression factors  
The  progression  of  established  CKD  is  variable  and depends  on  several  risk  factors  or  markers.  Non-
modifiable factors include genetics, race,  age,  and  sex.   For  instance,  there  is  much  evidence  that  the  
rate  of progression  of  CKD  is  faster  among  patients  who  are elderly 16, male 17 or African-American 18.  
Most important, among the modifiable progression factors is systemic hypertension 19, 20. Proteinuria is a 
reliable marker of the severity of CKD and a powerful and  independent  predictor  of  its  progression 21, 22. 
Controversy prevails as to whether proteinuria is a risk factor for the progression  of  clinical  
nephropathies. 
Patients with persistently high rates of urinary protein excretion (>3–5 g in 24 h) in general have a much 
faster rate  of  progression  than  those  with  mild  or  moderate proteinuria (<1–3 g in 24 h)22. Metabolic 
factors have been implicated  in  the progression  of  CKD.  The  Diabetes  Control  and Complications  Trial23 
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and  the  UK  Prospective Diabetes Study 24 established that poor diabetes control accelerates the  
progression  of  diabetic  nephropathy  in  both  type  1 and  type  2  diabetes.  Experimental evidence has 
also shown  a  link  between  hyperlipidaemia  and  the progression of diabetic and non-diabetic 
nephropathies 25. A link between hyperuricaemia and the development of systemic hypertension, 
cardiovascular disease, and renal disease has been postulated 26.  The  worldwide  pandemic  of  obesity  
could  also  affect the  progression  of  CKD: obesity has been associated with  the  initiation  and  
progression  of  glomerulonephritides 27, 28; the  incidence  of  focal  and  segmental glomerulosclerosis  is  
higher  in  obese  than  in  lean individuals  29 and the progression of IgA nephropathy is thought  to  be  
faster  in  overweight  patients. Whether these  links  are  causal  or  simply  associated  with  CKD remains  
unclear;  obesity  is  associated  with hypertension,  albuminuria  and  dyslipidaemia,  all  of which are 
potential modifiers of the progression of CKD 30.  
Cigarette smoking has been implicated in the initiation and progression of CKD. A graded increased risk of 
ESRD was noted in non-diabetic nephropathies with increasing  cigarette smoking;  the  incidence  of ESRD 
was increased by 5,9 times among heavy smokers.  And heavy smokers had also a risk of developing 
albuminuria three times that of non-smokers 31. Also the consumption of analgesics, especially paracetamol 
and non-steroidal anti-inflammatory agents, could be linked with a higher risk of  developing CKD 32-34. 
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Pathophysiology 
Approximately  1  million glomerular capillary units are present in each kidney, each contributing to the 
total  GFR 35.  In the face of renal injury (regardless of the etiology), the kidney has an innate ability to 
maintain GFR, despite progressive destruction of nephrons, as the remaining healthy nephrons manifest 
hyperfiltration and compensatory hypertrophy. This nephron adaptability allows for continued normal 
clearance of plasma solutes. Plasma levels of substances, such as urea and creatinine start to show 
measurable increases only after total GFR has decreased to 50%. The plasma creatinine value 
approximately double with a 50% reduction in GFR  (Krishna Murthy et al., 2012 A Study of Estimated 
Glomerular Filtration Rate In Chronic Kidney Disease).  
The hyperfiltration and hypertrophy of residual nephrons, although beneficial for the reasons noted, has 
been hypothesize to represent a major cause of progressive renal dysfunction. The progression of chronic 
kidney disease tends to follow a stereotypical course in many cases; the increased glomerular capillary 
pressure may damage the capillaries: a common histologic finding in these cases is focal segmental 
glomerulosclerosis (FSGS) with tubulointerstitial fibrosis 36. 
Decreased renal function interferes with the kidneys' ability to maintain fluid and electrolyte homeostasis  
(Thompson et al., 2009 Fluid and electrolyte problems in renal disfunction). The ability to concentrate urine 
declines early and it is followed by decreases in ability to excrete phosphate, acid and potassium. When 
renal failure is advanced (GFR ≤ 10 mL/min/1.73 m²), the ability to dilute urine is lost; thus urine osmolality 
is usually fixed close to that of plasma (300 to 320 mOsm/kg) and urinary volume does not respond readily 
to variations in water intake. 
Aging and renal function 
The biologic process of aging initiates various structural and functional changes within the kidney 37, 38.  
Renal mass progressively declines with advancing age and glomerulosclerosis leads to a decrease in renal 
weight.  Histologic examinations show a decrease in glomerular number of as much as 30-50% by age 70 
years. The GFR peaks during the third decade of life at approximately 120 mL/min/1.73 m²; it then 
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undergoes an annual mean decline of approximately 1 mL/min/1.73 m², reaching a mean value of 70 
mL/min/1.73 m² at age 70 years.  Ischemic obsolescence of cortical glomeruli is predominant, with relative 
sparing of the renal medulla. Juxtamedullary glomeruli see a shunting of blood from afferent to efferent 
arterioles, resulting in redistribution of blood flow favoring the renal medulla. These anatomic and 
functional changes in renal vasculature appear to contribute to an age-related decrease in renal blood flow. 
Given the histologic evidence for nephronal senescence with age, a decline in the GFR is expected. 
However, a wide variation in the rate of GFR decline is reported because of measurement methods, race, 
gender, genetic variance and other risk factors for renal dysfunction.  
 
Calcium and phosphate abnormalities 
Abnormalities of Ca++, phosphate, parathyroid hormone (PTH), vitamin D metabolism and renal 
osteodystrophy can occur. A study by Schwarz et al suggested that lower serum calcium was associated 
with higher risk of CKD progression 39. Decreased renal production of calcitriol contributes to hypocalcemia 
and it develops primarily from decreased intestinal calcium absorption because of low plasma calcitriol 
levels. It also possibly results from increased calcium-phosphate binding, caused by elevated serum 
phosphate levels 40. Decreased renal excretion of phosphate results in hyperphosphatemia. Secondary 
hyperparathyroidism is common and can develop in renal failure before abnormalities in Ca++ or 
phosphate concentrations occur. For this reason, monitoring PTH in patients with moderate CKD, even 
before hyperphosphatemia occurs, has been recommended. Phosphate retention begins in early CKD 41; 
when the GFR falls, less phosphate is filtered and excreted, but because of increased PTH secretion, which 
increases renal excretion, serum levels do not rise initially. As the GFR falls toward CKD stages 4-5, 
hyperphosphatemia develops from the inability of the kidneys to excrete the excess dietary intake 42. 
Hyperphosphatemia suppresses the renal hydroxylation of inactive 25-hydroxyvitamin D to calcitriol, so 
serum calcitriol levels are low when the GFR is less than 30 mL/min/1.73 m². Increased phosphate 
concentration also effects PTH concentration by its direct effect on the parathyroid glands (post-
transcriptional effect).  
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Hyperkalemia and hypokaliemia 
Hyperkalaemia is common in patients with chronic kidney disease (CKD), in part because of the effects of 
kidney dysfunction on potassium homeostasis and in part because of the cluster of comorbidities (and their 
associated treatments) that occur in patients with CKD 43; nevertheless, the ability to maintain potassium 
excretion at near-normal levels is generally maintained in CKD, as long as aldosterone secretion and distal 
flow are maintained. Another defense against potassium retention in patients with CKD is increased 
potassium excretion in the gastrointestinal tract, which also is under control of aldosterone. Hyperkalemia 
usually does not develop until the GFR falls to less than 20-25 mL/min/1.73 m², at which point the kidneys 
have decreased ability to excrete potassium. Hyperkalemia can be observed sooner in patients who ingest a 
potassium-rich diet or have low serum aldosterone levels. Common sources of low aldosterone levels are 
diabetes mellitus and the use of ACE inhibitors, NSAIDs or beta-blockers. Hyperkalemia in CKD can be 
aggravated by an extracellular shift of potassium, such as occurs in the setting of acidemia or from lack of 
insulin. 
  Hypokalemia (K < 3.5) is uncommon but can develop in patients with very poor intake of potassium, 
gastrointestinal or urinary loss of potassium, or diarrhea or in patients who use diuretics (Thompson et al., 
2009 Fluid and electrolyte problems in renal disfunction). 
Metabolic acidosis 
Anions accumulate during the course of CKD 44-46 and unmeasured anions, such as indoxyl sulfate and p-
cresyl sulfate, probably accelerate CKD progression 47 and complications 48, 49, including bone disease, 
muscle protein catabolism and progressive glomerular filtration rate loss. The KDOQI guidelines, based on 
“evidence and opinion,” call for maintenance of the serum bicarbonate level at ≥22 mEq/L to lessen these 
complications 9. In stage 5 CKD, accumulation of phosphates, sulfates and other organic anions are the 
cause of the increase in anion gap. Metabolic acidosis has been shown to have deleterious effects on 
protein balance, leading to negative nitrogen balance, increased protein degradation, increased essential 
aminoacid oxidation and reduced albumin synthesis 50. In addition, metabolic acidosis is a factor in the 
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development of renal osteodystrophy 51, because bone acts as a buffer for excess acid, with resultant loss 
of mineral 52. Acidosis may interfere with vitamin D metabolism and patients who are persistently more 
acidotic are more likely to have osteomalacia or low-turnover bone disease.  
Salt- and water-handling abnormalities 
Salt and water handling by the kidney is altered in CKD. Extracellular volume expansion and total-body 
volume overload results from failure of sodium and free-water excretion 53. This generally becomes 
clinically manifested when the GFR falls to less than 10-15 mL/min/1.73 m², when compensatory 
mechanisms have become exhausted. As kidney function declines further, sodium retention and 
extracellular volume expansion lead to peripheral edema and, not uncommonly, pulmonary edema and 
hypertension.  
Anemia 
Normochromic normocytic anemia principally develops from decreased renal synthesis of erythropoietin, 
the hormone responsible for bone marrow stimulation for red blood cell (RBC) production. The anemia 
starts early in the course of the disease and becomes more severe as, with the shrinking availability of 
viable renal mass, the GFR progressively decreases: the prevalence of anemia increased with stage of CKD, 
from 8.4% at stage 1 to 53.4% at stage 5 54. No reticulocyte response occurs. RBC survival is decreased and 
bleeding tendency is increased from the uremia-induced platelet dysfunction.  
Bone disease 
Chronic kidney disease-related mineral and bone disease (CKD-MBD) is a syndrome defined as a systemic 
mineral metabolic disorder associated with CKD which can result in disorders of the bone metabolism 
and/or the cardiovascular system 55. Cortical bone thinning, abnormalities in bone turnover and 
primary/secondary mineralization, elevated levels of circulating sclerostin, increased apoptosis in 
osteoblasts and osteocytes, disturbance of the coupling phenomenon, iatrogenic factors, accumulated 
micro-crackles, crystal/collagen disorientation and chemical modification of collagen crosslinks are all 
possible candidates found in CKD that could promote osteopenia and/or bone fragility 56. This disease 
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consists of three components: abnormalities observed in laboratory examinations, including parathyroid 
gland dysfunction; abnormality in the bone metabolism; and abnormality in the soft tissue calcification 
including vascular calcification. CKD-MBD may result from alteration in levels of serum phosphorus, PTH, 
vitamin D and alkaline phosphatase.  
Skeletal manifestations 
 
If serum levels of PTH remain elevated, a high ̶ bone turnover lesion, known as osteitis fibrosa, develops 57. 
This is one of several bone lesions and develop in patients with severe CKD. Osteitis fibrosa is common in 
patients with ESRD.    The pathogenesis of another bone disease, the adynamic bone disease 58, is not well 
defined, but several factors may contribute, including high calcium load, use of vitamin D sterols, increasing 
age, previous corticosteroid therapy, peritoneal dialysis and increased level of N-terminally truncated PTH 
fragments.   Low-turnover osteomalacia in the setting of CKD is associated with aluminum accumulation 59. 
It is markedly less common than high-turnover bone disease.   Another form of bone disease is dialysis-
related amyloidosis, which is now uncommon in the era of improved dialysis membranes. This condition 
occurs from beta-2-microglobulin accumulation in patients who have required chronic dialysis for at least 8-
10 years; it manifests with cysts at the ends of long bones. 
 
Prognosis 
Patients with CKD generally experience progressive loss of kidney function and are at risk for ESRD. The rate 
of progression depends on age, the underlying diagnosis, the success of implementation of secondary 
preventive measures and the individual patient. Timely initiation of chronic renal replacement therapy is 
imperative to prevent the uremic complications of CKD that can lead to significant morbidity and death. 
Lower estimated glomerular filtration rate, higher albuminuria and male sex pointed to a faster progression 
of kidney failure 60. Also, a lower serum albumin, calcium and bicarbonate level and a higher serum 
phosphate level were found to predict an elevated risk of kidney failure 60. 
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Hospitalization 
Unadjusted rates of hospitalization in the CKD population, reflecting its total disease burden, are 3-5 times 
higher than those of patients without CKD 61. After adjustment for gender, prior hospitalizations and 
comorbidity, rates for patients with CKD are 1.4 times higher. Rates of hospitalization of these patients for 
cardiovascular disease and bacterial infection are particularly elevated CKD 61. 
 
Dialysis and Mortality 
The mortality rates associated with CKD are striking. After adjustment for age, gender, race, comorbidity 
and prior hospitalizations, mortality in patients with CKD in 2009 was 56% greater than that in patients 
without CKD 61. For patients with stages 4-5 CKD, the adjusted mortality rate is 76% greater.  Mortality rates 
are consistently higher for men than for women and for black than for white individuals and patients of 
other races. The highest mortality rate is within the first 6 months after the beginning of dialysis. Mortality 
then tends to improve over the next 6 months, before increasing gradually over the next 4 years. The 5-
year survival rate for a patient undergoing long-term dialysis is approximately 35% and approximately 25% 
in patients with diabetes. At every age, patients with ESRD on dialysis have significantly increased mortality 
when compared with non-dialysis patients and individuals without kidney disease. At 60 years old, a 
healthy person can expect to live for more than 20 years, whereas the life expectancy of a patient aged 60 
years who is starting hemodialysis is closer to 4 years. Among patients aged 65 years or older who have 
ESRD, mortality rates are 6 times higher than in the general population 61. 
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Prognostic relevance of CKD in cardiovascular disease 
In coronary artery disease (CAD), CKD represents a potent and independent risk factor for adverse outcome 
62. Patients with chronic kidney disease have a high burden of cardiovascular morbidity and mortality. The 
vast majority of patients with chronic kidney disease do not progress to end-stage renal failure, but do have 
a significantly higher incidence of all cardiovascular co-morbidities. Traditional cardiovascular risk factors 
(such as hypertension, dyslipidemia, diabetes and obesity) only partially account for this increased 
incidence of cardiovascular disease 63. There are many  other cardiovascular risk factors that are either 
“uremia specific”, or at least much more common in patients with  CKD  than  in  the  general  population.  
These  factors include anemia, hyperparathyroidism, carnitine deficiency, hyperhomocysteinemia, low 
vitamin C, high lipoprotein A levels and small apolipoprotein A size 64. In patients with kidney disease the 
basic biology underlying cardiovascular disease may be similar to that in patients without kidney disease, 
but it would seem many more risk factors are involved as a consequence of renal dysfunction. Although 
emphasis is placed on delaying the progression of chronic kidney disease, it must be appreciated that for 
many patients it is vital to address their cardiovascular risk factors at an early stage to prevent premature 
cardiovascular death 65. Antithrombotic agents and percutaneous coronary interventions (PCI) are clearly 
emerging as the cornerstones of treatment patterns in patients presenting with ACS 66. However, despite 
the increasing number of CKD patients with a broad range of CAD at presentation, evidence-based data 
with established or newer drugs and interventional strategies are still lacking in this population because 
CKD patients have typically been excluded from randomized trials. Ideally, these are the patients to whom 
recent therapeutic advances should be aggressively applied, in order to minimize their increased risk. 
However, application of strategies for reducing cardiovascular morbidity and mortality seem to be limited 
in CKD patients, when compared to patients with normal renal function.   
NSTEMI and CKD 
Chronic kidney disease is present in a substantial proportion of patients with ACS; indeed, large registries 
report that almost 40% of patients with NSTEMI and 30% of those with STEMI have CKD 67, 68. Several 
observational studies have found that, in the setting of NSTEMI, in-hospital outcomes and mid- to long-
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term mortality are worse among patients with CKD 69-71. The GRACE (Global Registry of Acute Coronary 
Events) study, a large prospective multinational registry, including the full spectrum of patients with ACS, 
evaluated the prognostic impact of serum creatinine (sCr) levels on hospital mortality and adverse 
outcomes in 11.774 NSTEMI patients 69. Patients were divided into three groups according to their 
creatinine clearance values: >60 ml/min or normal renal function (including patients with minimally 
impaired renal function), 30-60 ml/min or moderate renal insufficiency, and <30 ml/min or severe renal 
insufficiency. In comparison with patients with normal renal function, patients with moderate and severe 
renal insufficiency were at a significantly increased risk of hospital mortality and major bleeding episodes. 
The significant contribution of renal function evaluation to risk stratification was demonstrated by Gibson 
et al. 72 who pooled data from five international multicenter trials (TIMI 11A and B, TIMI 12, OPUS-TIMI 16, 
and TACTICS-TIMI 18) and analyzed 13.307 patients with NSTEMI. Notably, these trials excluded patients 
with a sCr level above 2.0 mg/dl. As a consequence, moderate to severe renal insufficiency (GFR <60 
ml/min/1.73 m2) was present in 16% of patients, while only less than 1% of the patients had a GFR<30 
ml/min/1.73 m2. In this study, a significant and graded association was observed between reduced GFR and 
short-term (30 days) and mid-term (6 months) mortality: 1.3% and 2.5% for patients with normal renal 
function, 2.1% and 3.8% for patients with mild renal insufficiency and 5% and 9.5% for patients with 
moderate to severe renal insufficiency, respectively (P for trend <0.001). In parallel, there was a stepwise 
increase in the incidence of stroke, major bleeding, recurrent myocardial infarction and recurrent ischemia 
with worsening GFR. Interestingly, within each GFR category, high TIMI (Thrombolysis in Myocardial 
Infarction) risk scores and augmented levels of biomarkers (C-reactive protein, B-type natriuretic peptide 
and troponin I) were associated with a significant increase in mortality as compared with low TIMI scores 
and normal levels of biomarkers, demonstrating the prognostic value of GFR in addition to the traditional 
clinical risk stratification of patients with NSTEMI.  
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SA and CKD 
Chronic kidney disease is strongly associated with a higher risk of cardiovascular disease 6, 73-75, and studies 
have shown that at least 25% of the patients in dialysis had CAD 76, 77; even earlier stages of CKD have been 
associated with worse outcomes in patients with CAD 78, 79.  In the MASS II 80, a randomized trial that 
evaluated the long-term relative efficacies of three possible therapeutic strategies for patients with 
multivessel CAD, stable angina, and preserved left ventricular function, 611 patients were randomly 
assigned to medical treatment MT (n=203), PCI (n=205), or CABG (n=203). All patients had angiographicaly 
documented proximal multivessel coronary stenosis of more than 70% by visual assessment and 
documented ischemia. Exclusion criteria included unstable angina or acute MI necessitating emergency 
revascularization, ventricular aneurysm necessitating surgical repair, left ventricular ejection fraction of less 
than 40%, a history of PCI or CABG, single-vessel disease, or previous cardiac surgery. Patients were 
categorized in normal renal function (RF) and mild or moderate CKD groups depending on their GFR  based 
on the National Kidney Foundation (NFK) classification.  The results of this trial confirm that CAD 
accompanied by CKD has a worse prognosis, regardless of the therapeutic strategy for CAD. The lowest GFR 
group had a 4.5-fold increased risk of death within 5 years compared with the normal GFR group.  
Additionally, these data suggest that the different treatment strategies available for stable CAD may have 
differential beneficial effects according to the range of GFR strata.  Authors showed that patients with 
stable multivessel CAD and CKD, mainly in early stages, had more events when kept in MT over 5 years of 
follow-up.  Of note, CABG patients compared with the PCI or MT patients had a better free-event survival 
curve and less overall mortality rates only in patients with mild CKD (or stage 2 CKD). However, among 
patients with moderate CKD, CABG surgery did not convey a survival benefit over PCI or MT.    Prior studies 
in high-risk populations, such as those who already have CAD or who have many risk factors for 
cardiovascular disease, have suggested that the level of kidney function is a risk factor for cardiovascular 
disease outcomes 74, 81-84. 
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CHRONIC KIDNEY DISEASE AND CORONARY ARTERY DISEASE 
Acute coronary syndrome 
Definition 
The term acute coronary syndrome (ACS) refers to any group of clinical symptoms compatible with acute 
myocardial ischemia and covers the spectrum of clinical conditions ranging from unstable angina (UA) to 
non-ST-segment elevation myocardial infarction (NSTEMI) to ST-segment elevation myocardial infarction 
(STEMI) 85. Unstable angina and NSTEMI are closely related conditions: their pathophysiologic origins and 
clinical presentation are similar, but they differ in severity. A diagnosis of NSTEMI can be made when the 
ischemia is sufficiently severe to cause myocardial damage that results in the release of a biomarker of 
myocardial necrosis into the circulation (cardiac-specific troponins T or I or muscle and brain fraction of 
creatine kinase [CK-MB]). In contrast, the patient is considered to have experienced UA if no such 
biomarker can be detect in the bloodstream hours after the initials onset of ischemic chest pain. Unstable 
angina exhibits one or more of three principle presentations: rest angina (usually lasting major 20 minutes), 
new-onset (< 2 months previously) severe angina and an increased pattern of occurrence (increasing in 
intensity, duration, frequency or any combination of these factors) 86. 
 
Etiology 
Acute coronary syndrome (ACS) is caused primarily by atherosclerosis. Most cases of ACS occur from 
disruption of a previously non-severe lesion (an atherosclerotic lesion that was previously hemodynamically 
insignificant yet vulnerable to rupture). The vulnerable plaque is characterized by a large lipid pool, 
numerous inflammatory cells, and a thin fibrous cap 87. The major trigger for coronary thrombosis is 
considered to be plaque rupture 88, 89 caused by the dissolution of the fibrous cap and the dissolution is the 
result of the release of metalloproteinases (collagenases) from activated inflammatory cells 90. This event is 
followed by platelet activation and aggregation, activation of the coagulation pathway and 
vasoconstriction. This process culminates in coronary intraluminal thrombosis and variable degrees of 
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vascular occlusion 91. Distal embolization may occur. The severity and duration of coronary arterial 
obstruction, the volume of myocardium affected, the level of demand on the heart and the ability of the 
rest of the heart to compensate are major determinants of a patient's clinical presentation and outcome 92.  
Baseline blood glucose levels appear to be an independent risk factor for a major adverse cardiac event 
(MACE) in patients with suspected ACS 93. Other significant predictors of MACE include male sex, older age, 
family history, hypertension, dyslipidemia, ischemic findings on ECG and positive troponin-tests 94. 
 
Prognosis 
The prognosis of patients with acute coronary syndromes generally depends on the occurrence and extent 
of myocardial damage 95. Patients presenting without persistent ST-segment elevation or a typical enzyme 
rise have the lowest incidence of mortality and morbidity 96. Intermediate complication rates are seen in 
those presenting without ST-segment elevation but with a rise in cardiac enzymes 96, whereas prognosis is 
worst in patients with ST-segment elevation and substantial myocardial damage. Apart from this simple 
classification, analyses of the GUSTO-1 (Global Utilization of Streptokinase and Tissue plasminogen 
activator for Occluded coronary arteries) population have demonstrated that age, heart rate, blood 
pressure and signs of heart failure are the key factors in predicting outcome in patients with STEMI 97, 98.  
The Global Registry of Acute Coronary Events (GRACE) reports that the six-month mortality rate is 13% for 
patients with NSTEMI ACS and 8% for those with unstable angina 98.  
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Stable coronary artery disease 
Definition 
Stable coronary artery disease (or stable angina, SA) is generally characterized by episodes of reversible 
myocardial demand/supply mismatch, related to ischaemia or hypoxia, which are usually inducible by 
exercise, emotion or other stress and reproducible, but which may also be occurring spontaneously 99.  
Such episodes of ischaemia/hypoxia are commonly associated with transient chest discomfort (angina 
pectoris). SA also includes the stabilized, often asymptomatic, phases that follow an ACS. The various 
clinical presentations of SA are associated with different underlying mechanisms that mainly include: 1) 
plaque-related obstruction of epicardial arteries; 2) focal or diffuse spasm of normal or plaque-diseased 
arteries; 3) microvascular dysfunction; and 4) left ventricular dysfunction caused by prior acute myocardial 
necrosis and/or hibernation (ischaemic cardiomyopathy).  These mechanisms may act singly or in 
combination. However, stable coronary plaques with and without previous revascularization may also be 
completely clinically silent 99. 
 
Etiology 
Myocardial ischaemia and hypoxia in stable coronary artery disease are caused by a transient imbalance 
between blood supply and metabolic demand. The consequences of ischaemia occur in a predictable 
temporal sequence that involves: 
a) increased H+ and K+ concentration in the venous blood that drains the ischaemic territory 100; 
b) signs of ventricular diastolic and subsequently systolic dysfunction with regional wall motion 
abnormalities 101; 
c) development of ST–T changes 99; 
d) cardiac ischaemic pain (angina)  
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 Angina is ultimately caused by the release of ischaemic metabolite, such as adenosine, that stimulate 
sensitive nerve endings, although angina may be absent even with severe ischaemia owing, for instance, to 
impaired transmission of painful stimuli to the cortex and other as-yet-undefined potential mechanisms 102. 
 
Prognosis 
Within the population with stable CAD, an individual’s prognosis can vary considerably, depending on 
baseline clinical, functional and anatomical characteristics. Prognostic assessment is an important part of 
the management of patients with stable coronary artery disease. On the one hand, it is important to 
reliably identify those patients with more severe forms of disease, who may have an improvement in 
outcome with more aggressive investigation and, potentially, intervention, including revascularization 99. 
On the other hand, it is also important to identify those patients with a less severe form of disease and a 
good prognosis, thereby avoiding unnecessary invasive and non-invasive tests and revascularization 
procedures. Conventional risk factors for the development of CAD 103-105, such as hypertension 106, 
hypercholesterolaemia 107, diabetes 108,sedentary lifestyle 109, obesity 109,smoking 106, 110 and a family history 
111 have an adverse influence on prognosis in those with established disease, presumably through their 
effect on the progression of atherosclerotic disease processes. 
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Treatment of patients with CAD and CKD 
Treatment of CAD in patients with CKD is particularly problematic. Traditionally, patients with advanced 
CKD and ESRD receiving dialysis have not been included in randomized CAD trials evaluating either medical 
or interventional therapies. Thus, only scarce data deriving from limited observational studies are available 
and, to date, no optimal treatment strategy has been defined for this subgroup of patients.  
  
Coronary reperfusion strategies 
Doubts still exist on how CKD patients should be treated in the early phase of CAD. In particular, there are 
concerns about the use of aggressive reperfusion strategy (fibrinolytic therapy and primary PCI). 
Undoubtedly, landmark megatrials, such as the GISSI (Gruppo Italiano per lo Studio della Streptochinasi 
nell’Infarto Miocardico), the ISIS (International Study of Infarct Survival) and the GUSTO (Global Utilization 
of Streptokinase and Tissue Plasminogen for Occluded Coronary Arteries) trials, have shown the benefit of 
thrombolytic agents in reducing mortality in patients with ACS 112-114. However, in all these trials, no 
subgroup analysis was performed in patients with CKD, and scarce data have been published on the use of 
thrombolytics in these patients. Reperfusion therapy was used less frequently in patients with any degree 
of CKD than in patients without renal insufficiency. Renal insufficiency should not preclude the success rate 
of percutaneous or pharmacological reperfusion therapies, but it may be associated with increased 
incidence of major adverse events (MACE). The influence of renal insufficiency in patients with STEMI 
receiving fibrinolytic therapy was investigated by Gibson et al 114. Despite appropriate treatment with 
thrombolytics and adjunctive therapies for acute myocardial infarction (including early PCI in many 
patients) and even though the epicardial and myocardial reperfusion rates were equivalent, there was a 
stepwise decrease in survival going from normal to mildly and severely impaired renal function that 
continued through up to two years of follow-up. The incidence of intracranial hemorrhage was also 
increased in patients with CKD, suggesting that primary PCI may represent a favorable alternative therapy. 
Nevertheless, the outcomes of primary PCI in patients with STEMI and CKD have not been well 
characterized, because such patients are typically excluded from clinical trials. According to previous 
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studies and guidelines, an invasive strategy is superior to an initial conservative strategy (invasive 
management only after failed medical therapy or for objective evidence of ischemia) and an early invasive 
strategy is superior to a delayed invasive strategy. In the KAMIR study, an invasive (within 24 hours after 
admission) strategy decreased mortality compared to a conservative strategy except for severe CKD. In the 
timing of an invasive strategy, there were trends showing that an early invasive strategy was superior to a 
delayed strategy in patients with mild CKD, but this tendency decreased as renal function decreased 115. 
 
Standard medical therapy 
Berger et al. 116 compared the patterns of care and the effect of standard STEMI therapy on 30-day 
mortality between ESRD patients on chronic dialysis (either peritoneal dialysis or haemodialysis) and non-
ESRD patients. They confirmed that aspirin, beta-blockers, and ACE-inhibitors are less likely to be used in 
ACS patients on dialysis, even among those considered “ideal candidates” for these medications, than in 
patients not receiving dialysis. Nevertheless, the authors observed a similar absolute reduction in short-
term mortality with aspirin, beta-blocker and ACE-inhibitor therapy when comparing the dialysis and non-
dialysis groups. Aspirin was associated with a 21% absolute reduction in mortality in dialysis patients and a 
23% reduction in non-dialysis patients. Beta-blocker therapy was associated with a 14% absolute reduction 
in mortality in both the dialysis and non-dialysis patients. The ACE-inhibitor use was associated with a 16% 
absolute reduction in 30-day mortality in dialysis patients and a 5% reduction in non-dialysis patients. 
Recently, data from the ACTION registry documented, lower use of short-term therapies, in-hospital 
procedures, cardioprotective medications and higher rates of medication overdosing among patients with 
CKD 68. Finally, despite these high rates of adverse outcomes, patients with CKD were less likely to receive 
discharge counseling related to cardiovascular disease risk reduction. Thus, all these studies confirm less 
aggressive care in CKD patients with CAD that parallel the degree of renal dysfunction and demonstrate 
that beneficial therapies are underutilized in patients with CKD despite increased prevalence of 
hypertension, congestive heart failure and coronary artery disease, and despite the fact that these 
medications are associated with a substantial survival benefit in patients with normal renal function. 
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Antithrombotic therapy 
 Refinement of the antithrombotic strategies among CKD patients in CAD setting is still a major and unmet 
need. The challenge is daunting because, on the one hand, renal insufficiency is associated with 
prolongation of bleeding time and abnormal platelet aggregation and adhesion 117 and, on the other hand, 
a state of hypercoagulation has been demonstrated with high levels of von Willebrand factor 118, fibrinogen, 
factors VII, VIII, and XIII and enhanced thrombin generation 117. The combination of these alterations puts 
the patient with CKD at risk, simultaneously, for thrombosis and hemorrhage. Thus, use of well-established 
antiplatelet drugs, such as aspirin and clopidogrel, should be weighed against bleeding risk in renal 
patients. Current practice guidelines recommend the addition to aspirin of another antiplatelet agent 
(ticlopidine, clopidogrel, prasugrel, ticagrelor) for treatment of high-risk CAD patients. Despite never 
specifically investigated in CKD patients, some differences, in terms of bleeding risk, possibly exist among 
these drugs. In the CREDO (Clopidogrel for the Reduction of Events During Observation) trial the 
effectiveness of clopidogrel in reducing adverse cardiovascular events seemed to be greatest in patients 
with normal renal function, whereas patients with moderate CKD appeared to have experienced less 
benefit 119. In the PLATO (Platelet Inhibition and Patient Outcomes) study clinical evidence was provided 
that ticagrelor is a more effective antiplatelet agent than clopidogrel in patients with CAD, regardless of 
renal function and without any need for dose reduction to prevent major bleeding 120.   In addition to 
antiplatelet agents, heparin has become the standard of care in patients with ACS: the two preparations 
generally available are unfractionated heparin (UFH) and low-molecular weight heparin (LMWH). A major 
difference between these two therapeutic agents is their mechanism of clearance: at low doses, UHF is 
cleared primarily by macrophages and endothelial cell binding, whereas LMWH is cleared primarily by renal 
mechanisms 121. Clinical studies on enoxaparin, the most widely used LMWH in NSTEMI, excluded patients 
with CKD, so that the optimal dosing for renal patients has not been established 122, 123.  Until conclusive 
results are available regarding optimal dosing, it may be safer to use UFH in CKD patients presenting with 
ACS. It should be highlighted, however, that bleeding risk increases in parallel with the increasing severity 
of baseline renal insufficiency also in patients receiving UHF alone 124. Impaired renal clearance of many 
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pharmacological agents may increase the probability of overdosing in patients with reduced renal function, 
further increasing their bleeding risk 125. This is particularly true for renally excreted antithrombotic agents, 
such as enoxaparin, tirofiban and eptifibatide that are recommended at a lower dose in CKD patients. Use 
of newer antithrombotic agents, such as platelet glycoprotein (GP) IIb/IIIa receptor inhibitors, has become 
the standard of care for the higher-risk CAD patients, mainly for those undergoing PCI. However, patients 
with CKD were also excluded from entry into most randomized trials investigating GPIIb/IIIa antagonists. 
Thus, it is not clear if they may derive the same therapeutic benefit with equivalent safety from these 
pharmacological agents, as do patients with normal renal function. Moreover, because agents such as 
tirofiban and eptifibatide are largely cleared through the kidneys, moderate to severe renal insufficiency 
would be expected to increase the mean plasma concentration of these drugs, producing a greater 
inhibition of platelet aggregation. Since platelet-bound abcximab is eliminated by the reticuloendothelial 
system 126, its use in patients with renal insufficiency should not be associated with greater impairment of 
platelet function. Thus, unlike tirofiban and eptifibatide, abciximab does not require dosing adjustment in 
CKD patients.  
 
 
Statins  
Coronary artery disease patients with CKD are less likely to be treated with statins, despite the evidence of 
reduced mortality with statins use in patients with or at risk for coronary events 69, 83, 127, 128.  In addition to 
the long-term benefit of statin therapy in ACS patients, data from National Registry of Myocardial Infarction 
4 suggest that administration of statins within the first 24 hour of hospitalization for acute myocardial 
infarction significantly lowers the rate of early complications and in-hospital mortality, possibly due to their 
pleiotropic effects 129. Indeed, acute myocardial infarction is associated with a number of abnormalities, 
including inflammation, endothelial dysfunction and coagulation disorders, all of which appear to be 
dampened by statins 130.  Patients with CKD have more co-morbidities and, as a consequence, more 
contraindications to these medications. Statins are primarily eliminated by the liver, while the renal route is 
usually a minor elimination pathway. However, reluctance to prescribe statins in patients with CKD is likely 
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due to remaining uncertainty regarding their clinical effects in patients with CKD. In particular, no clear 
evidence of a positive relationship between blood cholesterol and cardiovascular events has been found in 
these patients. As they approach end-stage renal disease, there appears to be increased oxidation of low-
density lipoprotein, with progressive lowering of total cholesterol levels. The influence of dyslipidemia 
upon cardiovascular outcomes shows an increasing cardiovascular event rate among patients with severe 
CKD having low cholesterol levels. This “low-cholesterol paradox” has been attributed to the effects of 
chronic malnutrition and inflammation, which become increasingly important in severe CKD 131. This 
paradox has raised the question of the utility of lipid-lowering therapy, although previous evidence than 
statin therapy may delay progression of renal dysfunction 132. Moreover, some concerns about drug toxicity 
related to high statin doses exist in CKD patients. Indeed, high statin doses have been associated with an 
increased risk of myopathy in CKD patients 133. 
 
 
PLATELETS 
Platelet biology 
Platelets were discovered by the pathologist Giulio Bizzozero in 1882. He observed them microscopically in 
the circulating blood of living animals and in the blood removed from the blood vessels. Platelets, also 
called thrombocytes, are anucleated discoid cell fragments with a diameter of 1-4 µm and a thickness of 1 
µm.  Platelets derived from the cytoplasmatic fragmentation of megakaryocytes, their precursor cells, in 
the bone marrow. Megakaryocytes are rare myeloid cells that reside within the bone marrow and 
represent less than 0,1% of the myeloid cells 134; they could be found also in the lungs and in the peripheric 
bloodstream. Megakaryocytes tailor their cytoplasm and membrane systems for platelet biogenesis. For 
the release of platelets, megakaryocytes have to enlarge considerably their diameter (100 µm) and they fill 
with high concentrations of ribosomes which allow the production of platelet-specific proteins. Cellular 
enlargement is mediated by repeated cycles of endomitosis, a process that amplifies the DNA by as much 
as 64-fold 135.  Platelet release by megakaryocytes involves the development of cytoplasmic ramifications, 
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the so called “pro-platelets”, of 100-500 µm of length. This process starts from a single site on 
megakaryocyte with the emission of pseudopodal extensions, that stretch, in 4-10 hours, into pro-platelets. 
In the final portion of the pro-platelet, the bundles of microtubules form loops that come out and fall in 
pro-platelet causing the formation of bulbous tips of 3-5 µm in diameter 136.  Then the single platelets are 
released into the bloodstream (Figure 2). 
 
Figure 2. Schematic overview of platelets release by megakaryocytes. (B) Megakaryocytes maturation is 
characterized by repeated cycles of endomitosis and by a significant maturation of the cytoplasm with the formation 
of internal membranes, granules and organelles while the microtubules extend (C) Shortly before the formation of 
pro-platelets, microtubules are consolidated into a mass beneath the plasma membrane and blend in linear beams 
thicker branches that fill pro-platelets determining the elongation (D) In the terminal portion of the pro-platelets, the 
bundles of microtubules form loops that come out and fall in pro-platelets causing the formation of bulbous tips. (E) 
The entire cytoplasm of megakaryocytes is converted into pro-platelets that are released from the cell. The individual 
platelets are then released from the ends of pro-platelet. From J Clin Invest 2005; 115 (2): 3348-54  
  
 34 
 
Besides the prevention of bleeding, that is their physiological role, platelets have other important 
functions, for example in the inflammatory process 137-139: in fact into their granules, platelets store 
chemokines, cytokines and growth factors.  Every day 1011 platelets are produced and their average 
lifespan is about 8-10 days, after which time they reach senescence and they are removed from the 
bloodstream by the spleen and liver, and this mechanism also works in the case of morphological or 
functional abnormalities of platelets. In physiological conditions, platelet count in peripheral blood is 
approximately 250.000/µl, whereas the rate of platelet production may change in pathologic conditions: a 
platelet count lower than 100.000 platelets/µl is defined as thrombocytopenia and could lead to an 
increased risk of bleeding; an higher platelet count, more than 600.000 platelets/µl, is defined as 
thrombocytosis and could lead to an increased risk of thrombotic events. 
Structurally, platelets consist of: 
- A plasma membrane rich in phospholipids including phosphatidylserine and phosphatidylinositol, 
negatively charged and abundant in the cytoplasmic side of the membrane where they act as a substrate 
for the phospholipase. The glycocalyx is rich in glycoproteins, some of which perform receptor functions in 
response to stimuli and agonists, giving to the platelets the ability to convey information and to give rise to 
a cellular response 140. 
- Internal membranes formed by the open canalicular system and by the tubular dense on which are 
anchoring the enzymes involved in the synthesis of prostanoids. 
- A cytoskeleton composed of microtubules and microfilaments, which are important in the process of 
platelet activation and secretion. 
- Mitochondria, lysosomes and peroxisomes. 
- Secretory granules: lysosomes, dense granules (also called delta granules) and alpha granules.  Lysosomes 
contain hydrolytic enzymes such as elastase, which may affect the vessel wall and thus promote 
atherosclerosis; dense granules are rich in nucleotides (ADP and ATP), serotonin, histamine, pyrophosphate 
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and calcium; alpha granules contain proteins important for the haemostatic function such as von 
Willebrand factor (VWF), fibrinogen, P-selectin, glycoprotein IIb/IIIa, PECAM-1, CD40 ligand, platelet factor-
4 PF-4), thromboglobulin, beta thrombomodulin, thrombospondin, platelet derived growth factor (PDGF), 
Factor V, Factor X, interleukin 1 and PAI-1. The content of these granules is secreted during platelet 
activation (Table 2) . 
 
 
Table 2. Platelet granular and secreted molecules (adapted from Parise et al, 2005) 
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Platelet functions 
Platelets play a key role in haemostasis and in blood coagulation. Vascular and tissue injury involves 
removal of the anti-thrombotic endothelial cell layer and exposure of matrix molecules to different degrees 
according to the depth of the injury. Major matrix molecules include several types of collagen and laminin. 
Von Willebrand factor (VWF) has a major role in haemostasis by binding to collagen in the first instance and 
by binding to activated platelets at a later stage. Platelets, carried by the bloodstream, are swept up against 
exposed matrix, adhere, become activated, undergo a number of changes and, in turn, bind further 
platelets to form a thrombus preventing further bleeding but limited in size. Each of these phases is 
thought to involve specific or specific sets of platelet receptors 141. 
Platelets play important roles in several diverse processes beyond haemostasis and thrombosis, including 
promoting inflammatory and immune responses, maintaining vascular integrity and contributing to wound 
healing. Platelets can recruit leukocytes and progenitor cells to sites of vascular injury and thrombosis; they 
spur thrombin generation; they store, produce and release pro-inflammatory and anti-inflammatory and 
angiogenic factors and microparticles into the circulation 142. Platelets are important not only in thrombus 
formation occurring upon plaque rupture, but they play a pivotal role also in early stage of plaque 
development by releasing numerous cytokines (such as IL-1, CD40L, beta-thromboglobulin), chemokines 
(such as RANTES, PF4), growth factors (such as PDGF, TGF, EGF) and adhesion proteins (such as fibrinogen, 
fibronectin, von Willebrand factor).  
Platelet secretion - The ability of platelets to store and release bioactive mediators allows them to play an 
important role in modulating the function of other cells. As described before, platelets contain three types 
of storage whose contents are released into the circulation or translocated to the platelet surface upon 
platelet activation.  
Platelet production of bioactive mediators - Platelets are not only storage houses for bioactive molecules: in 
fact they also generate lipid-derived mediators such as thromboxane A2 and participate in transcellular 
metabolism, which results in the production of both pro-inflammatory and anti-inflammatory molecules. In 
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addition, platelets have several unique, extranuclear mechanisms for translating mRNA into protein in a 
signal-dependent manner and can produce, among other proteins, interleukin-1b and tissue factor, which 
may link haemostasis and inflammation.                                                               
Platelet–leukocyte interactions - Analogously to the interactions of leukocytes with inflamed endothelium, 
leukocytes can roll on a template of adherent platelets, firmly adhere and then transmigrate through the 
adherent platelets. Although some of the receptor–ligand pairs and signaling molecules that mediate 
platelet–leukocyte interactions may differ from those involved in endothelial cell–leukocyte interactions, 
many of the fundamental aspects are similar. Rolling and adhesion of leukocytes on platelets or endothelial 
cells are regulated by adhesive receptors, cellular geometry, and, perhaps of greatest overall relevance, 
shear forces generated within flowing blood. 
The selectin family of adhesive receptors mediates the initial stage of cellular rolling.  P-selectin plays an 
essential role in platelet–leukocyte contacts, whereas both P-selectin and E-selectin are present on 
endothelial cells and contribute to endothelial cell–leukocyte interactions. The third selectin, L-selectin, is 
present on leukocytes. The best-characterized leukocyte ligand for P-selectin is P-selectin glycoprotein 
ligand (PSGL)-1, which can interact with all selectin subtypes under inflammatory conditions. Ligation of 
PSGL-1 transmits signals within the leukocyte that are necessary for adhesion mediated by leukocyte 
integrins. Although unnecessary for leukocyte rolling on P-selectin, the cytoplasmic domain of PSGL-1 is 
essential for activation of leukocyte beta2 integrins.  
Immobilized and released chemokines are also required for firm leukocyte adhesion and arrest. Prominent 
among the chemokines released by platelets that influence leukocyte function and platelet–leukocyte 
interactions are PF4/CXCL4, RANTES (regulated on activation, normal T-cell expressed and secreted; CCL5) 
and growth-related oncogene-alpha 142. 
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Platelet transcriptome 
Platelets, although they do not have a nucleus, contain between 2000 and 7000 transcripts derived from 
megakaryocytes 143. They have the translational capacity necessary for protein synthesis 144-146 and they are 
to do de novo protein synthesis through translation of megakaryocyte-derived mRNA; their  transcriptome 
is derived from megakaryocytes through a very well controlled mechanism since not all mRNAs are 
transferred to platelets, depending on physiological and pathological conditions 147. Platelet mRNAs from 
healthy subjects encode for surface receptors and glycoproteins, for proteins involved in metabolism, 
signaling, inflammation and immunity 143, 148. When activated, platelets can use their transcriptome to do 
new protein synthesis, thus modifying their proteome and, as a consequence, their functions 149.                           
In pathological conditions, specific mRNAs could vary and, recently, it has been shown that platelets 
harbour an abundant array of microRNAs, which are known as key regulators of mRNA translation 150, and 
some of them coordinate with reactivity to specific agonists and to pathological states 151. Thus, platelets 
may make use of post-transcriptional gene regulation for their morphology and physiologic functions and 
microRNAs may play a significant role by binding to their target mRNAs. 
 
Platelets and atherothrombosis 
Atherothrombosis 
Atherothrombosis, defined as atherosclerotic plaque disruption with superimposed thrombosis, is the 
leading cause of mortality in the Western world 152. Atherosclerosis is a diffuse process that starts early in 
childhood and progresses asymptomatically through adult life. Later in life, it is clinically manifested as 
coronary artery disease (CAD), stroke, transient ischaemic attack (TIA) and peripheral arterial disease (PAD). 
From the clinical point of view, it should envision this disease as a single pathologic entity that affects 
different vascular territories.  The most important factors in atherothrombosis include activated endothelial 
cells, inflammatory leukocytes (which are a source of thrombogenic stimuli), smooth muscle cells (which 
act as a source of procoagulants and an amplifier of inflammatory responses during thrombosis) and 
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platelets (which act as an important source of further inflammatory mediators and are involved in 
thrombus formation by aggregating). Endothelial dysfunction is a systemic, reversible disorder considered 
the earliest pathologic process of atherothrombosis 153, 154. It is involved in the recruitment of inflammatory 
cells into the vessel wall and in the initiation of atherosclerosis. Endothelial cells produce cytokines, express 
adhesion molecules such as ICAM-1 (intercellular adhesion molecule-1), VCAM (vascular cell adhesion 
molecule-1) and selectins, such as E- or P-selectin, which bind monocytes loosely to the endothelial surface, 
and assist leukocytes and other blood-derived cells in atheroma infiltration.  Secondary changes may occur 
in the underlying media and adventitia, particularly in advanced disease stages. Lesions progress to 
fibroatheroma by developing a cap of smooth muscle cells and collagen. Atherosclerotic lesions can 
progress without compromising the lumen because of compensatory vascular enlargement (positive 
remodelling) 155. Importantly, lipid-rich lesions leading to acute coronary syndromes (ACS) are often mildly 
stenotic, due to significant positive remodelling and therefore are not detectable by angiography. Plaque 
disruption and subsequent thrombus formation is responsible for the onset of most ACSs and strokes. The 
magnitude of the thrombotic process triggered upon plaque disruption is modulated by different elements 
that determine plaque and blood thrombogenicity: local shear rate, tissue factor (TF), apoptotic 
microparticles, circulating monocytes and others. The atherosclerotic and thrombotic processes appear to 
be interdependent and could therefore be integrated under the term “atherothromhrombosis”, a term that 
includes both atherosclerosis and its thrombotic complications 153-156.  In spite of a common 
pathophysiologic pathway, atherosclerotic lesions are very heterogeneous and the “high-risk plaque” of 
each vascular bed has unique characteristics. Insights into the disease have advanced beyond the notion of 
progressive occlusion of the coronary artery into the recognition that plaque disruption and superimposed 
thrombus formation are the leading causes of acute coronary syndromes and cardiovascular death. 
Consequently, plaque composition (as a determinant of risk of disruption), rather than luminal stenosis, has 
become the major determinant of this disease 157. Histologically, these rupture-prone (also called 
vulnerable or high-risk) lesions consist of a large core of extracellular lipid, a dense accumulation of 
macrophages, reduced numbers of vascular smooth muscle cells and a thin fibrous cap. So these plaques 
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are less stable and have a greater propensity to rupture than the fibrous, collagen-rich plaques. Plaque 
disruption usually occurs at the weakest point (“shoulder”), where the cap is often thinnest and most 
heavily infiltrated with inflammatory cells 158.    Once the plaque is disrupted, the highly thrombogenic, 
lipid-rich core, with abundant tissue factor, is exposed to the bloodstream, triggering the formation of a 
superimposed thrombus that leads to vessel occlusion and subsequent ischaemic symptoms distal to it 159. 
 
Role of platelets in atherothrombosis 
The primary role of platelets is to arrest bleeding and promote vessel repair. In addition to preventing 
excess bleeding, platelets also play an important role in surveying and maintaining the integrity of the 
endothelium, in part through the release of pro-angiogenic cytokines and growth factors. Dysregulated 
platelet-endothelial interactions have increasingly been recognized as an important pathogenic mechanism 
in the development of atherosclerosis. In response to specific pro-inflammatory signals, endothelial cells 
become more adhesive toward platelets, stimulating the production of various platelet-derived 
inflammatory molecules that provide a positive feedback loop for further endothelial cell activation. 
Endothelial-bound platelets are highly effective at recruiting leukocytes from flowing blood and also 
enhance leukocyte adhesion and transmigration to the site of the pro-inflammatory stimulus. Therefore, 
pathological derangement of these key interactions among platelets, endothelial cells and leukocytes 
facilitates the inflammatory process that underlies the development of atherosclerosis 137. Under normal 
physiological conditions, platelets circulate in close proximity to the endothelium without forming stable 
adhesion contacts due to the anti-adhesive properties of quiescent endothelial cells. However, after 
vascular injury, platelets rapidly adhere to sites of endothelial disruption to establish a haemostatic plug 
that prevents excess blood loss. This process is critically dependent on the efficiency of platelet adhesion to 
the subendothelial matrix, as well as on the ability of the platelets to undergo rapid biochemical and 
morphological changes that support aggregation and the localized activation of the coagulation cascade. 
After damage to the vessel wall, subendothelial matrix proteins that are highly reactive to platelets, 
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including collagen, von Willebrand factor (VWF), fibronectin and laminin, become exposed to the blood and 
immediately engage specific receptors on the platelet surface. The contribution of specific ligands and 
receptors mediating platelet adhesion is critically dependent on the prevailing blood-flow conditions. 
Under conditions of high shear stress, as encountered in arterioles and stenotic arteries, VWF plays a 
critical role in recruiting platelets from blood flow 140. This tethering function of subendothelial VWF is 
dependent on the interaction of its A1 domain with the glycoprotein Ibα (GPIbα) component of the platelet 
GPIb-V-IX complex 160. Circulating plasma VWF has limited binding potential for GPIbα, however, once 
immobilized onto subendothelial collagen (type I, III, and VI), the unfolded VWF macromolecule provides a 
linear array of A1 domains that facilitate binding to multiple GPIbα receptors 161, 162. The bond between 
GPIbα and VWF has a rapid dissociation rate that is unable to support stable adhesion, requiring the 
contribution of other ligand-receptor interactions to promote stable adhesion 163.  Once tethered to the site 
of vascular injury, platelets form stable adhesion contacts with collagen and other matrix macromolecules. 
Platelet binding to collagen is mediated by GPVI 164, 165 and integrin α2β1 166, whereas fibronectin and 
laminin engage integrin α5β1 and α6β1, respectively 167. Once adherent, platelets undergo a remarkably 
complex series of morphological and biochemical changes that lead to the release of platelet granule 
contents and up-regulation of the adhesive function of integrin αIIbβ3. Activated αIIbβ3 binds multiple 
ligands, including VWF 168, fibrinogen 169, fibrin and fibronectin 170 and is indispensable for the formation of 
stable platelet aggregates 171. Central to platelet activation is the generation and release of soluble agonists 
at sites of vascular injury. These include thromboxane A2 (TxA2) which is synthesized from arachidonic acid 
via cyclooxygenase (COX) and thromboxane synthase, and ADP released from platelet dense granules. 
These endogenous agonists can act in an autocrine or paracrine manner to enhance platelet activation by 
engaging specific G protein coupled receptors: P2Y1 172 and P2Y12 173 (ADP) and the thromboxane receptors 
TPα and TPβ 174; ADP and TxA2 act in a cooperative manner to enhance platelet activation and thrombus 
formation.  In addition to the synthesis and release of soluble agonists, platelets provide a catalytic surface 
for the assembly of coagulation complexes necessary for thrombin generation. Thrombin is among the 
most potent stimulators of platelets through proteolytic cleavage and activation of platelet protease-
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activated receptors (PARs), specifically PAR1 and PAR4, on human platelets 175. Also central to the 
haemostatic function of thrombin is its ability to generate fibrin polymers,  key step stabilizing formed 
thrombi.  
 
 
 
TISSUE FACTOR 
TF biology 
Structure 
Tissue Factor (TF), or Thromboplastin or CD142, the main activator of blood coagulation, is a 47 kDa 
transmembrane glycoprotein containing three domains: an extracellular domain (residues 1-219), a 
transmembrane domain (residues 220-242) and an intracellular domain (residues 243-263). The 
extracellular domain, representing the NH2-terminal part of the molecule, is composed of two fibronectin 
type III domains; it is involved in complex formation with factor VIIa and increases, in a membrane 
dependent fashion, the activity of the protease toward its natural substrates factor IX, factor X and factor 
VII by several orders of magnitude 176, 177. The transmembrane domain anchors TF to the membrane and the 
cytoplasmic COOH-terminal domain is involved in signal transduction (Figure 3) 
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Figure 3. Tissue Factor structure. The 47-kDa membrane bound single polypeptide chain consists of extracellular, 
transmembrane and cytoplasmic domains. There are two intrachain disulfide bridges, shown in blue, in the 
extracellular region which also contains factor VII/factor VIIa binding domain. There are three serine residues, shown 
in red, in the cytoplasmic domain for undergoing phosphorylation. 
 
 
Role 
Tissue Factor is considered the major player in blood coagulation and thrombotic complications of 
atherosclerosis 178. After vascular injury, clotting is initiated by the binding of plasma FVII/FVIIa to tissue 
factor (TF). The TF:FVIIa complex of the extrinsic pathway initiates blood coagulation by activating both FX 
and FIX. The FVIIIa:FIXa complex of the intrinsic pathway provides an alternative route to generate FXa, 
which participates in the prothrombinase complex (FVa:FXa). This complex activates prothrombin to 
thrombin, which plays a central role in the coagulation protease cascade. It activates FXI, which is an 
alternative way to generate FIXa 179, 180. Thrombin also activates FXIII, as well as various cofactors, cleaves 
fibrinogen and stimulates platelets via cleavage of protease activated receptors (PARs). Platelets accelerate 
the activation of the coagulation cascade by binding FXI via the receptor glycoprotein Ib-IX-V and by 
providing a thrombogenic surface for the assembly of the prothrombinase complex (FVa:FXa) 181 (Figure 4). 
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Figure 4. The coagulation cascade. TF:FVIIa complex initiates clotting by activating FX and FIX. Alternatively, FXI can 
activate FIXa. The prothrombinase complex (FVa:FXa) activates prothrombin (PT). Thrombin activates various 
proteases and cofactors. Thrombin cleavage of fibrinogen to soluble monomers (SFM), which are cross-linked by 
FXIIIa, and activation of protease-activated receptors (PARs) on platelets leads to the formation of a clot. from 
Arterioscler Thromb Vasc Biol. 2004;24:1015-1022 
 
TF is expressed in subendothelial cells, such as in smooth muscle cells and fibroblasts; endothelial cells do 
not express TF under physiological conditions but it may be stimulated by various cytokines.  The only 
physiologic inhibitor of the TF-FVIIa complex is the tissue factor pathway inhibitor (TFPI), a serine protease 
synthesized mainly by the vascular endothelium. A small percentage of TFPI is found also in platelets or in 
plasma, free or associated with lipoproteins. 
Although the main physiologic function of TF is the regulation of the processes of haemostasis and 
thrombosis, emerging evidence showed a broad spectrum of biological function for TF.  In fact, Tissue 
Factor is involved in many pathological conditions: cardiovascular complications 182, angiogenesis 183, tumor 
metastasis 184, wound repair, embryonic development, cell adhesion and migration, autoimmune disorders. 
Cardiovascular complications are closely associated with either inflammation or thrombosis and TF plays a 
major role in their pathogenesis. TF has been shown to be present in atherosclerotic plaques 185; in 
atherosclerosis, TF is expressed by macrophage-derived foam cells within atherosclerotic plaques 186. 
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Moreover, TF levels are higher in atheroma from patients with unstable angina compared with stable 
angina 187. These results strongly suggest that high levels of TF exposed upon plaque rupture trigger 
thrombosis and myocardial infarction (Figure 5). Thus, the classical view of TF is that it is expressed locally 
within an atherosclerotic lesion. Inhibition of TF would be expected to reduce thrombosis associated with a 
variety of diseases 181. Vessel-wall associated TF, however, does not entirely explain the thrombogenic 
potential of vascular lesions when they are exposed to flowing blood. It has been proposed that thrombus 
growth might be promoted by circulating (i.e., microparticles or platelet-associated) TF 188.    
 
Figure 5. Role of TF in thrombus formation after rupture of an atherosclerotic plaque. TF expressed by foam cells 
(orange) and in the necrotic core (yellow) of the plaque would be exposed to clotting factors in the blood and initiate 
clotting after plaque rupture. In addition, blood-borne TF may contribute to thrombus propagation. TF is constitutively 
expressed by adventitial cells (blue). EC, endothelial cells; SMC, smooth muscle cells. from Arterioscler Thromb Vasc 
Biol. 2004;24:1015-1022 
 
Moreover TF hypercoagulability leads to cardiovascular complications and vascular disease such as arterial 
hypertension 189, hypertrophy 190 and acute coronary syndrome 182, 191. In condition of hyperglycaemia, such 
as T2DM, the increased circulating advanced glycation end products (AGEs) lead to an increased expression 
of Tissue Factor 192; TF can also assume a pathogenic role in diabetic progression in a close relation with the 
inflammatory process: in fact, TF could be responsible for insulin resistance 193, 194.  
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Platelet-associated Tissue Factor 
At the beginning of 2000, Rauch et al. proposed that thrombosis occurring upon plaque rupture does not 
necessarily require the exposure of vessel wall-TF 195. In fact, platelets can be a source of active TF, the so 
called “blood-borne” TF or “circulating” TF, which can sustain the activation of the blood coagulation on the 
edge of a growing thrombus. Circulating TF is associated with increased blood thrombogenicity 196 and 
procoagulant microparticles (MPs) was found in human blood under normal and pathological conditions 188, 
197.  In the 2000, Rauch and Nemerson published the finding that TF-positive microparticles, released by 
activated monocytes, were up taken by activated platelets through a CD15-P-selectin transfer mechanism: 
platelet-associated TF, resulting from TF-positive MPs transfer, is an alternative source of procoagulant 
activity 198. In 2003 Camera et al 199 and Muller et al 200 showed the evidence that human platelets from 
healthy subjects express TF antigen, using different approaches (western blotting, confocal and immune 
electron microscopy). Moreover, Camera and colleagues reported, by using flow cytometry, that platelet 
activation resulted in the expression of TF besides other platelet activation markers (such as P-selectin), on 
platelet surface. The presence of TF protein and its functional activity was further confirmed showing the 
bindings of this protein to its physiologic ligand FVIIa and the capacity to generate FXa 199.  Moreover, TF 
mRNA was found in a sample of resting platelets depleted from leukocytes contamination, suggesting that 
platelets could perform de novo protein synthesis 33. Three years later, two independent groups provided 
the evidence that platelet activation results in the translation of TF mRNA, increasing the membrane-bound 
TF protein 201, 202. At present, published data suggest that three are the possible mechanisms responsible for 
the presence of TF in human platelets:  
1) the transfer from TF-positive MPs released by activated endothelial cells or leukocytes (as proposed by 
Rauch and Nemerson in 2000 195); 
2) the storage of TF protein within the alpha granules 203;  
3) the de novo protein synthesis from specific TF mRNA 201, 202. 
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 All these mechanisms are not mutually esclusive and one mechanism may dominate over the others 
depending on the pathophysiologic conditions (Figure 6). 
 
 
Figure 6. Schematic view of the three possible mechanisms responsible for the presence of TF in human platelets  
 
As shown above, previous studies carried out in our laboratory showed that in vitro platelet activation by 
classical agonists results in expression of functionally active TF  on the cell membrane 199. Furthermore, in 
2008, our group showed that NSTEMI patients have a greater number of TF positive platelets and platelet-
monocyte aggregates compared to stable CAD patients or healthy subjects, providing additional insight into 
the prothrombotic potential of CAD platelets 204.  The finding that both TF mRNA and protein are 
significantly higher in platelets from NSTEMI patients than in stable CAD patients supports the idea that 
platelets from stable CAD and ACS patients are potentially preconditioned to a different degree of reactivity 
on the transcriptional level 204, 205. 
In conclusion, platelet activation not only results in thrombus formation, but also leads to de novo protein 
synthesis through rapid and highly regulated translation of pre-existing megakaryocyte-derived mRNAs 206.  
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PLATELET AND PLASMA PROFILE IN CHRONIC KIDNEY DISEASE 
Platelet activation profile and CKD 
Patients with CKD suffer from complex haemostatic disorders. Uremic patients show a bleeding diathesis 
that is mainly due to abnormalities of primary haemostasis.  However these patients present also a high 
prevalence of cardiovascular and thrombotic complications.  
Indeed, platelet activation in CKD patients is a controversial issue: some authors have described a 
decreased platelet activation in these patients 207-212, while others a higher platelet activation 213-216. 
In 2004, Boccardo et al 207 described that ESRD patients present a decreased platelet function, although 
these patients have a high prevalence of cardiovascular and thrombotic complications. Patients with CKD 
show a bleeding diathesis, mainly due to abnormalities of primary haemostasis, although the pathogenesis 
of uremic bleeding is multifactorial; the interactions between platelet-platelet and platelet-vessel wall 
appear to be of crucial importance. Platelet dysfunction in uremic patients is partially due to uremic toxins 
present in circulating blood; platelet dysfunction arises by diverse mechanisms: for example, abnormalities 
of platelet alpha-granules consisting of storage pool defect denoted by reduction in ADP and serotonin and 
elevated cAMP levels in patients with terminal renal insufficiency, that may contribute to defective platelet 
aggregation and adhesion to injured vessels 208.   Interaction of platelets with vessel wall play a crucial role 
in promoting haemostasis at the site of the vessel lesion: decreased binding of both vWF and fibrinogen to 
stimulated uremic platelets may account for the defective function of the α2β3 complex in these patients. 
In particular the impaired binding activity is caused by dyalizable toxic substances 209, 210 or it is due to α2β3 
receptor occupancy by fibrinogen fragments present in uremic plasma, that prevent the cross-linking 
between adjacent platelets to form aggregates 211.  On this regard, in 1999, Kozek-Langenecker and 
collegues 212  reported that fibrinogen fragments, usually absent in human blood, but present in uremic 
plasma, may play a role in uremia platelet dysfunction. They described that adding fibrinogen fragments to 
normal PRP or isolated platelets, platelet aggregation decreases both in PRP as well as in isolated platelets. 
Moreover, they confirmed that fibrinogen fragments diminish the expression of activated GP IIb/IIIa. So 
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these data provide further support to the role of fibrinogen fragments in causing uremic platelet 
dysfunction.  
In literature it is also described that blood platelet activation and platelet interaction with circulating cells 
may increase the cardiovascular disease risk of patients with chronic kidney disease 213, 216.  Atherosclerotic 
cardiovascular disease is a major cause of morbidity and mortality in patients with renal disease 216. 
Although “traditional” atherothrombotic risk factors, such as hypertension, dyslipidemia and diabetes 
mellitus, may account for a large proportion of the excessive burden of cardiovascular disease in CKD 
patients, recent studies suggest that “non-traditional” risk factors, such as inflammation, oxidative stress 
and vascular calcification, may also contribute 64.  
Furthermore, CKD is also associated with a worse prognosis in patients undergoing PCI 68, 217-219, which is 
possibly attributable to inadequate platelet inhibition by standard antiplatelet therapy 220, 221. The 
successful treatment of coronary artery disease and cerebrovascular disease is frustrated by aspirin 
resistance (AR) 222-228.  Cardiovascular disease and thrombosis are common and often fatal complications of 
CKD, possibly due to excessive platelet activity 229-233.  In 2012, Blann and collegues 234 reported an 
association between AR and CKD. Patients who are AR (deﬁned by both arachidonic acid response by light 
transmission aggregometry) have lower GFR and have higher soluble P-selectin than patients who are 
sensitive to aspirin. As the platelet expression of CD62P (P-selectin) and increased soluble P-selectin both 
mark platelet activation 214, 231, 235-238, thus patients with the worse GFR have the greatest degree of platelet 
activation.  Despite being on aspirin, authors reported that patients still have increased platelet activity 
(soluble P-selectin, surface expression of CD62P) compared to the healthy controls, reﬂecting continuing 
alpha granule degranulation 239. Indeed, this alone may partially explain the continuing thrombosis risk 
despite the use of this drug and supports the hypothesis that aspirin does not inhibit the degranulation of 
alpha granules or the appearance of P-selectin at the surface of the platelet 214, 240-242. Also Thijs et al 213 
described blood platelet activation, evaluated as platelet surface expression of P-selectin and GP IIb/IIIa 
(PAC1), in patients with renal impairment: the expression of P-selectin and PAC1 is statistically significantly 
inversely related to the glomerular filtration rate in these patients.  CKD patients not only may present 
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aspirin resistance, but recent findings from placebo-controlled trials suggest that patients with decreased 
renal function might not accrue equal therapeutic benefit of clopidogrel as compared to patients with a 
normal renal function 119, 243.  In 2014, Breet et al 215 showed that patients with CKD have significantly higher 
platelet reactivity, determined in parallel by ADP- and AA-induced light transmittance aggregometry (LTA) 
and the VerifyNow System (P2Y12 and Aspirin). Patients with CKD more frequently have high on-
clopidogrel platelet reactivity (HCPR) and high on-aspirin platelet reactivity (HAPR) regardless of the 
platelet function used: high on-treatment platelet reactivity strongly influences the occurrence of 
atherothrombotic events in these patients. 
Uraemia and dialysis induce a pro-inﬂammatory state, with widespread microvascular and circulatory 
changes 244. Long recognized as having a role in inﬂammation, besides platelets, also platelet–leukocyte 
aggregates are known to contribute to ongoing injury at atheromatous sites and in plaque disruption 245.  In 
2002, Ashman et al 216 investigated circulating platelet–leukocyte interactions as a potential cardiovascular 
risk factor in CKD (continuous ambulatory peritoneal dialyzed (CAPD) and haemodialyzed) patients with no 
evidence of cardiovascular disease. Circulating platelet–monocyte aggregates are signiﬁcantly increased in 
parallel with a signiﬁcant reduction in PSGL-1 expression on monocytes in CKD patient compared with 
normal controls. The presence of higher platelet–monocyte aggregates in dialysis patients was associated 
with increased cardiovascular events.  After at least 1 year’s follow-up, eight patients of 11 within the group 
with higher platelet–monocyte aggregates have evidence of cardiovascular disease or have died for a 
cardiac death. In 2001, Furman et al 246 showed that when patients had 15.3 ± 3.0% platelet–monocyte 
aggregates, they were proven subsequently to have a myocardial infarction: they assessed that circulating 
platelet–monocyte aggregates are an early marker of myocardial infarction. 
Platelet–monocyte aggregates found in CKD patients are associated with cardiovascular events and they 
may contribute to local thrombotic changes in acute plaque erosion and in the evolution of atherosclerosis, 
but may yet prove an epiphenomenon reﬂecting widespread inﬂammatory changes in the microcirculation 
associated with uraemia.  
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Transcriptome and CKD  
There is now extensive evidence from a wide variety of approaches that suggests renal disease in the 
general population has a genetic component. Multiple techniques have been employed in an effort to 
identify genes that contribute to this genetic susceptibility 247. Many studies have now been carried out 
assessing the contribution of specific “candidate genes” that are involved in renal pathogenesis. Many 
efforts have been made to link specific genes or small numbers of related genes to various forms of renal 
disease in the general population. Recent genome-wide association studies (GWASs) using estimated 
glomerular filtration rate (eGFR) as the phenotype of interest have identified several loci that may affect 
renal function 248, 249: 13 new loci affecting renal function and CKD (in or near LASS2, GCKR, ALMS1, TFDP2, 
DAB2, SLC34A1, VEGFA, PRKAG2, PIP5K1B, ATXN2, DACH1, UBE2Q2 and SLC7A9) and 7 loci suspected to 
affect creatinine production and secretion (CPS1, SLC22A2, TMEM60, WDR37, SLC6A13, WDR72 and 
BCAS3). These loci potentially influence nephrogenesis, podocyte function, angiogenesis, solute transport 
and metabolic functions of the kidney 250.   In 2012 Plé and colleagues 251 reported that platelet 
abnormalities and changes in platelet proteome, that occur in circulating platelets exposed to uraemic 
toxins 252, could be subsequent to changes in the composition  and/or  regulation  of  the  platelet  
transcriptome. They observed that platelet mRNA and microRNA transcriptome is altered in CKD patients 
and could be restored partially upon dialysis. In particular, the level of metallothionein-encoding genes, 
such as MT1X, is increased in platelets of both uraemic and dialysis patients, in which plasma zinc 
deficiency is common 253. Particularly abundant in platelets and involved in platelet reactivity and 
haemostasis 254, zinc imbalances are involved in oxidative stress 255, a state that induces expression of 
metallothionein genes 256. Elevated levels of platelet metallothionein genes may thus result from the 
altered zinc homeostasis and oxidative stress conditions that prevail in uraemic and dialysis patients and 
that may contribute to the relatively high prevalence of CVD in these patients 257, 258. Additional genes 
deregulated in platelets of CKD patients could be linked to platelet-related disorders observed in uraemia. 
For instance, the mRNA encoding for LPAR4, which is suspected to inhibit platelet reactivity to 
lysophophatidic acid 259, is reduced by ∼ 50% in CKD patients.  Lysophosphatidic acid accumulation in 
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atherosclerotic lesions represents an important risk factor for the development of atherosclerosis and 
thrombosis 260 and the observed decrease in LPAR4 expression in CKD patients may explain the increased 
risk of cardiovascular events observed in these clinical cases. The authors also identified genes involved in 
lipid metabolism, such as glycine N-acyltransferase-like 2 (GLYATL2), phospholipase  C  eta  1  (PLCH1),  
phosphatidylcholine  transfer  protein (PCTP), OSBP2 and SERINC1, whose levels are deregulated in uraemic 
conditions. This may partially explain the altered synthesis of bioactive lipids 261, 262 and membrane lipid 
composition 263, 264 observed in platelets of uraemic patients.  The conditions associated with CKD did not 
affect the ability of platelets  to  synthesize  or  mediate  the  function  of  microRNAs.  However,  they 
observed  an  important  alteration  of  the  platelet microRNA profile in uraemic patients, as a total of 21 
(such as  miR-33a and -33b, miR-142-5p and -3p, miR-340 and -340*), out of 247 microRNAs expressed in 
platelets, displayed more than two-fold changes,  as  compared  to  healthy  subjects.    
As described before, CKD patients have a markedly increased morbidity and mortality, especially caused by 
cardiovascular disease (CVD) and specific mRNAs may vary in clinical conditions, such as ST-elevation 
myocardial infarction (STEMI) 265.  In 2011, our group 205 tested the hypothesis that patients with acute 
coronary syndrome (ACS) have different platelet mRNA composition compared to patients with stable 
angina (SA), assuming that platelets may be more thrombogenic on the transcriptional level. Heterogeneity 
of mRNA expression, particularly in the ACS population, is evident from the heat map of the gene 
expression proﬁles. Unsupervised hierarchical analysis show that differential expression proﬁles allowed 
clustering of SA patients in a distinct homogeneous group. On the contrary, non-ST-elevation myocardial 
infarction (NSTEMI) patients present a higher degree of inter-individual variation, which is conﬁrmed by 
qRT-PCR analysis on individual patients. This heterogeneity further supports the concept that differential 
gene expression does exist in CAD platelets and may be responsible for different degrees of activation and 
thrombogenicity in these patients. This is consistent with our previous observations on platelet-associated 
TF expression in CAD patients and on the prothrombotic potential of NSTEMI platelets 204: indeed, TF mRNA 
and protein are signiﬁcantly higher in NSTEMI than in SA resting platelets. Transcriptomic analysis provide 
consistent evidence that three genes (BAIAP2, CLTA and GP1BB) have a higher expression in NSTEMI in 
 53 
 
comparison with SA platelets, at both mRNA and protein level. A fourth transcript (PKIG) shows a higher 
expression in NSTEMI samples.  BAIAP2 and GP1BB belong to one of the modulated functional gene 
categories (cell surface receptor linked signal transduction). Perturbation of this biological process and, 
likely, of cell adhesion function may be involved in the platelet increased reactivity and prothrombotic 
potential found in NSTEMI. GP1BB up-regulation in NSTEMI highlights the role for the von Willebrand factor 
(VWF) pathway, as it is part of the GPIb-IX-V complex that forms VWF receptor. Binding of the GPIb-IX-V 
complex to VWF facilitates platelet adhesion to vascular endothelium at sites of injury and initiates a 
signalling cascade that leads to platelet activation, aggregation, haemostasis, and thrombosis. Consistent 
with this observation, authors found that PKIG, a potent inhibitor of cAMP-dependent protein kinase (PKA) 
266, is up-regulated in NSTEMI: an up-regulation of PKIG could mediate a higher degree of platelet reactivity 
and also potentiate the effect of GP1BB over-expression. BAIAP2 is involved in structural changes of the 
actin cytoskeleton downstream of the Rho GTPases Cdc42 and Rac 267, which are involved in the formation 
of membrane protrusions, such as lamellipodia and mediate platelet shape change 268. CLTA increased 
expression in NSTEMI platelets may affect intracellular trafﬁcking and GPCR signaling 269.   Platelet gene 
expression proﬁling reveals quantitative differences between ACS and stable CAD. The study provided 
evidence that NSTEMI platelets are potentially preconditioned on the transcriptional level to a higher 
degree of reactivity, which eventually lead to the thrombotic event. 
 
Plasma and platelet proteome and CKD 
Besides the traditional risk factors, such as hypertension, dyslipidemia and diabetes mellitus, also non-
traditional risk factors, such as inflammation, oxidative stress and vascular calcification, may contribute to 
CVD events in CKD patients 270. The prevalence and extent of vascular and valvular calcification and arterial 
stiffness are strong predictors of CVD and all-cause mortality in CKD patients. The chronic inflammation 
present in these patients may promote vascular calcification and, in particular, mediators and inhibitors, 
such as leptin 271, matrix-gla protein 272, tumor necrosis factor 273, bone morphogenetic protein 274, 
osteoproteogerin 275 and fetuin A 276 may be related to a process of accelerated vascular calcification.  In 
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particular, it has been demonstrated that CKD patients present low levels of fetuin A (also called alpha 2-
Heremans Schmid gly-coprotein [AHSG]), a plasma protein that inhibits ectopic calcium-phosphate 
production, precipitation and vascular calcification 277. Low fetuin A levels correlates with inflammation, 
accelerated atherosclerosis and CVD in uremic patients 270 and could, at least in part, explain the high 
prevalence of vascular calciﬁcation in this population. Since it has been demonstrated that at least four 
polymorphisms  exist  in  the  AHSG  gene  (at  amino acid  positions Thr248Met [C→T], Thr256Ser [C→G], 
Asp276Asn [G→A] and Arg317Cys [C→T]), genetic polymorphisms may have an effect on circulating levels 
of this protein 278.    Indeed, a recent study 270 showed that ESRD patients with the AHSG 256Ser allele have 
lower serum fetuin-A levels and higher all-cause and cardiovascular mortality  rates. Thus  these 
observations  suggest  a  signiﬁcant  gene–environment  interaction  in  which  the  involvement  of 
inﬂammatory processes may further enhance the adverse effects of low circulating fetuin-A levels.  
In 2011, Luczak et al 279 carried out a comparative proteomic analysis of blood plasma proteins from 
patients in various stages of renal dysfunction (CKD group) and healthy volunteers (HV group). In this study 
they wanted to assess whether and how the progression of CKD influences the composition of blood 
plasma proteins; the analysis between CKD and HV plasma proteome reveals that there are 4 proteins at 
different levels: alpha-1-microglobulin (α-1-m), apolipoprotein A-IV (apo-A-IV), γ-fibrinogen (Fb) and beta-
haptoglobin (Hp). As far as the plasma levels of α-1-m is concerned, there is a linear correlation between 
protein concentration and CKD progression; also for the plasma levels of apo-A-IV, authors found a 
significant increase of protein accumulation during the initial phase of the disease. These data suggest that 
α-1-m and apo-A-IV may find practical application as early markers of nephropathy. 
Also platelet proteome could be affected by chronic kidney disease: in fact, in 2010 Marques and collegues 
252 showed that platelet protein expression profile is altered in CKD patients. They analyzed the differences 
in the expression of proteins associated with the cytoskeleton and platelet-cell interaction energetic 
metabolism and oxidative  stress in normal and dysfunctional platelets from uremic patients. The main 
finding is that the platelet  expression  of  actin-interacting  protein-1  isotype  1,  a cytoskeleton-related  
protein,  is  down-regulated in  the dysfunctional  uremic  platelets.  Moreover,  integrin IIb, a protein 
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associated with platelet-cell interaction and  the oxidative stress-related proteins, glutathione-S-transferase 
isotypes 1 and 2 and peroxiredoxin VI, are up-regulated in dysfunctional uremic platelets when they were 
compared with the uremic platelets with normal functionality.  These observations may be in accordance 
with previous published results in which abnormalities have been reported in the organization of 
cytoskeleton in platelets from uremic patients, including a decreased association of actin-interacting 
protein with the cytoskeleton 280. 
Several studies have unequivocally demonstrated that oxidative stress is increased in uremic patients 281, 
282. Since in platelets, the main focus of oxidative stress is platelet activation 283, in the dysfunctional uremic 
platelets, the up-regulation of antioxidant-related enzymes, such as peroxiredoxin VI and the glutathione-S 
transferase isotypes 1 and 2, may mitigate the prostimulating platelet effect of circulating oxidative 
molecules, such as reactive aldehydes, oxidized thiols and lipid  peroxidation  products,  reducing  platelet  
functionality. 
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AIMS OF THE STUDY 
Chronic kidney disease (CKD) is emerging as a major health problem 3, 284, 285. Patients with CKD are at high 
risk of cardiovascular diseases and cerebrovascular diseases and they are more likely to die of CVD than to 
develop terminal renal failure 15. ‘Traditional’  atherosclerotic  risk  factors, such as diabetes, hypertension, 
dyslipidemia and older age, have  been  found  to be independent predictors of CVD in CKD 15, 286, 287.  In 
addition, haemodynamic and metabolic factors, such as volume overload, anemia, calcium and phosphorus 
imbalance, chronic inﬂammation and a hypercoagulable milieu are unique features of chronic kidney 
disease, that may contribute to the risk and pathogenesis of  CVD 288.  
CKD increases bleeding risk on one hand and thrombosis risk on the other 289.  The bleeding tendency of 
patients with uraemia is characterized by haemorrhagic symptoms and by abnormal prolongation of 
bleeding time. This bleeding tendency has been attributed classically to abnormalities of platelet function 
that include impaired adhesion 290 and decreased aggregation 290, 291 and to alteration in the balance of pro- 
and anti-thrombotic factors in blood 292, 293. On the other hand, blood platelet activation and platelet 
interaction with circulating cells increase the risk of thrombosis and, consequently, of cardiovascular events 
in CKD patients 213, 216.             
 CKD may also influence the response to antiplatelet therapy 119, 243.  Patients with CKD might have reduced 
Clopidogrel-induced platelet inhibition due to a speciﬁc impairment of the P2Y12 pathway 220, 294, 295. 
Moreover, despite the use of Aspirin, in some patients (~10%) thrombosis still occurs and this has lead to 
the concept of a ‘suboptimal response to aspirin’, also described as ‘high on-treatment platelet reactivity’ 
or ‘aspirin resistance’ (AR) 222, 223. This suboptimal response in patients undergoing percutaneous coronary 
intervention is associated with increased risk of thrombosis and increased major adverse clinical events 
(MACE) in long term follow-up 224-226, 296.   
Activated platelets express a great variety of molecules relevant for the atherothrombotic processes, 
including membrane glycoproteins involved in adhesion, aggregation and coagulation. In 2003, our group 
has shown that in vitro platelet activation by classical agonists results in expression of functionally active 
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Tissue Factor (TF), a major actor in the coagulation cascade and thrombotic complications of 
atherosclerosis 199.  In 2008, we have also provided evidence that patients with non-ST elevation myocardial 
infarction (NSTEMI) have a higher number of TF-positive platelets and platelet-monocyte aggregates than 
stable CAD patients or healthy subjects, providing additional insight into the prothrombotic potential of 
CAD platelets 204.  However, no study has been carried out so far to investigate whether the expression of 
platelet-associated TF may provide further insights into the bleeding or thrombotic risk of CAD patients 
with CKD. 
In 2003, Gnatenko et al 143 has shown for the first time that platelets have a transcriptome and that they 
contain between 2000 and 7000 transcripts derived from megakaryocytes; platelets can use their 
transcriptome to perform de novo protein synthesis in response to activation, thus modifying their 
proteome and, as a consequence, their function. Our group  has previously shown that specific changes in 
the expression/distribution or amount of platelet mRNAs and proteins are associated with CAD, suggesting 
that platelet are potentially preconditioned to a different degree of reactivity on the transcriptional level205. 
However no information is still available on the changes that may occur in platelet transcript profile in CAD 
patients with CKD.  
The plasma proteomic profile may also vary in pathologic conditions: the incorporation of proteomics into 
cardiovascular research provide a means of exploring the mechanisms of disease onset and progression.  
Proteomics have the potential to reveal those proteins that are associated with pathogenesis and could be 
potentially used as predictive or prognostic markers 297.  In end-stage renal disease (ESRD) patients, CKD 
influences the expression of plasma proteins involved in the development of atherosclerosis 252, 298-300.                
No study focused on the plasma protein changes that may occur in CVD patients with mild-to-moderate 
CKD has been yet carried out.  
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Based on this rational, the general aim of this study is to provide insights into 1) the platelet phenotype, 2) 
the platelet transcriptomic profiles, 3) the plasma proteomic profiles in CAD patients with and without CKD.   
In particular, the specific aims of the present project are to investigate:  
- platelet- and leukocyte-associated TF expression in order to better characterize the platelet 
haemostatic capacity of these patients and to assess whether platelet TF could contribute to the 
increased prothrombotic propensity or to the bleeding risk characteristic of CKD patients; 
- the global haemostatic function of whole blood, studying parameters that describe clot properties 
during its formation, in order to correlate blood parameters with the haemorrhagic/thrombotic 
phenotype present in these patients; 
- the platelet transcriptome, in order to gain insights into the molecular pathways associated with 
CKD and cardiovascular disease, and to identify potential predictive platelet biomarkers for 
classifying patients; 
- the plasma proteome, in order to reveal differentially expressed proteins in patients with CKD and 
cardiovascular disease and could be potentially used as predictive or prognostic biomarkers. 
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METHODS 
STUDY DESIGN 
The present project is an observational, case-control, and cross-sectional study. All the enrolled subjects 
were recruited at Centro Cardiologico Monzino IRCCS and gave their written, informed consent to 
participate in this study after receiving oral and written information; the investigation conforms to the 
principles outlined in the Declaration of Helsinki and was approved by our local Ethical Committee. 139 
consecutive acute coronary syndrome (ACS) patients, 31 with chronic kidney disease (CKD) and 108 without 
CKD, and 217 stable angina (SA), 49 with CKD and 168 without CKD were enrolled from December 2012 to 
April 2014. We also recruited 37 healthy subjects (HS) as control.  
 
Inclusion criteria: 
- Non-ST-segment elevation myocardial infarction (NSTEMI) (for the group of ACS patients): deﬁned 
as chest pain at rest with documented transient ST-segment depression or T-wave inversion in at 
least two contiguous electrocardiographic leads, without pathological Q-waves, with or without 
enzymatic evidence of myocardial necrosis.  The last spontaneous episode of chest pain had to 
have occurred within the 24 hours preceding study entry. All of the patients underwent coronary 
angiography in order to conﬁrm the presence of signiﬁcant coronary artery stenosis, which was 
deﬁned as the presence of at least one >75% stenosis in any major epicardial coronary vessel; 
- Stable CAD (for the group of SA patients): diagnosis was made, according to the AHA criteria, based 
on typical chest pain on exertion associated with ST segment depression >1.0 mm on an exercise 
test, and a coronary angiography that confirms the presence of significant coronary artery stenosis 
(≥75%). 
- CKD: diagnosis of chronic kidney disease only in the presence of glomerular filtration rate (GFR) <60 
ml/min/1.73m2. 
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Exclusion criteria: 
- Patients older than 80 years; 
-  Valvular heart disease, atrial ﬁbrillation, thyrotoxicosis, a history of haemorrhagic diathesis, 
platelet disorder or thrombocytopenia, malignancies, inﬂammatory diseases, major surgery or 
trauma within the preceding month, or severe liver disease.  
 
 
BIOLOGICAL MATERIAL COLLECTION 
At study admission, peripheral venous blood samples were collected without stasis, with a large bore 
needle (19G), discarding the first 4 mL, from each patient in order to:  
- performe fresh whole blood flow cytometry analysis of platelet activation; 
- study the global haemostatic function of whole blood by Rotem; 
- isolate platelets for transcriptome analysis; 
- separate plasma for proteomic studies. 
 
ASSESSMENT OF PLATELET PHENOTYPE BY FLOW CYTOMETRY 
Platelet activation has been evaluate by whole blood flow cytometry with a fluorescence-activated-cell 
sorter (FACS) Calibur (Becton Dickinson), using specific fluorochrome-labeled monoclonal antibodies; the 
immunostaining has been performed as previously described 199, 204, within 15 minutes after blood sampling 
to avoid artificial platelet activation. The sensitivity of fluorescence detectors has been set and monitored 
using CaliBRITE beads (Becton Dickinson) according to the manufacturer’s instruction.  
For this analysis, it was used blood collected into tubes with 0.129 mol/L buffered sodium citrate (3.8% 
sodium citrate) (vacutainer, Becton Dickinson, BD).  
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The expression of the following platelet activation markers has been assessed: Tissue Factor, P-selectin 
(CD62P) and activated glycoprotein IIb/IIIa (GP IIb/IIIa, PAC1).  Platelet activation has been also studied as 
formation of platelet-leukocyte aggregates, by specific antibodies (a leukocyte marker, such as CD45; a 
platelet marker, such as CD41; and a specific activation marker, Tissue Factor). Saturating concentrations of 
the following mouse anti-human monoclonal antibodies were used: CD41-PE (Instrumentation Laboratory, 
IL), also known as integrin α2b or GPIIb and used as a marker of platelet population; PAC1-FITC (Becton 
Dickinson, BD); CD62-FITC (IL); CD45-PerCP (BD); TF4507CJ-FITC (American Diagnostica, AD). FITC-, PE-, 
PerCP-conjugated isotype controls were used in all the experiment to quantify the background labeling.  
Briefly, for platelet activation staining, 5 µl of whole blood has been added to phosphate buffer saline (PBS 
1X, pH 7.4, Life Technologies) to a final volume of 100 µl in presence of saturating concentration of the 
above described antibodies (a sample was prepared for each marker of platelet activation and co-stained 
with CD41).  All the sample have been prepared to assess surface platelet activation marker expression in 
resting conditions and upon stimulated condition (prepared following the same labeling of the resting 
sample except for co-incubating ADP 10 µM, Sigma, together with antibodies, blood and PBS in a final 
volume of 100 µl). Samples have been incubated at room temperature for 15 minutes (kept away from 
light). Then, they have been diluted with 600 µl of paraphormaldeid (PFA, final concentration 1%; Sigma) to 
obtain fixation. Finally, they have been kept in the dark until analysis at FACSCalibur. Platelets positive to 
activation markers have been determined in 10.000 CD41-positive events per sample. 
All the data have been analyzed by CELLQuest software (Becton Dickinson, BD) and the results will be 
expressed as percentage of positive cell and as mean fluorescence intensity (MFI), calculated for the gated 
population. 
For the assessment of platelet-leukocyte aggregates, 100 µl of whole blood have been stained with 
saturating concentration of the above described antibodies; platelet-leukocyte formation has been studied 
in resting conditions and upon stimulated condition (prepared following the same labeling of the resting 
sample except for co-incubating ADP 10 µM). As previously described for platelet activation marker 
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assessment, samples have been incubated at room temperature for 15 minutes (kept away from light) and 
then diluted with 700 µl of BD Lysing Solution (10X diluited 1:10 with room temperature deionized water; 
final concentration 1X) for lysing red blood cells. Finally, they have been kept in the dark until analysis at 
FACSCalibur. Platelet-monocyte and -granulocyte aggregates have been determined in 1000 CD45-positive 
monocytes and 5000 CD45-positive granulocytes per sample. 
All the data have been analyzed by CELLQuest software (Becton Dickinson, BD) and the results will be 
expressed as percentage of platelet-leukocyte aggregates and TF-positive platelet-leukocyte aggregates. 
Assessment of platelet intracellular TF has been performed on 50 µl of whole blood previously fixed with 
PFA 1%; after 2 hours of cell fixation, blood has been washed with  PBS and centrifuged at 1500 g for 5 
minutes. Then, pellet have been resuspended with 100 µl of PBS-Triton 0,1% (Triton X-100, Carlo Erba) to 
obtain permeabilization of cell membrane and antibodies access to the antigen in the intracellular 
compartment. After 10 minutes, blood has been added with saturating concentration of the following 
mouse anti-human monoclonal antibodies: TF4508CJ-FITC (BD) and CD41-PE (IL). After 15 minutes of 
incubation in the dark, washing in PBS, centrifugation as before described and resuspension in PBS have 
been performed. TF-positive platelets have been determined in 10.000 CD41-positive events per sample. 
All the data were analyzed by CELLQuest software (Becton Dickinson, BD) and the results will be expressed 
as percentage of positive cell calculated for the gated population. 
 
PLATELET ISOLATION FROM WHOLE BLOOD 
Blood collected into three acid citrate dextrose (ACD) -containing vacutainers (BD) has been processed 
within 15 minutes from sampling and platelets have been isolated by centrifugation and filtration. 
Particular care has been taken in using an isolation technique that minimizes non-specific platelet 
activation and leukocyte contamination.  Briefly, whole blood has been centrifuged at 100 x g for 10 
minutes, at room temperature, without break, in order to obtain platelet rich plasma (PRP). PRP has been 
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transferred into a new tube, added with 4 µM prostaglandin (PG)E1 and 10 µM EDTA. All PRP obtained has 
been diluted 1:3 in HEPES-Tyrode’s buffer (by adding 2 volumes of HEPES Tyrode’s buffer to PRP volume). 
HEPES-Tyrode’s buffer’s composition is the following: 10 mmol/L HEPES, 134 mmol/L NaCl, 2,9 mmol/L KCl, 
1 mmol/L MgCl2, 12 mmol/L NaHCO3, 0,4 mmol/L Na2HPO4, 0,1% glucose, 5 mmol/L EDTA, 1 µM PGE1); all 
reagents are purchased from Sigma. Diluted PRP has been filtered through Filter Pall Purecell™, which 
captures residual contaminating leukocytes, whereas platelets pass through the filter and are collected in a 
new tube. Filter is washed with 2 volume of HEPES-Tyrode’s buffer in order to recover all platelets. 
Filtered PRP is then divided, since a volume corresponding to at least 800 million of platelet is necessary for 
transcriptome studies. Filtered PRP is analyzed by haematologic analyzer Sysmex (Sysmex XS-1000, Dasit) to 
obtain the platelet count and to assess the eventual presence of contaminating leukocytes. A samples of 
this PRP is used for the assessment of platelet activation: it has been stained with CD62P-FITC (IL) and 
CD41-PE (IL) and a comparison of P-selectin value in this sample with the value in fresh whole blood to 
confirm that the procedure does not lead to non-specific platelet activation has been performed; also 
leukocyte contamination has been assessed by flow cytometry analysis (staining with CD45 PerCP, BD). 
Only those preparations with less than 5 leukocytes per 105 platelets, without sign of activation are used for 
genomic analysis. 
The sample volume for transcriptome analysis has been centrifuged at 754 x g for 8 minutes and lysed in 
500 µL of QIAzol Lysis Reagent (QIAGEN), immediately frozen till RNA extraction. 
 
PLASMA PREPARATION FOR SUBQUENT PROTEOMIC STUDIES 
Blood collected into citrate-containing tubes has been centrifuged at 1700 x g for 10 minutes at 4°C. 
Plasma from the 0.129 mol/L buffered sodium citrate vacutainer has been placed in tube and quickly 
aliquotated in small volumes (200 µL) and frozen at -80°C. 
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EVALUATION OF WHOLE BLOOD HAEMOSTATIC FUNCTION BY THROMBOELASTOMETRY (ROTEM 
system)  
Global haemostatic function has been assessed by using Rotem coagulation analyzer (Tem International 
Gmbh, Munich, Germany); in particular we performed Na-TEM assay, used to recalcify the citrate whole 
blood, which provides a very sensitive assessment of the equilibrium of coagulation activation or inhibition; 
and Fib-TEM assay, that contains a platelet inhibitor (Citocalasin D), to avoid platelet contribution to clot 
formation and to assess and measure the formation of a clot only composed by fibrin. 
ROTEM is a system for the study of haemostasis that is based on the measurement of the elasticity of the 
blood through constant graphic recording of the firmness and the size of the clot during its formation and 
subsequent fibrinolysis. 
ROTEM system sets a reaction curve and kinetic parameters derived from the analysis of the curve, 
describing the kinetics of clot formation. 
Blood collected in a sodium citrate-containing vacutainer (BD) has been put into a cuvette and added with 
20 µL of 0.2 mol/L CaCl2 to triggers coagulation, according to the manufacturer’s instruction. The cuvette 
has been placed on a rod applied to the lower end of a vertical axis that rotates from left to right with a 
defined angle. The rotation has been detected optically. In case of clot formation, the clot adheres to the 
surface of the rod and cuvette; the movement is hindered and the amplitude of the angle decreases to the 
increase of clot firmness. All measurements is performed at 37°C. 
The following parameters have been recorded: 
- Clotting Time (min), CT: is the time required to form a clot of 2 mm of amplitude from the beginning of the 
assay; 
- Clot Formation Time (min), CFT: is the time to form a clot of 20 mm amplitude from a clot of 2 mm; 
- Maximum Clot Firmness (mm), MCF: represents the maximum amplitude of the curve before fibrinolysis 
reduce the size of the clot; 
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- Maximum Clot Firmness Time (min), MCF-t: is the time necessary to reach MCF starting from the 2 mm 
amplitude time-point; 
- Alpha Angle: is the angle between the tangent to the curve at the 2 mm amplitude time point and the 
baseline; 
- Clot Formation Rate, (CFR): is the linked to alpha angle and it is the angle between the baseline and the 
tangent at the maximum slope; 
- Actual clot firmness (mm), ACF: represents the clot firmness at actual time point after reaction start. ACF 
is not a parameter in its classical sense, but it is for orientation to judge the clot firmness at the actual 
point. 
 
TOTAL RNA EXTRACTION  
RNA extraction was performed using matherials RNasi free and always wearing gloves to avoid the 
presence of RNasi, enzymes that degrade RNA; reagents were purchased from Sigma Aldrich. Total RNA 
was isolated from platelet samples lysed in phenol/guanidine-based Qiazol Lysis Reagent (sample 
preparation was described above). 
The combination of organic extraction and chaotropic disruption contributes to efficient lysis and higher 
yields of total RNA. 
Each platelet sample in 500 µL of lysis reagent was added with 50 µL of 2M, pH4, sodium acetate and with 
100 µL chloroform. After shaking by vortex, sample were kept in ice for 15 minutes. After this, the 
homogenate was separated into aqueous and organic phases by centrifugation at 9000 x g, 4°c for 20 
minutes. RNA partitions to the upper, aqueous phase while DNA partitions to the interphase and proteins 
and lipids to the lower, organic phase. Aqueous phase was placed in a new tube and RNA was precipitated 
from the aqueous phase by adding 1 volume of isopropanol and incubating over night, at 4°C. Sample was 
centrifuged at 9000 x g, 4°C, for 15 minutes and, after removing isopropanol, the pellet was then washed 
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with 75% ethanol, 500 µL; sample was kept for ten minutes at room temperature and then centrifuged 
again at 9000 x g, 4°C, for 5 minutes. After removal of ethanol, pellet was dissolved in 15 µL RNase-free 
water.  
 
RNA QUALITY CONTROL 
RNA quantification was performed by Infinite M200 Pro Tecan, an instrument that calculates RNA 
concentration and purity, measuring absorbance at 230, 260 and 280 nm and giving the ratio of the 
absorbances 260/280, index of protein contamination if higher than 2, and the ratio of the absorbances 
260/230, index of solvent contamination if lower than 2.2. 
To evaluate the quality and integrity of extracted RNA the Agilent RNA 6000 Pico kit and reagents and the 
Bioanalyzer 2100 Agilent Technologies were used. 
 
GENOMIC ANALYSIS 
The primary objective of this study is the search for genes that are differentially expressed (DE) in distinct 
phenotype (class comparison), performing genome-wide transcriptional analysis in platelets of ACS patients 
with and without CKD. To do so, we enrolled 14 ACS with CKD patients and 26 ACS without CKD (controls). 
DE platelet transcripts were assessed by microarray profiling. 
RNA was reverse transcribed, labeled, and linearly amplified using the Total Prep RNA Amplification Kit (Life 
Technologies, Carlsbad, CA), in order to be hybridized to HumanHT-12 v.4 Expression BeadChip microarrays 
(Illumina, San Diego, CA), according to manufacturers' instructions. This platform provides genome-wide 
transcriptional coverage of annotated genes, gene candidates and splice variants (>25000 annotated genes, 
about 42000 unique transcripts, with >47000 50-mer gene-specific probes derived from the NCBI RefSeq 
Release 38 and the UniGene Build 99 databases). To estimate technical variability, 10% of the samples were 
hybridized in duplicate. Arrays were read using the high resolution confocal scanner iScan (Illumina) and 
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signal quantification and quality control (data mining) were performed with the Genome Studio v. 1.9.0 
software (Illumina). 
Primary analyses were performed using BRB-ArrayTools v. 4.4.1 developed by Dr. R. Simon and BRB-
ArrayTools Development Team (http://linus.nci.nih.gov/BRB-ArrayTools.html). Data variance stabilizing 
transformation and robust spline normalization were conducted with the lumi R package. Probes were 
filtered out under any of the following conditions: when the 97.5th percentile of intensities showed a 
detection P-value greater than 0.01 as calculated by Genome Studio (i.e., the 2.5th percentile of intensities 
did not significantly differ from the background level) and/or the P-value of the log-ratio variation was 
greater than 0.01 (i.e., probes that showed minimal variation across the entire set of arrays). Multiple 
probes were reduced to one per gene symbol by using the most variable probe measured by interquartile 
range across arrays. The number of genes that passed these filtering criteria was 6013. 
Replicate arrays were averaged and genes that were differentially expressed among classes were identified 
using random-variance univariate two-sample t-test. Genes were considered statistically significant if their 
parametric P-value was less than 0.001. To correct for multiple comparisons, we set the maximum allowed 
false discovery rate (FDR) at 0.05 (5% of false discoveries in the list of DE genes) with a confidence level of 
FDR assessment of 80%. The number of genes significant at 0.001 level of the univariate test was 191: the 
probability of getting at least 191 genes significant by chance (at the 0.001 level), if there are no real 
differences between the classes, was virtually equal to 0 at the global test. A fold-difference cut-off of ±1.2 
(ACS patients with CKD  vs ACS patients without CKD) was applied to this list to focus on most meaningful 
DE genes: thus the list of DE genes was reduced to 144. Further, we performed a univariate test using a 
Randomized block design adjusting for age deciles (block variable), to take into account and correct for the 
influence of age on gene expression differences between the two classes of patients. The number of genes 
significant at P < 0.001 and FDR < 0.1 in the univariate test was 60: the probability of getting at least 60 
genes significant by chance (at the 0.001 level), if there are no real differences between the classes, was 
equal to 0.002 at the global test. DE genes with a fold-difference of ±1.2 (ACS patients with CKD  vs ACS 
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patients without CKD ) were 38. The 60 DE genes were clustered using Pearson’s correlation (centered) and 
average linkage method. 
Quantitative trait analysis, testing the correlation between the glomerular filtrate rate (GFR) of each patient 
and platelet gene expression, was performed using the Spearman correlation test, setting the significance 
level of each univariate test at 0.001. 
Gene-annotation enrichment analysis for Gene Ontology (GO) biological processes (BP), molecular 
functions (MF), and cellular components (CC), and for KEGG pathways was performed on the entire dataset 
using three tests: the LS and the KS permutation tests, which find gene sets with more genes differentially 
expressed among the phenotype classes than expected by chance; and the Efron-Tibshirani's test, which 
uses 'maxmean' statistics to identify gene sets differentially expressed and returns the direction of this 
difference (+ up-, and – down-regulated gene set in ACS patients with CKD vs ACS patients without CKD 
comparison). A GO term or a KEGG pathway was considered significantly enriched if its P-value was lower 
than 0.005 for the ACS patients with CKD vs ACS patients without CKD comparison, with a univariate test 
for each gene with P < 0.01. Redundant GO terms were removed from the results of the above analyses 
using the web-based tool REVIGO (REduce and VIsualize Gene Ontology). 
 
PROTEOMIC STUDIES    
Because of human plasma proteome complexity and its enormous dynamic range, in order to overcome the 
problem of dynamic range, different strategies have been developed to remove the most abundant 
proteins. 
In this study we applied an immunoaffinity purification system using the ProteoPrep Blue Albumin 
depletion kit, which has been designed to specifically remove albumin and immunoglobulin from human 
plasma. The ProteoPrep Blue albumin and IgG depletion kit is a mixture of two medias: a blue dye 
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conjugated to an agarose base matrix and a Protein G Agarose, thus enabling the removal of 95% of 
albumin and 85% of IgG. 
In order to compare the different proteomic profile of plasma from patients with stable angina or ACS with 
and without chronic kidney disease, we employed a proteomic approach based on two dimensional 
electrophoresis for protein separation and mass spectrometry for their identification on a selected group of 
patients, 5 well-matched patients for each group.  Immunoenzymatic assays have been performed to 
confirm the results obtained by two dimensional electrophoresis on a larger cohort of patients. 
Two-dimensional electrophoresis and mass spectrometry 
200 μg of proteins from depleted plasma were diluted with a buffer to yield final concentrations of 7 mol/L 
urea, 2 mol/L thiourea, 0.2% w/v Sodium Dodecyl Sulfate (SDS), 4% w/v CHAPS, 2% v/v carrier ampholytes, 
pH 3-10, 20 mmol/L Tris, 55 mmol/L dithiothreitol, and bromophenol blue. IPG ready strips, 7 cm, pH 4-7 
linear gradient (Biorad, Italy), were actively rehydrated at 50 V for 24 h and, after focusing, were first 
equilibrated for 15 min using a solution containing 50 mmol/L Tris-HCl, 6 mol/L urea, 30% v/v glycerol, 2% 
w/v SDS and 2% w/v dithiothreitol, and then with the same buffer containing 4.5% w/v iodoacetamide 
instead of dithiothreitol. The focused proteins were then separated according to size on 7-17% 
polyacrylamide gradient gels and stained with Coomassie Colloidal Blue G-250. Briefly, the gels were fixed 
with a fixing solution containing 40% v/v methanol and 10% v/v acetic acid, and stained overnight with a 
solution containing 0.12% w/v Coomassie Blue G-250, 8% w/v (NH4)2SO4, 1.6% v/v phosphoric acid, and 
20% v/v methanol. They were then destained with a solution containing 25% v/v methanol. All of the 
images were scanned using a GS-800 densitomer (Biorad, Italy) before being analyzed by means of 
Progenesis SameSpot software (Nonlinear Dynamics, v 4.1). Each sample was analyzed by 2-DE in triplicate 
in order to evaluate gel reproducibility and improve the reliability of the qualitative and quantitative 
changes in protein expression measured by means of electrophoresis. Progenesis SameSpot software (v 
4.1, NonLinear Dynamics) was used for gel alignment, spot detection, spot quantification, and 
normalization for total spot volume in each gel, and the data were statistically analyzed using the 
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incorporated statistical package. The cut-off level for a differentially expressed protein was defined as at 
least a 1.2-fold increase or decrease in spot intensity. Statistically significant between-group differences for 
each protein were computed using analysis of variance (ANOVA) followed by Tukey’s post hoc test to allow 
both multiple group and individual group-to-group comparison; a p value of <0.05 was considered 
statistically significant. 
The differentially expressed protein spots were manually excised from the gels and underwent in-gel 
digestion with trypsin. The samples were then analyzed by means of LC-ESI-MS/MS, with the spectra being 
recorded by a Q-TOF spectrometer (Synapt-MS, Waters corporation, Milford, USA) connected to a nano-
UPLC chromatograph. The proteins were identified correlating the uninterpreted spectra with entries in 
UniProt using ProteinLynx Global Server (Version 2.3, Waters Corporation Milford, USA). 
Immunoenzymatic assays 
Plasma alpha-1 microglobulin concentration was measured using a commercially available ELISA kit 
(Immunology Consultant Laboratories, Portland, OR, USA) and the minimum detectable dose (MDD) was 
2.481 ng/ml.  Also Haptoglobin levels were measured by a sandwich ELISA, purchased from Immunology 
Consultant Laboratories, Portland, OR, USA) and the minimum detectable dose (MDD) was 0.819 ng/ml.  
Commercially available ELISA kits were also used to measure plasma Retinol binding protein 4 (MDD=0.224 
ng/ml) and Fetuin-A concentrations (0.62 ng/ml) (R&D Systems, Minneapolis, MN, USA). All protocols were 
performed following the manufacturer’s recommendations. 
For multiple comparisons of the normally distributed variables the two-ways analysis of variance (ANOVA) 
and the Tukey adjustment were performed.   For categorical comparisons chi square test was performed.   
P values >0.05 were considered statistically significant.  All data obtained were subjected to a Kolmogorov-
Smirnov normality test to check the normal distribution of the analyzed population.   
For obtained results, linear regression and correlation analysis were also performed.  All statistical analysis 
were performed using SAS 9.4 software  (Software of Analysis System).  
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STATISTICAL ANALYSIS 
Baseline categorical and continuous variables were expressed as n° (%) and as mean ± SD, respectively. 
Platelet activation markers were summarized as mean ± SD and were log-transformed before analysis; the 
effect of CKD in SA and ACS patients was evaluated by covariance analysis (ANCOVA) after adjustment for 
age, sex, presence of diabetes and anti-platelet drugs. Differences among groups were analyzed by using 
chi-square test for categorical variables and Student’s t-test for continuous variables. Only p<0.05 was 
regarded as statistically significant. 
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RESULTS 
PATIENT ENROLLMENT 
In this study we have enrolled, from December 2012 to April 2014, two cohorts of consecutive ACS patients 
(onset of symptoms in the previous 24 hours) with (n=31) and without CKD (n=108) and two cohorts of 
consecutive SA patients with (n=49) and without CKD (n=168): the number of CKD patients enrolled in each 
group reflects the frequency of the disease in the real world (~30%).  We also recruited 37 healthy subjects 
(HS) as control. All the study subjects were recruited at Centro Cardiologico Monzino IRCCS in Milan, Italy, 
and gave their written informed consent; the investigation conforms to the principles outlined in the 
Declaration of Helsinki and was approved by our local Ethical Committee. 
Table 3 reports the characteristics of patients enrolled in the study.  
Clinical, anamnestic and pharmacological characteristics of the patients included in this study matched the 
inclusion criteria previously described.  CKD patients are older and with a higher prevalence of diabetes 
that is an important risk factor in CKD patients; in patients with CKD the value of hemoglobin, of hematocrit 
and the number of RBC, as expected, are significantly lower compared to patients without CKD. 
Furthermore, patients are comparable in terms of past medical history and drug treatments, except for 
ipoglycaemic agents. 
  
 76 
 
 
Table 3. Clinical characteristics of enrolled patients and healthy subjects. Differences among groups analyzed by chi-square test for 
categorical variables and Student’s t-test for continuous variables. 
  
ACS-no CKD ACS-CKD SA-no CKD SA-CKD 
HEALTHY 
SUBJECTS
n=108 n=31 n=168 n=49 n=37
64±11 74±8 <0.01 66±8 70±7 <0.05 50±9
88(81.5) 19(61.3) <0.05 147(87.5) 40(81.6) n.s. 18(48)
88.1±20.7 42.7±12.9 <0.01 86.5±16.9 45.9±11.6 <0.01 n.a.
28.2±4.8 26.9±6.3 n.s. 27±3.5 29.7±5.1 n.s. 24±3.5
193±44 186±41 n.s. 191±44 192±57 n.s. 189±50
42±11 42±14 n.s. 49±20 43±9 n.s. 61±13
123±44 114±36 n.s. 116±38 104±46 n.s. 123±35
145±106 144±86 n.s. 137±85 147±91 n.s. 101±38
131±54 141±45 n.s. 127±51 139±51 n.s. 84±10
6.4±1.4 6.8±0.9 n.s. 7.9±2.4 7.4±1.5 n.s. 5.5±0.4
210±49 211±53 n.s. 200±48 197±47 n.s. 210±51
3.1±2.2 3.2±2.2 n.s. 3.1±2.5 2.7±1.9 n.s. 2.4±0.7
10.6±1.1 10.1±1.3 n.s. 11±1.5 10.6±0.9 n.s. 10.9±0.8
8±2.1 7.6±3.2 n.s. 6.9±1.8 7±1.5 n.s. 5.9±1.2
4.5±0.5 3.8±0.5 <0.01 4.6±0.6 4.4±0.6 <0.05 4.7±0.5
13.4±1.5 11.9±1.7 <0.01 14.1±1.3 13.2±1.9 <0.01 14.1±1.4
39.7±4.1 35.3±5 <0.01 41.3±3.6 39.1±5.1 <0.01 41.6±3.7
26(25.2) 4(13.8) n.s. 26(16.3) 4(9.3) n.s. 5(13.5)
23(45.1) 3(20) n.s. 74(54.4) 22(55) n.s. 6(16)
27(25) 16(51.6) <0.01 48(28.6) 22(44.9) <0.05 0(0)
66(62.9) 22(73.3) n.s. 107(74.8) 24(63.2) n.s. 3(8)
18(58.1) 6(50) n.s. 26(25.7) 14(42.4) n.s. 0(0)
67(64.4) 23(79.3) n.s. 122(75.8) 40(81.6) n.s. 2(5)
33(32.4) 6(20) n.s. 52(31.9) 16(38.1) n.s. 0(0)
25(23.8) 10(33.3) n.s. 80(48.5) 17(40.5) n.s. 0(0)
21(20.2) 8(25.8) n.s. 20(12.2) 9(21.4) n.s. 0(0)
94(87) 29(93.5) n.s. 159(95.8) 42(86) n.s. 0(0)
35(32) 15(48) n.s. 81(48) 26(53) n.s. 0(0)
11(10) 2(6) n.s. 8(5) 2(4) n.s. 0(0)
48(44) 12(39) n.s. 67(40) 14(29) n.s. 0(0)
14(13) 2(6.5) n.s. 7(4) 6(12) n.s. 37(100)
19(17.6) 12(38.7) <0.05 39(23.6) 19(43.2) <0.01 0(0)
44(41.9) 12(40) n.s. 101(61.2) 28(63.6) n.s. 0(0)
52(50) 18(62.1) n.s. 113(68.5) 38(77.6) n.s. 0(0)
P 
value
DRUG TREATMENT
Anti-platelet agents (%)
Ipoglycaemic medication (%)
Lipid-lowering agents (%)
Current Smoking (%)
Family history of CAD (%)
Type-2-diabetes (%)
Hypercholesterolemia (%)
Hypertriglyceridemia (%)
MPV (fL)
WBC (*103/ul)
RBC (*106/ul)
hemoglobin (g/dl)
RISK FACTORS
glycaemia (mg/dl)
Anti-hypertensive (%)
Hypertension (%)
PAST MEDICAL HISTORY
Prior IMA (%)
Prior PCI (%)
Prior CABG (%)
only P2Y12 inhibitors (%)
DAT (%)
no anti-platelet drugs (%)
glycosylated hemoglobin (%)
HAEMOCHROME
PLT (*103/ul)
IPF (%)
only ASA (%)
hematocrit (%)
BMI (kg/m2)
total cholesterol (mg/dl)
HDL cholesterol (mg/dl)
LDL cholesterol (mg/dl)
triglycerides (mg/dl)
P 
value
CHARACTERISTICS
Age, years (mean±SD)
Gender, %male
GFR (ml/min/1.73 m2)
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ASSESSMENT OF PLATELET ACTIVATION MARKERS BY FLOW CYTOMETRY 
Comparison between SA and ACS patients and healthy subjects (HS)  
Surface expression of platelet activation markers has been assessed by whole blood flow cytometry in SA 
and ACS patients and in a group of healthy subjects (HS). 
Classic platelet activation markers, such as activated glycoprotein IIb/IIIa (GP IIb/IIIa) and P-selectin, have 
been evaluated. Furthermore, a novel marker of platelet activation, Tissue Factor (TF), has been assessed. 
The expression of GP IIb/IIIa is not different among the three groups of subjects, both as mean amount of 
antigen expressed on each cell (MFI) (HS: 1.18±0.09; SA: 1.22±0,14; ACS: 1.18±0,12; p>0.05) and as 
percentage of GP IIb/IIIa-positive platelets  (HS: 0.44%±0,09; SA: 0.42%±0,06; ACS: 0.44%±0,1; p>0.05) 
(Figure 7). 
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Figure 7. GP IIb/IIIa expression on platelet surface of HS, SA and ACS patients assessed by flow cytometry in resting conditions. 
Values are reported as mean fluorescence intensity (MFI) as well as % of positive platelets. 
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As far GP IIb/IIIa platelet expression, also the expression of the other classical platelet activation marker P-
selectin is comparable among CAD patients (SA and ACS) and healthy subjects both in terms of mean 
fluorescence intensity (MFI) (HS: 1.29±0,12; SA: 1.55±0,21; ACS: 1,43±0,25; p>0.05) and in terms of 
percentage of P-selectin-positive platelets, although a trend toward a higher number of P-selectin-positive 
platelets is observed in CAD patients compared to healthy subjects (HS: 0.54%±0,04; SA: 0.79%±0,07; ACS: 
0.86%±0,17; p>0.05) (Figure 8). 
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Figure 8. P-selectin expression on platelet surface of HS, SA and ACS patients assessed by flow cytometry in resting conditions. 
Values are reported as mean fluorescence intensity (MFI) as well as % of positive platelets. 
 
Therefore, these data suggest that the expression of classical markers of platelet activation is not different 
among CAD patients (that are pharmacologically treated) and HS. 
 
On the contrary, as far as the expression of the novel marker TF is concerned, we have observed that it is 
significantly higher in SA and ACS patients compared to healthy subjects in terms of mean fluorescence 
intensity (HS: 1.56±0.48; SA: 2.12±0.68; ACS: 2.08±0.91; p<0.001). Moreover, the percentage of TF-positive 
platelets significantly increases with the gravity of the coronary artery disease, being highest in ACS 
patients (HS: 1.49%±0.3; SA: 2.72%±0.41; ACS: 5.23%±0.82; p<0.001). These results fully confirm previously 
data, published in 2008 by our group, that provided for the first time the evidence that platelet-associated 
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TF expression is higher in ACS patients compared to SA patients, it is functionally active and therefore it 
may account for the higher prothrombotic potential of ACS patients 204 (Figure 9). 
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Figure 9. Tissue Factor expression on platelet surface of HS, SA and ACS patients assessed by flow cytometry in resting conditions. 
Values are reported as mean fluorescence intensity (MFI) as well as % of positive platelets 
 
 
 
Comparison between SA and ACS patients with and without CKD  
In order to evaluate the effect of CKD on the platelet activation profile, whole blood analysis of platelet 
activation markers has been performed in SA and ACS patients with CKD in comparison to patients without 
CKD. The presence of platelet-leukocyte aggregates, that are another important marker of platelet 
activation, has been also assessed. 
The percentage of GP IIb/IIIa-positive platelets is not different in ACS patients with and without CKD 
(resting condition: 0.45%±0.14 in CKD patients versus 0.44%±0.10 in patients without CKD, p>0.05; after 
ADP stimulation: 68.32%±3.93 versus 56.11%±2.66, respectively, p>0.05). The same trend is also observed 
as mean fluorescence intensity (MFI) (resting condition: 1.20±0.11 in CKD patients versus 1.18±0.12 in 
patients without CKD, p>0,05; after ADP stimulation: 10.55±0.90 versus 8.63±0.58, respectively, p>0.05).   
In SA patients with CKD, no statistically significant differences are present in terms of percentage of GP 
IIb/IIIa-positive platelets in resting conditions and after ADP stimulation (0.26%±0.04 versus 0.42%±0.06, 
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respectively, p>0,05 in resting conditions; 73.18%±2.5 versus 66.57%±1.65,  respectively, p>0.05, after ADP 
stimulation); also the expression of GP IIb/IIIa in terms of mean amount of antigen expressed on each cells 
(MFI) is comparable among patients with and without CKD both in resting conditions and after ADP 
stimulation (resting condition: 1.17±0.3 versus 1.22±0.14, respectively, p>0,05; after ADP stimulation: 
12.47±1.22 versus 12.01±0.63, respectively, p>0.05) (Figure 10).  
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Figure 10. GP IIb/IIIa expression on platelet surface of ACS and SA patients assessed by flow cytometry in resting conditions and 
after ADP stimulation. Values are reported as % of positive platelets (panel A) and as mean fluorescence intensity (MFI) (panel B). 
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In ACS patients, the percentage of P-selectin-positive platelets is comparable among those with and 
without CKD (resting condition: 0.76%±0.18 versus 0.86%±0.17, respectively, p>0,05; after ADP stimulation: 
28.07%±3.21 versus 23.71%±1.49, respectively, p>0.05), as well as the mean fluorescence intensity (MFI) of 
P-selectin expression (resting condition: 1.42±0.18 versus 1.43±0.25, respectively, p>0,05; after ADP 
stimulation: 3.95±1.74 versus 3.54±1.62, respectively, p>0.05).  Also in SA patients, the expression of P-
selectin is comparable among patients with and without CKD both in terms of percentage of positive 
platelet (resting conditions: 0.92%±0.14 versus 0.79%±0.07, respectively, p>0,05; after ADP stimulation: 
38.40%±2.65 versus 28.62%±1.43, respectively, p>0.05) and mean fluorescence intensity (resting condition: 
1.43±0.22 versus 1.55±0.21, respectively, p>0,05; after ADP stimulation: 4.92±1.96 versus 4.37±2.10, 
respectively, p>0.05) (Figure 11).  
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Figure 11. P-selectin expression on platelet surface of ACS and SA patients assessed by flow cytometry in resting conditions and 
after ADP stimulation. Values are reported as % of positive platelets (panel A) and as mean fluorescence intensity (MFI) (panel B). 
 
These data indicate that the expression of these classical markers of platelet activation, GP IIb/IIIa and P-
selectin, is not different among patients with CKD and without CKD both in ACS and in SA patients. 
 
Conversely, the expression on platelet surface in resting condition of TF is significantly lower in ACS patients 
with CKD compared to patients without CKD (4.07%±1.05 and 5.23%±0.82 respectively, p<0,05), whereas 
there is not a significant difference after ADP stimulation (20.32%±2.58 and 21.71%±1.52 respectively, 
p>0,05).  Furthermore, the mean fluorescence intensity of TF expression is similar among patients with and 
without CKD both under resting conditions and after ADP stimulation (resting condition: 1.91±0.56 versus 
2.08±0.91, respectively, p>0,05; after ADP stimulation: 3.13±1.03 versus 3.32±1.49, respectively, p>0.05). 
This means that CKD patients have a lower number of TF-positive platelets compared to patients without 
CKD, but the mean expression of this marker on each platelet is not different among the two groups of 
patients.   The same trend in TF surface expression is also observed in SA patients with CKD compared to 
those without CKD in resting condition (1.96%±0.8 versus 2.72%±0.41, respectively, p<0,05) and, although 
not statistically significant, after ADP stimulation (12.93%±2.73 and 16.54%±1.52 respectively, p>0.05).     
The mean fluorescence intensity of TF expression is lower in SA patients with CKD patients, although not 
B 
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statistically different compared to patients without CKD (resting condition: 1.80±0.54 versus 2.12±0.68, 
respectively, p>0,05; after ADP stimulation: 3±0.88 versus 3.37±1.19, respectively, p>0.05) (Figure 12). 
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Figure 12. TF expression on platelet surface of ACS and SA patients assessed by flow cytometry in resting conditions and after ADP 
stimulation. Values are reported as % of positive platelets (panel A) and as mean fluorescence intensity (MFI) (panel B). 
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To further characterize the lower number of circulating TF-positive platelets found in CKD patients, 
intracellular staining of TF in resting, fixed and permeabilized platelets has been performed in a subgroup 
of ACS patients (n=15 with CKD and n=10 without CKD).  This approach confirms that the percentage of TF-
positive platelets is significantly lower in patients with CKD compared to patients without CKD 
(19.49%±4.04 and 27.53%±5.16 respectively, p<0,001) (Figure 13). 
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Figure 13. Platelet intracellular Tissue Factor expression of ACS patients assessed by flow cytometry. Values are reported as % of 
positive platelets. 
 
Of interest, when the number of TF-positive platelets has been correlated with the kidney function, a 
statistically significant positive correlation has been found between the glomerular filtration rate (GFR) and 
the percentage of TF-positive platelets (Figure 14).  
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Figure 14. Correlation between platelet intracellular Tissue Factor expression and the Glomerular Filtration Rate (GFR) of a 
subgroup of ACS patients (n=15 with CKD and n=10 without CKD). 
  
All together these data indicate that, also in presence of CKD, ACS patients have twice the amount of 
circulating TF-positive platelets compared to patients with SA.    
Of interest, CKD significantly affects the expression of TF resulting in a significantly lower number of TF-
positive platelets both in ACS and in SA patients: the worst is the kidney function, the lower is the number 
of circulating TF-positive platelets. 
 
Leukocyte-platelet aggregates (monocyte-platelet and granulocyte-platelet aggregates) that, as mentioned 
before, are another important marker of platelet activation, is comparable among ACS patients with CKD 
and without CKD (monocyte-platelet aggregates: 17.16%±2.24 and 15.93%±1.14 respectively p>0,05; 
granulocyte-platelet aggregates: 5.21%±0.45 and 4.62%±0.27, respectively p>0,05).  
A similar behaviour has been observed in SA patients with no difference among patients with and without 
CKD (monocyte-platelet aggregates: 14.62%±1.30 and 15.89%±1.05, respectively p>0,05; granulocyte-
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platelet aggregates: 4.43%±0.41 and 5.11%±0.39, respectively p>0,05). Also the comparison among the four 
groups of patients has shown no difference (Figure 15).  
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Figure 15 Formation of leukocyte-platelet aggregates (monocyte-platelet aggregates in the panel on the left; granulocyte-platelet 
aggregates in the panel on the right) of ACS and SA patients assessed by flow cytometry. Values are reported as % of leukocyte-
platelet aggregates. 
 
 
On the contrary, the analysis of TF-positive aggregates, TF-positive platelet-monocyte and TF-positive 
platelet-granulocyte aggregates, has shown a trend towards a lower number in CKD patients, both ACS and 
SA  (in ACS patients: TF positive platelet-monocyte aggregates: 1,58%±0.23 and 2,28%±0.39 respectively 
p>0,05; TF positive platelet-granulocyte aggregates: 0,09%±0.03 and 0,19%±0.08, respectively p>0,05; in SA 
patients: TF-positive platelet-monocyte aggregates: 1.98%±0.43 and 2.54%±0.37 respectively p>0.05; TF-
positive platelet-granulocyte aggregates: 0.11%±0.017 and 0.24%±0.07, respectively p>0,05) (Figure 16). 
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Figure 16. Tissue Factor expression on leukocyte-platelet aggregates (TF-positive monocyte-platelet aggregates in the panel on the 
left; TF-positive granulocyte-platelet aggregates in the panel on the right) of ACS and SA patients assessed by flow cytometry. 
Values are reported as % of TF-positive leukocyte-platelet aggregates. 
 
 
Overall, CKD patients (both ACS and SA patients) show a reduction in the expression of TF-associated to 
platelet and to leukocyte-platelet aggregates. In view of the haemorrhagic tendency of CKD patients, these 
data could account for the bleeding profile characteristic of these patients. 
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GLOBAL HAEMOSTATIC FUNCTION OF WHOLE BLOOD  
 
The global haemostatic function of whole blood has been assessed by thromboelastometry (ROTEM 
system), that measures the haemostasis and the interaction of coagulation factors, inhibitors and cellular 
components (in particular platelets) during the phases of clotting and subsequent fibrinolysis.  
The Na-TEM assay, used to recalcify citrate blood, has shown that the haemostatic function is significantly 
different in SA patients with CKD compared with SA patients without CKD. Indeed in CKD patients there is a 
significant shorter clot formation time, suggesting a higher procoagulant potential (CT=396±151 in patients 
with CKD, CT=457±113 in patients without CKD, p<0,01).  However, a reduced clot firmness (MCF) which 
correlates with clot instability has been observed in SA patients with CKD (MCF=55±18 in patients with CKD, 
MCF=60±5 in patients without CKD, p<0,05) (Figure 17). 
 
Figure 17. Representative Na-TEM thromboelastometric graphs from whole blood of SA patients without CKD, on the left, and of 
patients with CKD, on the right. 
  
CT: Clotting Time  
CFT: Clot Formation Time;  
MCF: Maximum Clot Firmness;  
MCF-t: time necessary to reach MCF starting from the 2mm amplitude time-point  
 
 
SA patients without CKD 
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In contrast to what observed in SA patients, ACS patients with CKD have a hypocoagulant phenotype: clot 
formation time is significantly prolonged (CT=677±399 in patients with CKD, CT=466±189 in patients 
without CKD, p<0,01,) while no differences has been observed in clot firmness (Figure 18). 
 
Figure 18. Representative Na-TEM thromboelastometric graphs from whole blood of ACS patients without CKD, on the left, and of 
patients with CKD, on the right. 
 
 
In order to define the relative contribution of platelet and of the coagulation pathway to the global 
haemostatic potential, thromboelastometry has been performed in the presence of a platelet inhibitor 
(Citocalasin D; Fib-TEM assay) thus allowing the formation and measurement of a pure fibrin clot.                  
Under these conditions, the rate of fibrin formation as well as the firmness of the fibrin clot are both 
significantly increased in ACS and SA patients with CKD compared to patients without CKD. In particular, in 
ACS patients: maximum clot firmness, MCF=25±17 in patients with CKD, MCF=16±5 in patients without 
CKD, p<0,01; actual clot firmness, ACF=25±17 in patients with CKD, ACF=17±5 in patients without CKD, 
p<0,01; rate of clot formation, alpha angle=75±16 in patients with CKD, alpha angle=71±6 in patients 
without CKD, p<0,05 (Figure 19).  
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Figure 19. Representative Fib-TEM thromboelastometric graphs from whole blood of ACS patients without CKD, on the left, and of 
patients with CKD, on the right. 
 
A similar trend has been observed in SA patients: clot formation rate, CFR=74±5 in patients with CKD, 
CFR=73±4 in patients without CKD, p<0,05; clot firmness, ACF=21±9 in patients with CKD, ACF=18±2 in 
patients without CKD, p<0,05 (Figure 20). 
 
Figure 20. Representative Fib-TEM thromboelastometric graphs from whole blood of SA patients without CKD, on the left, and of 
patients with CKD, on the right. 
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MCF: Maximum Clot Firmness;  
α- angle: angle between the baseline and a tangent to the curve 
clotting curve through the 2 mm point.  
 
MCF: Maximum Clot Firmness;  
α- angle: angle between the baseline and a tangent to the curve 
clotting curve through the 2 mm point.  
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QUALITY CONTROLS FOR PLATELET ISOLATION AND RNA EXTRACTION 
To check the absence of platelet activation in the samples of isolated platelets for the RNA extraction, the 
expression of platelet P-selectin has been detected by flow cytometry and it has been compared with 
platelet P-selectin expression in whole blood.  The developed technique and the care in handling the 
samples allow to have all the isolated platelet preparations not activated by the procedure of separation. 
Moreover, to study platelet-derived RNAs, it’s necessary that the transcriptome analysis is performed only 
on platelet RNAs, not contaminated with leukocyte-derived RNAs; to check leukocyte contamination, all 
preparations has been analyzed for absence of leukocytes both by flow cytometry (Figure 21) and by 
haematologic analyzer: both the instruments have given the same results. Only platelet samples with less 
than 50 leukocytes per 106 platelets were considered suitable for RNA analysis. 
 
 
Figure 21. Control of leukocyte contamination in isolated platelets by flow cytometry. A, leukocytes detection in whole blood on 
the basis of side scatter characteristics and positivity to CD45; B, detection of leukocyte contamination in isolated platelet samples 
applying the same setting used for leukocytes acquisition in whole blood and the same strategy of gating and analysis. 
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RNA was extracted from pure platelet preparations and quantified by a highly sensitive absorbance reader. 
RNA quality control and quantitation is essential before any downstream application. A positive correlation 
was found between the platelet number in each sample and the amount of recovered RNA suggestive of 
the good optimization of the method applied (r=0.78) (Figure 22).  Generally, we obtained 1 µg of RNA from 
1 billion of platelets. We checked the quality of these RNAs by using Agilent RNA 6000 Pico bioanalyzer and 
the obtained profiles showed the typical platelet RNA pattern, with the 18S ribosomal RNA more abundant 
than the 28S ribosomal RNA. The 260/280 ratio indicated absence of contaminant proteins (Figure 23).   
 
 
Figure 22. Correlation between the number of platelets isolated from a patient and the amount of recovered RNA in a 
representative subset of samples. 
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Figure 23. panel A: RNA elettropherograms by Agilent bioanalyzer to assess quality of recovered platelet RNAs; panel B: 
quantification and quality control by Infinite M200Pro. 
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GENOMIC DATA: DIFFERENTIAL PLATELET GENE EXPRESSION PROFILES BETWEEN PATIENTS 
WITH AND WITHOUT CKD 
Platelet genome-wide transcriptome profiles have been performed on a subgroup of ACS patients (n=14 
with CKD, n=26 without CKD) well-matched for age, sex and risk factors, by microarray analysis of RNA 
samples, in order to study expression signatures that may differentially modulate platelet reactivity in 
patients with chronic kidney disease compared to patients without CKD. Gene profiling has detected more 
than 6000 distinct transcripts as being present in ACS with and without CKD. 
Differential expression analysis, analyzed by two-sample T-test, followed by correction for multiple testing 
to obtain false discovery rate (FDR) <0.05, has identified several changes in gene expression profile 
between patients with and without CKD. In particular, 144 unique mRNAs with a significant ± 1.2-fold or 
greater difference in expression between ACS patients with and without CKD has been identified: 104 of 
these genes were over-expressed, whereas 40 had a lower expression in platelets of CKD patients 
compared to those of patients without CKD. (Figure 24). 
 
Figure 24. Volcano plot of differential gene expression in platelets of ACS patients with and without CKD 
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After adjustment for age, 60 mRNAs with a significant difference in expression between ACS patients with 
and without CKD have been identified (p<0.001, FDR<0.1): 44 of them were over-expressed, whereas 16 
showed a decreased expression in platelets of ACS patients with CKD compared to platelets of ACS patients 
without CKD. On a global test analysis, the probability of getting at least 60 genes significant by chance (at 
the 0.001 level) if there are no real differences between the classes has been 0.002.  Hierarchical clustering 
has shown that differential gene expression profiles correctly discriminate between platelets of patients 
with and without CKD and there are at least seven different clusters of co-regulated gene (Figure 25 and 
Table 4).   
 
Figure 25. Heat map of clustered differential gene profiles in platelets of ACS patients with and without CKD 
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Table 4. Genes that are differentially expressed between patients with and without CKD 
  
Parametric 
p-value
FDR Geom 
mean ACS
Geom mean 
ACS-CKD
FC CKD 
vs. ACS
Symbol Name
1.31E-05 0.0788 116.26 134.36 1.15 TTC7B tetratricopeptide repeat domain 7B
6.85E-05 0.0927 151.16 192.86 1.28 ZNF524 zinc finger protein 524
7.23E-05 0.0927 182.1 225.96 1.23 TMEM204 transmembrane protein 204
9.20E-05 0.0927 114.1 128.72 1.12 ZKSCAN3 zinc finger with KRAB and SCAN domains  3
9.88E-05 0.0927 501.61 794.28 1.59 DMTN dematin actin binding protein
0.000118 0.0927 158.21 224.07 1.41 TTYH3 tweety fami ly member 3
0.0001282 0.0927 141.48 128.24 -1.10 TSSC4 tumor suppress ing subtransferable candidate 4
0.0001327 0.0927 115.29 124.75 1.09 AMOTL2 angiomotin l ike 2
0.0001418 0.0927 115.03 108.11 -1.06 ZNF785 zinc finger protein 785
0.0001744 0.0927 268.62 386.01 1.43 TANGO2 transport and golgi  organization 2 homolog (Drosophi la)
0.0002089 0.0927 116.07 137.59 1.19 AGTRAP angiotens in II  receptor-associated protein
0.000261 0.0927 133.59 181.6 1.35 UBE2O ubiquitin-conjugating enzyme E2O
0.0002714 0.0927 153.63 193.74 1.27 UBE3B ubiquitin protein l igase E3B
0.0002729 0.0927 161.38 247.69 1.54 HPSE heparanase
0.0002834 0.0927 143.82 181.41 1.27 PIP5K1C phosphatidyl inos i tol -4-phosphate 5-kinase, type I, gamma
0.0002925 0.0927 172.41 219.04 1.27 NOTCH2NL notch 2 N-terminal  l ike
0.0003332 0.0927 130.94 159.35 1.22 STARD3NL STARD3 N-terminal  l ike
0.0003333 0.0927 118.98 129.45 1.09 DUSP13 dual  speci fici ty phosphatase 13
0.0003354 0.0927 389.23 593.58 1.52 HDGF hepatoma-derived growth factor
0.0003452 0.0927 129.3 119.01 -1.09 TPMT thiopurine S-methyltransferase
0.0003507 0.0927 125.14 142.62 1.14 PRPF6 pre-mRNA process ing factor 6
0.0003905 0.0927 183.6 262.61 1.43 MLLT11 myeloid/lymphoid or mixed-l ineage leukemia  (tri thorax homolog, Drosophi la); trans located to, 11
0.0003982 0.0927 1388.03 875.38 -1.59 HGD homogentisate 1,2-dioxygenase
0.0004116 0.0927 223.69 266.48 1.19 TCTA T-cel l  leukemia  trans location a l tered
0.0004127 0.0927 418.46 569.39 1.37 C9orf16 chromosome 9 open reading frame 16
0.0004127 0.0927 310.76 196.67 -1.58 TMEM45A transmembrane protein 45A
0.0004245 0.0927 147.52 194.94 1.32 NCKIPSD NCK interacting protein with SH3 domain
0.0004646 0.0927 213.81 456.42 2.13 OSBP2 oxysterol  binding protein 2
0.0004778 0.0927 122.07 143.37 1.18 CASP9 caspase 9, apoptos is -related cysteine peptidase
0.0004811 0.0927 1224.97 888.2 -1.38 PRR13 prol ine rich 13
0.0004992 0.0927 149.46 177.27 1.19 PEF1 penta-EF-hand domain conta ining 1
0.000511 0.0927 126.68 117.3 -1.08 DHX9 DEAH (Asp-Glu-Ala-His ) box hel icase 9
0.0005199 0.0927 145.09 172.48 1.19 CTNNBIP1 catenin, beta  interacting protein 1
0.0005316 0.0927 649.89 355.42 -1.83 RPL35 ribosomal  protein L35
0.0005742 0.0927 125.51 143.63 1.15 IL21R interleukin 21 receptor
0.0005764 0.0927 517.11 746.51 1.45 LRP10 low dens i ty l ipoprotein receptor-related protein 10
0.0005881 0.0927 148.72 132.73 -1.12 BRMS1 breast cancer metastas is  suppressor 1
0.0006073 0.0927 117.52 134.74 1.15 KPNA3 karyopherin a lpha 3 (importin a lpha 4)
0.000608 0.0927 204.44 163.89 -1.25 SNRPB smal l  nuclear ribonucleoprotein polypeptides  B and B1
0.0006212 0.0927 292.56 220.07 -1.33 HNRNPAB heterogeneous  nuclear ribonucleoprotein A/B
0.0006318 0.0927 1177.42 834.99 -1.41 SOD2 superoxide dismutase 2, mitochondria l
0.0006688 0.0944 212.93 303.75 1.43 HLA-G major his tocompatibi l i ty complex, class  I , G
0.0007106 0.0944 530.96 332.58 -1.60 RPL5 ribosomal  protein L5
0.0007134 0.0944 167.04 207.65 1.25 SHC1 SHC (Src homology 2 domain conta ining) transforming protein 1
0.0007156 0.0944 154.06 196.59 1.28 COL6A3 col lagen, type VI, a lpha 3
0.0007222 0.0944 363.53 618.87 1.69 DAP death-associated protein
0.0007972 0.0978 156.99 198.58 1.27 FURIN furin (pa ired bas ic amino acid cleaving enzyme)
0.0008165 0.0978 129.3 151.86 1.18 C17orf62 chromosome 17 open reading frame 62
0.0008249 0.0978 125.8 154.84 1.23 ABCB10 ATP-binding cassette, sub-fami ly B (MDR/TAP), member 10
0.0008308 0.0978 2953 1868.11 -1.58 GNB2L1 guanine nucleotide binding protein (G protein), beta  polypeptide 2-l ike 1
0.0008492 0.0978 140.46 161.52 1.15 CDIPT CDP-diacylglycerol --inos i tol  3-phosphatidyl transferase
0.0008604 0.0978 161.29 205.3 1.27 WASF2 WAS protein fami ly, member 2
0.0008947 0.0978 173.74 239.54 1.37 HCFC1R1 host cel l  factor C1 regulator 1 (XPO1 dependent)
0.0009134 0.0978 140.65 158.73 1.12 KTI12 KTI12 homolog, chromatin associated (S. cerevis iae)
0.0009145 0.0978 160.57 177.73 1.11 UBR4 ubiquitin protein l igase E3 component n-recognin 4
0.0009209 0.0978 189.16 151.61 -1.25 DOCK2 dedicator of cytokines is  2
0.0009324 0.0978 216.87 278.72 1.28 PDLIM7 PDZ and LIM domain 7 (enigma)
0.0009752 0.0978 110.52 123.25 1.11 EFNB1 ephrin-B1
0.0009776 0.0978 346.94 264.86 -1.31 CIB1 ca lcium and integrin binding 1 (ca lmyrin)
0.0009916 0.0978 140.7 175.03 1.25 ERCC1 excis ion repair cross -complementation group 1
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Spearman analysis has revealed that 98 unique genes significantly correlate (p<0.001; FDR<0.05) with the 
decrease of glomerular filtration rate (GFR), i.e. with the severity of the renal failure: the expression levels 
of 79 genes have shown an inverse correlation with GFR and 19 a positive correlation. The probability of 
getting at least 98 genes significant by chance (at the 0.001 level) if there are no real differences between 
the classes has been 0.007. (Figure 26).   
 
  
Figure 26. Many genes significantly correlated with the glomerular filtration rate (GFR): in panel A, gene expression levels that have 
an inverse correaltion with GFR; in panel B, gene expression levels that are positive correlated with GFR. 
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Enrichment analysis of Gene Ontology (GO) categories has allowed the identification of biological processes 
(BP), cellular components (CC) and molecular functions (MF) whose expression was significantly altered in 
platelets of ACS with CKD in comparison with platelets of ACS without CKD (Table 5). 
 
 
  
GO 
ont.
GO term Number of 
genes
LS permutation p-
value
KS permutation p-
value
Efron-Tibshirani's 
GSA test p-value
BP nuclear-transcribed mRNA catabol ic process , nonsense-mediated decay 99 0.00001 0.00001 0.017 (-)
BP SRP-dependent cotrans lational  protein targeting to membrane 92 0.00001 0.00001 0.017 (-)
BP protein targeting to ER 94 0.00001 0.00001 0.017 (-)
BP trans lational  elongation 91 0.00001 0.00001 0.015 (-)
BP trans lational  termination 82 0.00001 0.00001 0.018 (-)
BP ribonucleoprotein complex assembly 74 0.00001 0.00178 0.003 (-) 
BP ribonucleoprotein complex subunit organization 77 0.00001 0.00531 0.004 (-) 
BP negative regulation of autophagy 11 0.00012 0.00435 < 0.001 (+) 
BP platelet aggregation 40 0.00016 0.01574 0.009 (+)
BP G2 DNA damage checkpoint 14 0.00022 0.01363 0.001 (+) 
BP platelet degranulation 56 0.0003 0.00049 0.022 (+)
BP ribosomal  smal l  subunit biogenes is 15 0.00046 0.0005 0.027 (-)
BP pinocytos is 9 0.00073 0.00364 0.031 (+)
BP regulation of endocytos is 62 0.00073 0.00025 0.088 (+)
BP mitotic spindle organization 14 0.0008 0.03588 0.005 (+) 
BP ameboidal  cel l  migration 88 0.00087 0.02858 0.001 (+) 
BP ca lcium-mediated s ignal ing 33 0.00095 0.0206 0.012 (+)
BP synaptic transmiss ion, dopaminergic 6 0.00152 0.00199 0.007 (+)
BP homeostas is  of number of cel l s 92 0.00168 0.02418 0.051 (-)
BP mRNA stabi l i zation 19 0.00174 0.03477 0.041 (+)
BP cel lular response to nerve growth factor s timulus 8 0.00238 0.00054 0.002 (-) 
BP cel lular response to s tarvation 44 0.00241 0.02605 0.028 (+)
BP phagocytos is 88 0.00251 0.00651 0.172 (+)
BP response to hydrogen peroxide 50 0.00264 0.03034 0.079 (-)
BP regulation of mitochondria l  membrane potentia l 27 0.00267 0.00594 0.007 (-)
BP platelet morphogenes is 13 0.00296 0.05584 0.074 (+)
BP modulation by symbiont of host cel lular process 5 0.00325 0.00039 0.027 (+)
BP regulation of lamel l ipodium organization 14 0.00356 0.29628 0.002 (+) 
BP transmembrane receptor protein serine/threonine kinase s ignal ing pathway 95 0.00376 0.02467 0.017 (+)
BP regulation of membrane protein ectodomain proteolys is 5 0.00456 0.01854 0.013 (+)
BP mitotic recombination 17 0.00473 0.01646 0.006 (-)
BP serotonin transport 8 0.00486 0.02122 0.008 (+)
BP regulation of dopamine metabol ic process 6 0.00537 0.01314 0.004 (+) 
BP 'de novo' protein folding 34 0.0061 0.00084 0.131 (+)
BP protein homool igomerization 76 0.00806 0.00353 0.053 (+)
BP protein folding 93 0.00844 0.00097 0.092 (+)
BP cel lular response to topologica l ly incorrect protein 44 0.00908 0.07441 0.003 (+) 
BP Rho protein s ignal  transduction 30 0.00969 0.00168 0.005 (+) 
BP rRNA metabol ic process 55 0.01254 0.00349 0.032 (-)
BP regulation of metal loenzyme activi ty 5 0.01613 0.00285 0.024 (-)
BP 'de novo' posttrans lational  protein folding 31 0.01732 0.00152 0.168 (+)
BP regulation of DNA-templated transcription in response to s tress 22 0.01774 0.00113 0.163 (+)
BP respiratory electron transport chain 70 0.02651 0.00258 0.108 (-)
BP pos i tive regulation of cel l  divis ion 21 0.02679 0.09165 0.003 (+) 
BP regulation of transcription from RNA polymerase II  promoter in response to s tress 20 0.03315 0.00403 0.176 (+)
BP neutra l  l ipid metabol ic process 39 0.05738 0.00281 0.029 (+)
BP acylglycerol  metabol ic process 38 0.06976 0.00426 0.037 (+)
BP regulation of protein s tabi l i ty 64 0.07554 0.0033 0.047 (+)
BP negative regulation of RNA spl icing 13 0.17594 0.15046 < 0.001 (-) 
BP DNA-dependent DNA repl ication 44 0.20998 0.47116 < 0.001 (-) 
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Table 5.  Gene Ontology (GO) analysis of biological processes (BP), cellular components (CC) and molecular functions (MF) 
significantly different among patients with and without CKD 
 
 
Gene set enrichment analysis of expressed genes has shown that many biological processes and/or 
molecular pathways are altered in CKD platelets.  In particular, gene expression changes in a number of 
functions/processes were up-regulated in ACS patients with CKD: platelet aggregation (MYL9, FERMT3, 
ITGB3, STXBP3...), platelet degranulation (PDGFB, PDGFA, ITGA2B, LAMP2…), platelet morphogenesis 
(CLEC1B, CASP9, CASP3…), regulation of actin cytoskeleton (CAPZB, GSN…), regulation of transcription from 
RNA polymerase II promoter in response to stress (UBB, SIRT2, NOTCH1…) (Figure 27).   
  
CC smal l  ribosomal  subunit 46 0.00001 0.00001 0.008 (-)
CC large ribosomal  subunit 56 0.00001 0.00001 0.02 (-)
CC cytosol ic ribosome 82 0.00001 0.00001 0.018 (-)
CC cortica l  cytoskeleton 36 0.00018 0.00554 0.005 (+) 
CC actin fi lament bundle 33 0.00021 0.03187 0.017 (+)
CC actomyos in 37 0.00027 0.02331 0.018 (+)
CC smal l  nuclear ribonucleoprotein complex 20 0.00067 0.02257 0.021 (-)
CC nuclear repl isome 9 0.0009 0.00672 < 0.001 (-) 
CC sarcoplasm 21 0.00098 0.03499 0.004 (+) 
CC sarcoplasmic reticulum 21 0.00098 0.03499 0.004 (+) 
CC trans lation preini tiation complex 12 0.00104 0.00025 0.016 (-)
CC polysome 20 0.00124 0.00118 0.022 (-)
CC lamel l ipodium 63 0.00126 0.0564 0.084 (+)
CC repl ication fork 21 0.00148 0.00252 < 0.001 (-) 
CC platelet dense tubular network 7 0.00267 0.14285 0.016 (+)
CC eukaryotic trans lation ini tiation factor 3 complex 13 0.00276 0.00826 0.019 (-)
CC cel l  tra i l ing edge 7 0.00497 0.06893 0.059 (+)
CC uropod 7 0.00497 0.06893 0.059 (+)
CC rough endoplasmic reticulum membrane 11 0.01946 0.00479 0.026 (+)
CC MHC protein complex 15 0.0757 0.00443 0.271 (-)
MF mRNA binding 54 0.00029 0.03093 0.013 (-)
MF rRNA binding 24 0.00091 0.00111 0.011 (-)
MF immunoglobul in binding 10 0.00116 0.00777 0.006 (+)
MF ubiquitin binding 35 0.00151 0.00454 0.057 (+)
MF smal l  conjugating protein binding 38 0.00185 0.00245 0.037 (+)
MF ion channel  inhibitor activi ty 10 0.00199 0.0184 0.001 (+) 
MF trans lation factor activi ty, nucleic acid binding 52 0.00231 0.00147 0.021 (-)
MF smal l  GTPase regulator activi ty 70 0.00492 0.01221 0.088 (+)
MF pre-mRNA binding 10 0.04631 0.0013 0.002 (-) 
MF hydrolase activi ty, acting on ether bonds 5 0.0624 0.00444 0.057 (+)
MF peroxiredoxin activi ty 6 0.0645 0.00424 0.143 (-)
MF cargo receptor activi ty 11 0.52337 0.00392 0.479 (+)
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Figure 27. Up-regulated gene expression in biological functions/processes of ACS patients with CKD 
PLATELET MORPHOGENESIS 
REGULATION OF ACTIN CYTOSKELETON 
REGULATION OF TRANSCRIPTION IN RESPONSE TO STRESS 
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Conversely, some GO categories were down-regulated in platelets of ACS patients with CKD, such as 
translational elongation (EEF1D, EEF1A1, RPS17, RPL10A, RPL33, RPL9…), ribonucleoprotein complex 
assembly and subunit organization (RPL38, RPS19, EIF3M, EIF3L), negative regulation of RNA splicing 
(RPS26, RPS13, PTBP3…) (Figure 28).   
 
 
  
TRANSLATIONAL ELONGATION 
 103 
 
 
 
 
Figure 28. Down-regulated gene expression in biological functions/processes of ACS patients with CKD 
  
RIBONUCLEOPROTEIN COMPLEX ASSEMBLY AND ORGANIZATION 
NEGATIVE REGULATION OF RNA SPLICING 
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Gene expression enrichment analysis performed using the KEGG database, for understanding high-level 
functions and utilities of the biological system from molecular-level information, has confirmed that some 
processes (for example those involved in focal adhesion) have transcripts mostly up-regulated in CKD 
platelets, as well as others are down-regulated in CKD platelets (such as those involving ribosomes and 
their functions) (Figure 29).   
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Figure 29.  Focal adhesion (panel A) pathway and ribosome (panel B) 
 
Class prediction by Lasso Logistic Regression analysis and cross-validation has shown that the percent of 
patients correctly classified during cross-validation in a gene expression and covariates combined model is 
88%: the analysis has allowed to identify 20 differentially expressed genes that cluster the group of patients 
with or without CKD with an error of  12%. 
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PROTEOMIC DATA: CKD PATIENTS PRESENT A DIFFERENT PLASMA PROTEOME PATTERN 
COMPARED TO PATIENTS WITHOUT CKD       
 In order to compare the proteomic profile of plasma of ACS and SA patients with and without chronic 
kidney disease, a proteomic approach, based on two dimensional electrophoresis for protein separation 
and mass spectrometry for their identification, has been employed on a selected group of patients, 5 well-
matched patients for each group.  Then, immunoenzymatic assays have been performed to confirm the 
results obtained by two dimensional electrophoresis on a larger cohort of patients.                                                       
The proteomic study has revealed that patients with CKD present a different plasma proteome pattern 
compared to patients without CKD (both SA and ACS): in particular, in ACS patients the image analysis has 
shown that 8 protein spots, corresponding to different isoforms of 3 proteins (α1-microglobulin, Retinol 
binding protein 4 and Hemopexin), are significantly up-regulated in patients with CKD, and two proteins, 
Fetuin A and α1-antichimotrypsin, are down-regulated in CKD patients (Figure 30 and Table 6). 
 
Figure 30.  Representative image of 2-DE of plasma proteins from ACS patients. Differentially expressed proteins in patients with or 
without CKD are circled.  
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# Accession  Description Fold Anova (p) Highest Mean 
185 P02760 AMBP protein precursor   1.6 0.0015 CKD 
210 P02753 Retinol-binding protein 4 1.5 0.0005 CKD 
208 P02753 Retinol-binding protein 4 2.1 0.005 CKD 
259 P02790 Hemopexin  1.3 0.0007 CKD 
184  Unknown protein 1.7 0.001 CKD 
252 P02765 Fetuin A  1.4 0.005 No CKD 
106 P01011 Alpha 1 antichymotrypsin precursor  1.3 0.012 No CKD 
257  Unknown protein 1.4 0.02 No CKD 
 
Table 6. Differentially expressed proteins in ACS patients with or without CKD 
 
In SA patients the image analysis has revealed that 8 protein spots, corresponding to different isoforms of 4 
proteins (Haptoglobin, Retinol binding protein 4, α1β-glycoprotein and Ceruloplasmin), are significantly up-
regulated in patients with CKD (Figure 31 and Table 7). 
                           
Figure 31. Representative image of 2-DE of plasma proteins from SA patients. Differentially expressed proteins in patients with or 
without CKD are circled. 
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# Accession  Description Fold Anova (p) Highest Mean 
83 P04217 Alpha 1B glycoprotein precursor  1.2 0.005 CKD 
152 P00738 Haptoglobin beta chain  1.3 0.03 CKD 
155 P00738 Haptoglobin beta chain  1.2 0.016 CKD 
156 P00738 Haptoglobin beta chain  1.3 0.0004 CKD 
210 P02753 Retinol-binding protein 4 1.3 0.004 CKD 
218 P00738 Haptoglobin alpha chain   3.4 0.015 CKD 
219 P00738 Haptoglobin alpha chain   4.2 0.005 CKD 
236 P00450 Ceruloplasmin  1.6 0.05 CKD 
 
Table 7. Differentially expressed proteins in SA patients with or without CKD 
 
 
The immunoenzymatic assays, performed on a larger cohort of ACS patients (n=31 with CKD and n=108 
without CKD) and SA patients (n=49 with CKD and n=168 without CKD), have confirmed the up-regulation in 
CKD patients of α1-Microglobulin (A1M), that is 2-fold higher in ACS CKD patients and 1.5-fold higher in SA 
CKD patients, Retinol Binding Protein 4 (RBP4), 1.5-fold higher both in ACS and SA CKD patients and  
Haptoglobin (HPT), 1.2-fold higher both in ACS and SA CKD patients (Figure 32). 
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Figure 32. Immunoenzymatic analysis: A1M, RPB4 and HPT plasma concentrations. 
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The plasma levels of all these proteins have shown a negative correlation with the glomerular filtration rate 
(GFR), being higher with the increase of kidney disease (Figure 33). 
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Figure 33 Correlation between A1M (panel A), RBP4 (panel B) and HPT (panel C) plasma levels and the Glomerular Filtration Rate 
(GFR). 
 
Immunoenzymatic analysis has not confirmed the differences observed for Fetuin-A, which is present at 
similar levels in the plasma of patients with and without CKD (both in ACS and in SA patients) (Figure 34 and 
35). 
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Figure 34. Immunoenzymatic analysis of Fetuin A plasma concentrations. 
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Figure 35. Correlation between Fetuin A plasma levels and the Glomerular Filtration Rate (GFR). 
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DISCUSSION 
Patients with chronic kidney disease (CKD) have a high burden of cardiovascular morbidity and mortality; 
indeed, in coronary artery disease (CAD), CKD represents a potent and independent risk factor for adverse 
outcome 62. “Traditional” atherosclerotic risk factors such as diabetes, hypertension, dyslipidemia and older 
age, have been found to be independent predictors of CAD in CKD 15. Moreover, CKD patients present also 
“non-traditional” cardiovascular risk factors such as inflammation, oxidative stress, vascular calcification 
and a uremic milieu, that may contribute to the risk and pathogenesis of CAD 288. Patients with CKD may 
experience two opposite haemostatic complications: bleeding diathesis and thrombotic tendencies. The 
bleeding profile has been attributed classically to abnormalities of platelet function that include impaired 
adhesion 290 and decreased aggregation 290, 291 and to alteration in the balance of pro- and anti-thrombotic 
factors in blood 292, 293, while the thrombotic risk seems to be also due to an activated coagulation system of 
CKD patients 207, 208. 
 Furthermore, CKD may influence the response to antiplatelet therapy: patients with CKD have less 
therapeutic benefit of antiplatelet therapy 119, 243. Recent ﬁndings suggest that renal function might affect 
the clinical efﬁcacy of Clopidogrel. It has been hypothesized that patients with chronic kidney disease might 
have reduced Clopidogrel-induced platelet inhibition due to a speciﬁc impairment of the P2Y12 pathway 243. 
Moreover, despite the use of 75 mg/die Aspirin, in some patients (~10%) thrombosis still occurs and this 
implies that, in these subjects, Aspirin is sub-effective 301. This suboptimal response in patients undergoing 
percutaneous coronary intervention is associated with increased risk of thrombosis and increased major 
adverse clinical events (MACE) in long-term follow-up 224-226, 296.   
Some years ago, our group described that ACS patients present a higher expression, compared to SA 
patients, of platelet-associated TF, a more recently described marker of platelet activation, that may 
account for the higher prothrombotic potential of ACS patient 204. In order to further characterize the effect 
of CKD on the platelet activation profile, in this study we have focused our attention in particular on the 
expression of Tissue Factor (TF) and of the other classical markers of platelet activation. We have found 
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that the expression levels of the classical platelet activation markers, P-selectin and GP IIb/IIIa, were 
comparable between patients with and without CKD, both in stable angina (SA) and in ACS patients. On the 
contrary, we observed that CKD significantly affects platelet Tissue Factor expression; several approaches 
have been used to support this finding and the results can be summarized as follows: 1) in resting 
conditions the percentage of circulating platelets carrying TF on their surface is significantly lower in 
patients with CKD compared to patients without CKD; a similar feature was observed analyzing the 
percentage of TF-positive monocyte-platelet and granulocyte-platelet aggregates; 2) after ex vivo ADP 
stimulation, the percentage of TF-positive platelets is also overall lower in CKD patients compared to that of 
patients without CKD; 3) the total platelet content of TF, evaluated by performing intracellular staining, 
confirms that patients with CKD have significantly lower number of circulating TF positive platelets; 4) there 
is a highly significant inverse correlation between the number of TF positive platelets and the severity of 
renal failure. 
The finding that CAD patients with CKD are characterized by a lower number of circulating TF-positive 
platelets and leukocyte-platelet aggregates provides further information on the platelet dysfunction state 
responsible for the haemostatic abnormalities typical of these patients and suggests potential new 
mechanisms contributing to the higher bleeding rather than the thrombotic risk of CKD patients.  
 
In order to further characterize this peculiar phenotype found in CKD patients and their haemostatic 
tendencies, we took advantage from the use of thromboelastometry, a technique that provides clinically 
relevant information on the dynamics of clot development, stabilization and dissolution reflecting in vivo 
haemostasis. While the assay confirmed a higher prothrombotic potential in ACS compared to SA patients 
(in line with the platelet-associated TF expression), the presence of CKD exerted different effect on the 
global haemostatic potential. Indeed, CKD resulted in a shorter and slower clotting time in SA and ACS 
patients, respectively. Since the contribution of the coagulation cascade to the fibrin clot formation is 
similar between SA and ACS patients with CKD, we can speculate that the differences observed in the global 
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haemostatic capacity previously described might be related to a platelet function more “compromised” in 
ACS patients with CKD compared to SA patients. 
 
The presence of TF in platelets has been proposed first in 2000 by Giesen et al. who postulated that 
thrombus formation and propagation, upon atherosclerotic plaque rupture, could take advantage from 
blood-born tissue factor: circulating platelets, carrying TF derived from microparticles, may themselves 
trigger the activation of the coagulation cascade 188. Since then, several papers have documented the 
presence of TF in human platelets, suggesting that at least three mechanisms are involved in the presence 
of TF in platelets: 1) the microparticle-transfer mechanism; 2) the storage within the α-granules and the 
open canalicular system and 3) the de novo protein synthesis from the TF specific messenger RNA (mRNA). 
In 2003 our group provided the evidence that human CD34+-derived megakaryocytes express the TF mRNA 
199. Thus, although it is commonly believed that the only mechanism responsible for the presence of TF in 
platelets is through the uptake of TF-positive microparticles released by activated endothelial cells or 
leukocytes, it can be speculated that the TF mRNA and protein detectable in platelets could be the result of 
a direct transfer from megakaryocytes. Recently our group, using an in vitro cell culture model able to 
recapitulate megakaryocyte differentiation and platelet biogenesis, has provided consistent evidence that 
TF is an endogenously synthesized protein that characterizes megakaryocyte maturation. Since the cell 
system used allowed us to study mRNA and protein expression in the absence of any crosstalk with other 
cell or microparticle, we have also provided the evidence for the direct transfer of both TF mRNA and 
protein from megakaryocytes to a subset of platelets where it contributes to their thrombin generation 
capacity. Of interest, the percentage of TF-positive platelets that we have observed in vitro (both with Meg-
platelets and with CD34+-derived platelets) was virtually identical to the amount found in blood from 
healthy individuals. This striking data suggests that a fine-tuned mechanism, which deserves further 
investigation in order to dissect the molecular pathways involved in its regulation, is responsible for the 
controlled delivery of TF from megakaryocytes to platelets. All together these data support the concept 
that, under physiological conditions, a percentage of TF expressing megakaryocytes are committed to 
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release in the bloodstream a constant number of platelets containing either TF protein or TF pre-mRNA 302. 
Under pathological conditions, such as ACS, cancer, autoimmune diseases, alterations in the 
megakaryocyte transcriptome and proteome as well as in the release of new platelets may occur and the 
increase in the number of TF-positive platelets may be the result of a (A) mechanism taking place in the 
bloodstream and resulting in the splicing of the TF pre-mRNA and de novo protein synthesis or (B) a 
mechanism taking place in the bone marrow inducing more megakaryocytes to express TF and to release 
TF-positive 303. We have recently reported that in spontaneously hypertensive stroke-prone rats the 
percentage of circulating TF-positive platelets directly correlated with blood pressure and is the results of 
an increased number of TF-positive megakaryocytes which release in the bloodstream a higher number of 
TF-positive platelets (M. Brambilla et al. Captopril downregulates circulating Tissue Factor expression in 
stroke-prone rats. Manuscript in preparation).  
Therefore, based on these findings, it could be speculated that the lower number of circulating TF-positive 
platelets as well as the lower expression of TF-associated to platelets that we have observed in CKD 
patients, may be the result of: 1) a mechanism acting at the megakaryocyte level affecting both the number 
and the amount of TF per platelet; 2) a mechanism acting in the bloodstream, where uremic toxins might 
affect the platelet protein composition. 
 
As previously mentioned, although platelets don’t have a nucleus, they contain ~2000-7000 transcripts 143, 
148, 304, 305. Microarray analysis of the platelet transcriptome from healthy subjects identified mRNAs that 
encode for cell surface receptors and glycoproteins, as well as proteins involved in metabolism, signaling, 
inflammation, and immunity 143, 306, 307. The finding that platelets can use their mRNA pool to perform new 
protein synthesis in response to cellular activation is of great importance, since these mechanisms allow 
them to modify their protein phenotype and, as a consequence, their functions 149. It has been reported 
that specific mRNAs may vary in clinical conditions such as sickle cell disease 308, STEMI 265 and NSTEMI 205. 
Identification of disease-associated platelet-specific transcripts is of particular relevance in platelet 
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pathophysiology, since it may lead to the discovery of novel therapeutic targets.    No data are so far 
available on the platelet transcriptome profiling associated with CKD in CAD patients. The platelet gene 
expression profile, performed on a subgroup of ACS patients with and without CKD, identified 60 unique 
differentially expressed genes: 44 genes increased and 16 genes decreased in patients with chronic kidney 
disease. Functional annotation clustering and gene set enrichment analysis of the differentially expressed 
genes have shown that many biological processes and/or molecular pathways are altered in CKD platelets.  
In particular, we have observed the up-regulation of genes involved in platelet aggregation (such as MYL9, 
FERMT3, ITGB3, STXBP3, etc) and degranulation (such as PDGFB, PDGFA, ITGA2B, LAMP2, etc), regulation of 
actin cytoskeleton (such as CAPZB, GSN, etc), anti-oxidant genes (such as GPx4, ATOX1, etc), thrombosis-
related genes (such as ZNF331, ZNF524, etc). Genes involved in translational elongation (such as EEF1D, 
EEF1A1, RPS17, RPL10A, RPL33, RPL9, etc), ribonucleoprotein complex assembly and subunit organization 
(RPL38, RPS19, EIF3M, EIF3L, etc) were among those down-regulated. 
The findings that genes involved in platelet activation are up-regulated (~1.3 fold change) in CKD patients 
seems apparently in contradiction with the well-documented platelet function studies 210, 212, 309, 310. It is 
worth mentioning, however, on this regard, that the down-regulation of genes involved in translational 
elongation and ribonucleoprotein complex assembly and subunit organization, that we have observed, is 
far higher (~1.8 fold change) compared to the up-regulated genes. This may affect the de novo protein 
synthesis capacity of platelets from CKD patients and globally account for the documented platelet 
dysfunction. 
Furthermore, Spearman correlation analysis between the glomerular filtration rate (GFR) and the 
expression of platelet genes revealed that the expression of 98 unique genes significantly correlates with 
the decrease of GFR: the expression levels of 79 genes were negatively and 19 positively correlated. Among 
the negatively correlated genes, we found glutathione peroxidase 4 (GPx4) and antioxidant 1 copper 
chaperone (ATOX1), genes which play a prominent role in the defence against oxidative damage to cells 311. 
It could be speculated that this might be a mechanism used by platelets to counteract oxidative stress 
conditions in CKD.  In line with this concept is also the expression of  ZNF331 and ZNF524, which are two 
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zinc finger proteins essential for megakaryocyte development, platelet release and, overall, haemostasis 312.                    
The increased expression of these genes observed together with the reduction of GFR might be again a 
mechanism acting at the bone marrow level in order to control and maintain haemostasis.  Among the 
genes positively correlated with the GFR, it is worth mentioning C-type lectin domain family 2 (CLEC2) 
which is a platelet-activating receptor essential for stable aggregate formation 313.  Increased bleeding 
times and defective arterial thrombus formation in CLEC2–deﬁcient mice has been previously described 313. 
Although we have not investigated in the present study whether the lower levels of CLEC2 mRNA are 
paralleled by a lower amount of CLEC2 protein, this finding may pave the way for further investigation 
which may help to dissect the mechanisms responsible for the higher haemorrhagic risk of CKD patients. 
 
Similarly to the transcriptome, also the plasma proteomic profile may change in clinical conditions: 
proteomics has the potential to reveal proteins associated with the etiopathogenesis of diseases and that 
could be used as diagnostic or prognostic biomarkers 297, 314-317. In literature there is evidence that patients 
with end-stage renal disease (ESRD) present changes in the expression of plasma proteins associated to 
atherosclerosis 252, 298-300, but despite the increasing number of CVD patients with mild-to-moderate CKD, 
there are no studies focused on the plasma protein changes that may occur in these patients. The plasma 
proteomic analysis of the patients enrolled in our study (CVD patients with mild-to-moderate CKD) has 
shown a significant increase in the expression of α 1-Microglobulin (A1M), Retinol Binding Protein 4 (RBP4) 
and Haptoglobin (HPT) in patients with CKD (both SA and ACS patients). 
α1-Microglobulin, member of the lipocalin family, is a tissue housekeeping protein with a central role in 
cleaning of oxidative waste products (free radicals and heme groups), macromolecular repair, and 
antioxidation protection; in literature its urinary increase is described in CKD patients and it is considered a 
diagnostic marker of renal failure 318-320. 
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The plasma increase of A1M levels in CKD patients enrolled in our study confirms and highlights the 
importance of this protein as early marker of pathology. It should be considered however that with the 
worsening of CKD, the protective effects of the protein are weakened by the increased urinary excretion.  
In this proteomic study, we have also observed for the first time the plasma over-expression of Retinol 
binding protein 4 and Haptoglobin, two new CKD-related proteins. 
Retinol binding protein4, belonging, as A1M, to the lipocalin family, is an adipokine involved in the early 
phases of the development of inflammation and insulin resistance 321. Circulating RBP4 has  been  found  to  
be  associated  with  some measures of subclinical cardiovascular disease (CVD). Speciﬁcally, plasma RBP4 
levels have been shown to be positively correlated with  the  echocardiographically  measured  left  
ventricular  wall thickness  and  carotid  intima-media  thickness  (IMT) 322, 323. The presence of clinical 
arteriosclerosis is associated with higher circulating RBP4 324 and it has been associated with any prior 
cerebrovascular disease and with any prior hospitalization for CVD 325. Although a well-documented  
relationship  exists  between  RBP4 and  CVD,  it  remains  to  be  elucidated  whether  RBP4  is  causally 
involved in the development of CVD 325, 326. The higher plasma levels of RBP4 in the enrolled CKD patients 
compared to those without CKD further underline the higher CVD risk. 
Haptoglobin is an acute phase protein able to irreversibly bind to haemoglobin, thus preventing iron loss 
and renal damage. HPT-haemoglobin complexes are endocytosed by the cluster of differentiation receptor 
163 (CD163) in mature tissue macrophages present in the spleen, liver, Kupfer cells of the liver and bone 
marrow 327. Haptoglobin also acts as an anti-oxidant, has antibacterial activity and plays a role in 
modulating many aspects of the acute phase response 328, 329.   
As mentioned before, these three proteins present a negative correlation with the value of glomerular 
filtration rate (GFR): the worst is the kidney function, the higher are plasma levels of these proteins. 
Overall, in CKD patients, there is the over-expression of protective proteins, but also of proteins that could 
promote the progression of CVD.   
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In conclusion, all these data shed new light on additional mechanisms involved in CKD-associated 
haemostatic (thrombotic and haemorrhagic) profile of CAD patients. The peculiar platelet phenotype 
(lower amount of TF-positive platelets and leukocyte-platelet aggregates), found in CKD patients, doesn’t 
seem to account for the prothrombotic potential that could be ascribed to these patients, but rather it may 
provide further explanation for their bleeding risk which is related to platelet dysfunction. 
Furthermore, the global haemostatic capacity of whole blood assessed in the presence of an inhibitor of 
platelet contribution to clot formation has revealed that CKD patients have a higher procoagulant potential 
which may in part account for their thrombotic tendencies. 
CKD patients present also a differential gene expression profile compared to patients without CKD. Among 
the pathways affected by CKD, interestingly, we found a significant down-regulation of genes involved in 
RNA processing and protein synthesis thus potentially affecting the total RNA expression and overall the 
platelet function. 
Finally this proteomic study has revealed that patients with chronic kidney disease have a different plasma 
proteome pattern both in ACS and SA patients: the plasma proteomic analysis has identified differentially 
expressed proteins involved in mechanisms responsible for the progress of the renal and cardiovascular 
disease (pro-inflammatory proteins), but also in protective mechanisms (anti-oxidant and anti-
inflammatory proteins). 
 
 
 
 
 
 
 122 
 
 
 
 
 
 
 
 
 
 
 
 
 
REFERENCES 
 
 123 
 
REFERENCES 
1. K/doqi clinical practice guidelines for chronic kidney disease: Evaluation, classification, and 
stratification. American journal of kidney diseases : the official journal of the National Kidney 
Foundation. 2002;39:S1-266 
2. Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165-180 
3. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: Epidemiology, social, 
and economic implications. Kidney international. Supplement. 2005:S7-S10 
4. Mills KT, Xu Y, Zhang W, Bundy JD, Chen CS, Kelly TN, Chen J, He J. A systematic analysis of 
worldwide population-based data on the global burden of chronic kidney disease in 2010. Kidney 
international. 2015 
5. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes 
of death, 1990-2013: A systematic analysis for the global burden of disease study 2013. Lancet. 
2015;385:117-171 
6. Go AS, Chertow GM, Fan D, McCulloch CE, Hsu CY. Chronic kidney disease and the risks of death, 
cardiovascular events, and hospitalization. The New England journal of medicine. 2004;351:1296-
1305 
7. Matsushita K, van der Velde M, Astor BC, Woodward M, Levey AS, de Jong PE, Coresh J, Gansevoort 
RT. Association of estimated glomerular filtration rate and albuminuria with all-cause and 
cardiovascular mortality in general population cohorts: A collaborative meta-analysis. Lancet. 
2010;375:2073-2081 
8. Lysaght MJ. Maintenance dialysis population dynamics: Current trends and long-term implications. 
Journal of the American Society of Nephrology : JASN. 2002;13 Suppl 1:S37-40 
9. Levey AS, Coresh J, Balk E, Kausz AT, Levin A, Steffes MW, Hogg RJ, Perrone RD, Lau J, Eknoyan G. 
National kidney foundation practice guidelines for chronic kidney disease: Evaluation, classification, 
and stratification. Annals of internal medicine. 2003;139:137-147 
10. Meguid El Nahas A, Bello AK. Chronic kidney disease: The global challenge. Lancet. 2005;365:331-
340 
11. Bergman S, Key BO, Kirk KA, Warnock DG, Rostant SG. Kidney disease in the first-degree relatives of 
african-americans with hypertensive end-stage renal disease. American journal of kidney diseases : 
the official journal of the National Kidney Foundation. 1996;27:341-346 
12. Brenner BM, Chertow GM. Congenital oligonephropathy and the etiology of adult hypertension and 
progressive renal injury. American journal of kidney diseases : the official journal of the National 
Kidney Foundation. 1994;23:171-175 
13. Collins AJ, Kasiske B, Herzog C, Chavers B, Foley R, Gilbertson D, Grimm R, Liu J, Louis T, Manning W, 
Matas A, McBean M, Murray A, St Peter W, Xue J, Fan Q, Guo H, Li S, Roberts T, Snyder J, Solid C, 
Wang C, Weinhandl E, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, Frazier E, Johnson 
R, Sheets D, Forrest B, Berrini D, Constantini E, Everson S, Frederick P, Eggers P, Agodoa L. Excerpts 
from the united states renal data system 2004 annual data report: Atlas of end-stage renal disease 
in the united states. American journal of kidney diseases : the official journal of the National Kidney 
Foundation. 2005;45:A5-7, S1-280 
14. Hillege HL, Fidler V, Diercks GF, van Gilst WH, de Zeeuw D, van Veldhuisen DJ, Gans RO, Janssen 
WM, Grobbee DE, de Jong PE. Urinary albumin excretion predicts cardiovascular and 
noncardiovascular mortality in general population. Circulation. 2002;106:1777-1782 
15. Sarnak MJ, Levey AS, Schoolwerth AC, Coresh J, Culleton B, Hamm LL, McCullough PA, Kasiske BL, 
Kelepouris E, Klag MJ, Parfrey P, Pfeffer M, Raij L, Spinosa DJ, Wilson PW. Kidney disease as a risk 
factor for development of cardiovascular disease: A statement from the american heart association 
councils on kidney in cardiovascular disease, high blood pressure research, clinical cardiology, and 
epidemiology and prevention. Circulation. 2003;108:2154-2169 
16. Jungers P, Chauveau P, Descamps-Latscha B, Labrunie M, Giraud E, Man NK, Grunfeld JP, Jacobs C. 
Age and gender-related incidence of chronic renal failure in a french urban area: A prospective 
 124 
 
epidemiologic study. Nephrology, dialysis, transplantation : official publication of the European 
Dialysis and Transplant Association - European Renal Association. 1996;11:1542-1546 
17. Hannedouche T, Chauveau P, Kalou F, Albouze G, Lacour B, Jungers P. Factors affecting progression 
in advanced chronic renal failure. Clinical nephrology. 1993;39:312-320 
18. Tarver-Carr ME, Powe NR, Eberhardt MS, LaVeist TA, Kington RS, Coresh J, Brancati FL. Excess risk 
of chronic kidney disease among african-american versus white subjects in the united states: A 
population-based study of potential explanatory factors. Journal of the American Society of 
Nephrology : JASN. 2002;13:2363-2370 
19. Klahr S, Levey AS, Beck GJ, Caggiula AW, Hunsicker L, Kusek JW, Striker G. The effects of dietary 
protein restriction and blood-pressure control on the progression of chronic renal disease. 
Modification of diet in renal disease study group. The New England journal of medicine. 
1994;330:877-884 
20. Jafar TH, Stark PC, Schmid CH, Landa M, Maschio G, de Jong PE, de Zeeuw D, Shahinfar S, Toto R, 
Levey AS. Progression of chronic kidney disease: The role of blood pressure control, proteinuria, 
and angiotensin-converting enzyme inhibition: A patient-level meta-analysis. Annals of internal 
medicine. 2003;139:244-252 
21. Iseki K, Ikemiya Y, Iseki C, Takishita S. Proteinuria and the risk of developing end-stage renal 
disease. Kidney international. 2003;63:1468-1474 
22. Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. The New England journal of 
medicine. 1998;339:1448-1456 
23. Effect of intensive therapy on the development and progression of diabetic nephropathy in the 
diabetes control and complications trial. The diabetes control and complications (dcct) research 
group. Kidney international. 1995;47:1703-1720 
24. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of 
nephropathy in type 2 diabetes: The united kingdom prospective diabetes study (ukpds 64). Kidney 
international. 2003;63:225-232 
25. Keane WF, Kasiske BL, O'Donnell MP, Kim Y. The role of altered lipid metabolism in the progression 
of renal disease: Experimental evidence. American journal of kidney diseases : the official journal of 
the National Kidney Foundation. 1991;17:38-42 
26. Johnson RJ, Kivlighn SD, Kim YG, Suga S, Fogo AB. Reappraisal of the pathogenesis and 
consequences of hyperuricemia in hypertension, cardiovascular disease, and renal disease. 
American journal of kidney diseases : the official journal of the National Kidney Foundation. 
1999;33:225-234 
27. de Jong PE, Verhave JC, Pinto-Sietsma SJ, Hillege HL. Obesity and target organ damage: The kidney. 
International journal of obesity and related metabolic disorders : journal of the International 
Association for the Study of Obesity. 2002;26 Suppl 4:S21-24 
28. Kambham N, Markowitz GS, Valeri AM, Lin J, D'Agati VD. Obesity-related glomerulopathy: An 
emerging epidemic. Kidney international. 2001;59:1498-1509 
29. Verani RR. Obesity-associated focal segmental glomerulosclerosis: Pathological features of the 
lesion and relationship with cardiomegaly and hyperlipidemia. American journal of kidney diseases : 
the official journal of the National Kidney Foundation. 1992;20:629-634 
30. Bonnet F, Deprele C, Sassolas A, Moulin P, Alamartine E, Berthezene F, Berthoux F. Excessive body 
weight as a new independent risk factor for clinical and pathological progression in primary iga 
nephritis. American journal of kidney diseases : the official journal of the National Kidney 
Foundation. 2001;37:720-727 
31. Pinto-Sietsma SJ, Mulder J, Janssen WM, Hillege HL, de Zeeuw D, de Jong PE. Smoking is related to 
albuminuria and abnormal renal function in nondiabetic persons. Annals of internal medicine. 
2000;133:585-591 
32. Klag MJ, Whelton PK, Perneger TV. Analgesics and chronic renal disease. Current opinion in 
nephrology and hypertension. 1996;5:236-241 
 125 
 
33. Perneger TV, Whelton PK, Klag MJ. Risk of kidney failure associated with the use of acetaminophen, 
aspirin, and nonsteroidal antiinflammatory drugs. The New England journal of medicine. 
1994;331:1675-1679 
34. Morlans M, Laporte JR, Vidal X, Cabeza D, Stolley PD. End-stage renal disease and non-narcotic 
analgesics: A case-control study. British journal of clinical pharmacology. 1990;30:717-723 
35. Schwartz GJ, Furth SL. Glomerular filtration rate measurement and estimation in chronic kidney 
disease. Pediatr Nephrol. 2007;22:1839-1848 
36. Kriz W, Gretz N, Lemley KV. Progression of glomerular diseases: Is the podocyte the culprit? Kidney 
international. 1998;54:687-697 
37. Hallan SI, Matsushita K, Sang Y, Mahmoodi BK, Black C, Ishani A, Kleefstra N, Naimark D, Roderick P, 
Tonelli M, Wetzels JF, Astor BC, Gansevoort RT, Levin A, Wen CP, Coresh J. Age and association of 
kidney measures with mortality and end-stage renal disease. JAMA : the journal of the American 
Medical Association. 2012;308:2349-2360 
38. de Boer IH. Chronic kidney disease-a challenge for all ages. JAMA : the journal of the American 
Medical Association. 2012;308:2401-2402 
39. Schwarz S, Trivedi BK, Kalantar-Zadeh K, Kovesdy CP. Association of disorders in mineral 
metabolism with progression of chronic kidney disease. Clinical journal of the American Society of 
Nephrology : CJASN. 2006;1:825-831 
40. Menon V, Greene T, Pereira AA, Wang X, Beck GJ, Kusek JW, Collins AJ, Levey AS, Sarnak MJ. 
Relationship of phosphorus and calcium-phosphorus product with mortality in ckd. American 
journal of kidney diseases : the official journal of the National Kidney Foundation. 2005;46:455-463 
41. Bellasi A, Mandreoli M, Baldrati L, Corradini M, Di Nicolo P, Malmusi G, Santoro A. Chronic kidney 
disease progression and outcome according to serum phosphorus in mild-to-moderate kidney 
dysfunction. Clinical journal of the American Society of Nephrology : CJASN. 2011;6:883-891 
42. Voormolen N, Noordzij M, Grootendorst DC, Beetz I, Sijpkens YW, van Manen JG, Boeschoten EW, 
Huisman RM, Krediet RT, Dekker FW. High plasma phosphate as a risk factor for decline in renal 
function and mortality in pre-dialysis patients. Nephrology, dialysis, transplantation : official 
publication of the European Dialysis and Transplant Association - European Renal Association. 
2007;22:2909-2916 
43. Kovesdy CP. Management of hyperkalaemia in chronic kidney disease. Nature reviews. Nephrology. 
2014;10:653-662 
44. DuBose TD, Jr. Acid-base physiology in uremia. Artificial organs. 1982;6:363-369 
45. Ray S, Piraino B, Chong TK, el-Shahawy M, Puschett JB. Acid excretion and serum electrolyte 
patterns in patients with advanced chronic renal failure. Mineral and electrolyte metabolism. 
1990;16:355-361 
46. Kraut JA, Kurtz I. Metabolic acidosis of ckd: Diagnosis, clinical characteristics, and treatment. 
American journal of kidney diseases : the official journal of the National Kidney Foundation. 
2005;45:978-993 
47. Kawakami T, Inagi R, Wada T, Tanaka T, Fujita T, Nangaku M. Indoxyl sulfate inhibits proliferation of 
human proximal tubular cells via endoplasmic reticulum stress. American journal of physiology. 
Renal physiology. 2010;299:F568-576 
48. Niwa T. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular 
disease: Experimental and clinical effects of oral sorbent ast-120. Therapeutic apheresis and dialysis 
: official peer-reviewed journal of the International Society for Apheresis, the Japanese Society for 
Apheresis, the Japanese Society for Dialysis Therapy. 2011;15:120-124 
49. Barreto FC, Barreto DV, Liabeuf S, Meert N, Glorieux G, Temmar M, Choukroun G, Vanholder R, 
Massy ZA. Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney 
disease patients. Clinical journal of the American Society of Nephrology : CJASN. 2009;4:1551-1558 
50. Eustace JA, Astor B, Muntner PM, Ikizler TA, Coresh J. Prevalence of acidosis and inflammation and 
their association with low serum albumin in chronic kidney disease. Kidney international. 
2004;65:1031-1040 
 126 
 
51. Lefebvre A, de Vernejoul MC, Gueris J, Goldfarb B, Graulet AM, Morieux C. Optimal correction of 
acidosis changes progression of dialysis osteodystrophy. Kidney international. 1989;36:1112-1118 
52. Lemann J, Jr., Bushinsky DA, Hamm LL. Bone buffering of acid and base in humans. American 
journal of physiology. Renal physiology. 2003;285:F811-832 
53. Tomey MI, Winston JA. Cardiovascular pathophysiology in chronic kidney disease: Opportunities to 
transition from disease to health. Annals of global health. 2014;80:69-76 
54. Stauffer ME, Fan T. Prevalence of anemia in chronic kidney disease in the united states. PloS one. 
2014;9:e84943 
55. Moe S, Drueke T, Cunningham J, Goodman W, Martin K, Olgaard K, Ott S, Sprague S, Lameire N, 
Eknoyan G. Definition, evaluation, and classification of renal osteodystrophy: A position statement 
from kidney disease: Improving global outcomes (kdigo). Kidney international. 2006;69:1945-1953 
56. Kazama JJ, Matsuo K, Iwasaki Y, Fukagawa M. Chronic kidney disease and bone metabolism. Journal 
of bone and mineral metabolism. 2015;33:245-252 
57. Mac Way F, Lessard M, Lafage-Proust MH. Pathophysiology of chronic kidney disease-mineral and 
bone disorder. Joint, bone, spine : revue du rhumatisme. 2012;79:544-549 
58. Bover J, Urena P, Brandenburg V, Goldsmith D, Ruiz C, DaSilva I, Bosch RJ. Adynamic bone disease: 
From bone to vessels in chronic kidney disease. Seminars in nephrology. 2014;34:626-640 
59. Reginato AJ, Falasca GF, Pappu R, McKnight B, Agha A. Musculoskeletal manifestations of 
osteomalacia: Report of 26 cases and literature review. Seminars in arthritis and rheumatism. 
1999;28:287-304 
60. Tangri N, Stevens LA, Griffith J, Tighiouart H, Djurdjev O, Naimark D, Levin A, Levey AS. A predictive 
model for progression of chronic kidney disease to kidney failure. JAMA : the journal of the 
American Medical Association. 2011;305:1553-1559 
61. Collins AJ, Foley RN, Herzog C, Chavers B, Gilbertson D, Ishani A, Kasiske B, Liu J, Mau LW, McBean 
M, Murray A, St Peter W, Guo H, Gustafson S, Li Q, Li S, Peng Y, Qiu Y, Roberts T, Skeans M, Snyder 
J, Solid C, Wang C, Weinhandl E, Zaun D, Arko C, Chen SC, Dalleska F, Daniels F, Dunning S, Ebben J, 
Frazier E, Hanzlik C, Johnson R, Sheets D, Wang X, Forrest B, Constantini E, Everson S, Eggers P, 
Agodoa L. Us renal data system 2010 annual data report. American journal of kidney diseases : the 
official journal of the National Kidney Foundation. 2011;57:A8, e1-526 
62. Herzog CA, Asinger RW, Berger AK, Charytan DM, Diez J, Hart RG, Eckardt KU, Kasiske BL, 
McCullough PA, Passman RS, DeLoach SS, Pun PH, Ritz E. Cardiovascular disease in chronic kidney 
disease. A clinical update from kidney disease: Improving global outcomes (kdigo). Kidney 
international. 2011;80:572-586 
63. Drawz PE, Baraniuk S, Davis BR, Brown CD, Colon PJ, Sr., Cujyet AB, Dart RA, Graumlich JF, 
Henriquez MA, Moloo J, Sakalayen MG, Simmons DL, Stanford C, Sweeney ME, Wong ND, Rahman 
M. Cardiovascular risk assessment: Addition of ckd and race to the framingham equation. American 
heart journal. 2012;164:925-931 e922 
64. Stenvinkel P, Pecoits-Filho R, Lindholm B. Coronary artery disease in end-stage renal disease: No 
longer a simple plumbing problem. Journal of the American Society of Nephrology : JASN. 
2003;14:1927-1939 
65. Wright J, Hutchison A. Cardiovascular disease in patients with chronic kidney disease. Vascular 
health and risk management. 2009;5:713-722 
66. Bassand JP, Hamm CW, Ardissino D, Boersma E, Budaj A, Fernandez-Aviles F, Fox KA, Hasdai D, 
Ohman EM, Wallentin L, Wijns W. Guidelines for the diagnosis and treatment of non-st-segment 
elevation acute coronary syndromes. European heart journal. 2007;28:1598-1660 
67. Wong JA, Goodman SG, Yan RT, Wald R, Bagnall AJ, Welsh RC, Wong GC, Kornder J, Eagle KA, Steg 
PG, Yan AT. Temporal management patterns and outcomes of non-st elevation acute coronary 
syndromes in patients with kidney dysfunction. European heart journal. 2009;30:549-557 
68. Fox CS, Muntner P, Chen AY, Alexander KP, Roe MT, Cannon CP, Saucedo JF, Kontos MC, Wiviott SD. 
Use of evidence-based therapies in short-term outcomes of st-segment elevation myocardial 
infarction and non-st-segment elevation myocardial infarction in patients with chronic kidney 
 127 
 
disease: A report from the national cardiovascular data acute coronary treatment and intervention 
outcomes network registry. Circulation. 2010;121:357-365 
69. Santopinto JJ, Fox KA, Goldberg RJ, Budaj A, Pinero G, Avezum A, Gulba D, Esteban J, Gore JM, 
Johnson J, Gurfinkel EP. Creatinine clearance and adverse hospital outcomes in patients with acute 
coronary syndromes: Findings from the global registry of acute coronary events (grace). Heart. 
2003;89:1003-1008 
70. James SK, Lindahl B, Siegbahn A, Stridsberg M, Venge P, Armstrong P, Barnathan ES, Califf R, Topol 
EJ, Simoons ML, Wallentin L. N-terminal pro-brain natriuretic peptide and other risk markers for the 
separate prediction of mortality and subsequent myocardial infarction in patients with unstable 
coronary artery disease: A global utilization of strategies to open occluded arteries (gusto)-iv 
substudy. Circulation. 2003;108:275-281 
71. Januzzi JL, Cannon CP, DiBattiste PM, Murphy S, Weintraub W, Braunwald E. Effects of renal 
insufficiency on early invasive management in patients with acute coronary syndromes (the tactics-
timi 18 trial). The American journal of cardiology. 2002;90:1246-1249 
72. Gibson CM, Dumaine RL, Gelfand EV, Murphy SA, Morrow DA, Wiviott SD, Giugliano RP, Cannon CP, 
Antman EM, Braunwald E. Association of glomerular filtration rate on presentation with 
subsequent mortality in non-st-segment elevation acute coronary syndrome; observations in 
13,307 patients in five timi trials. European heart journal. 2004;25:1998-2005 
73. Schiffrin EL, Lipman ML, Mann JF. Chronic kidney disease: Effects on the cardiovascular system. 
Circulation. 2007;116:85-97 
74. Manjunath G, Tighiouart H, Ibrahim H, MacLeod B, Salem DN, Griffith JL, Coresh J, Levey AS, Sarnak 
MJ. Level of kidney function as a risk factor for atherosclerotic cardiovascular outcomes in the 
community. Journal of the American College of Cardiology. 2003;41:47-55 
75. Fried LF, Shlipak MG, Crump C, Bleyer AJ, Gottdiener JS, Kronmal RA, Kuller LH, Newman AB. Renal 
insufficiency as a predictor of cardiovascular outcomes and mortality in elderly individuals. Journal 
of the American College of Cardiology. 2003;41:1364-1372 
76. Gowdak LH, de Paula FJ, Cesar LA, Martinez Filho EE, Ianhez LE, Krieger EM, Ramires JA, de Lima JJ. 
Screening for significant coronary artery disease in high-risk renal transplant candidates. Coronary 
artery disease. 2007;18:553-558 
77. Herzog CA, Littrell K, Arko C, Frederick PD, Blaney M. Clinical characteristics of dialysis patients with 
acute myocardial infarction in the united states: A collaborative project of the united states renal 
data system and the national registry of myocardial infarction. Circulation. 2007;116:1465-1472 
78. Hyre AD, Fox CS, Astor BC, Cohen AJ, Muntner P. The impact of reclassifying moderate ckd as a 
coronary heart disease risk equivalent on the number of us adults recommended lipid-lowering 
treatment. American journal of kidney diseases : the official journal of the National Kidney 
Foundation. 2007;49:37-45 
79. Henry RM, Kostense PJ, Bos G, Dekker JM, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. Mild renal 
insufficiency is associated with increased cardiovascular mortality: The hoorn study. Kidney 
international. 2002;62:1402-1407 
80. Hueb W, Lopes NH, Gersh BJ, Soares P, Machado LA, Jatene FB, Oliveira SA, Ramires JA. Five-year 
follow-up of the medicine, angioplasty, or surgery study (mass ii): A randomized controlled clinical 
trial of 3 therapeutic strategies for multivessel coronary artery disease. Circulation. 2007;115:1082-
1089 
81. Mann JF, Gerstein HC, Pogue J, Bosch J, Yusuf S. Renal insufficiency as a predictor of cardiovascular 
outcomes and the impact of ramipril: The hope randomized trial. Annals of internal medicine. 
2001;134:629-636 
82. Dries DL, Exner DV, Domanski MJ, Greenberg B, Stevenson LW. The prognostic implications of renal 
insufficiency in asymptomatic and symptomatic patients with left ventricular systolic dysfunction. 
Journal of the American College of Cardiology. 2000;35:681-689 
83. Anavekar NS, McMurray JJ, Velazquez EJ, Solomon SD, Kober L, Rouleau JL, White HD, Nordlander 
R, Maggioni A, Dickstein K, Zelenkofske S, Leimberger JD, Califf RM, Pfeffer MA. Relation between 
 128 
 
renal dysfunction and cardiovascular outcomes after myocardial infarction. The New England 
journal of medicine. 2004;351:1285-1295 
84. Solomon SD, Rice MM, K AJ, Jose P, Domanski M, Sabatine M, Gersh BJ, Rouleau J, Pfeffer MA, 
Braunwald E. Renal function and effectiveness of angiotensin-converting enzyme inhibitor therapy 
in patients with chronic stable coronary disease in the prevention of events with ace inhibition 
(peace) trial. Circulation. 2006;114:26-31 
85. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Jr., Ganiats TG, Holmes DR, Jr., Jaffe AS, Jneid H, 
Kelly RF, Kontos MC, Levine GN, Liebson PR, Mukherjee D, Peterson ED, Sabatine MS, Smalling RW, 
Zieman SJ. 2014 aha/acc guideline for the management of patients with non-st-elevation acute 
coronary syndromes: Executive summary: A report of the american college of cardiology/american 
heart association task force on practice guidelines. Circulation. 2014;130:2354-2394 
86. Kumar A, Cannon CP. Acute coronary syndromes: Diagnosis and management, part ii. Mayo Clinic 
proceedings. Mayo Clinic. 2009;84:1021-1036 
87. Finn AV, Nakano M, Narula J, Kolodgie FD, Virmani R. Concept of vulnerable/unstable plaque. 
Arteriosclerosis, thrombosis, and vascular biology. 2010;30:1282-1292 
88. Falk E, Shah PK, Fuster V. Coronary plaque disruption. Circulation. 1995;92:657-671 
89. Friedman M, Van den Bovenkamp GJ. The pathogenesis of a coronary thrombus. The American 
journal of pathology. 1966;48:19-44 
90. Shah PK, Falk E, Badimon JJ, Fernandez-Ortiz A, Mailhac A, Villareal-Levy G, Fallon JT, Regnstrom J, 
Fuster V. Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of 
atherosclerotic plaques. Potential role of matrix-degrading metalloproteinases and implications for 
plaque rupture. Circulation. 1995;92:1565-1569 
91. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM. Lessons from sudden coronary death: A 
comprehensive morphological classification scheme for atherosclerotic lesions. Arteriosclerosis, 
thrombosis, and vascular biology. 2000;20:1262-1275 
92. Herrick JB. Landmark article (jama 1912). Clinical features of sudden obstruction of the coronary 
arteries. By james b. Herrick. JAMA : the journal of the American Medical Association. 
1983;250:1757-1765 
93. Gardner LS, Nguyen-Pham S, Greenslade JH, Parsonage W, D'Emden M, Than M, Aldous S, Brown A, 
Cullen L. Admission glycaemia and its association with acute coronary syndrome in emergency 
department patients with chest pain. Emergency medicine journal : EMJ. 2014 
94. Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, 
Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS. Multiple biomarkers for the prediction of first 
major cardiovascular events and death. The New England journal of medicine. 2006;355:2631-2639 
95. Boersma E, Pieper KS, Steyerberg EW, Wilcox RG, Chang WC, Lee KL, Akkerhuis KM, Harrington RA, 
Deckers JW, Armstrong PW, Lincoff AM, Califf RM, Topol EJ, Simoons ML. Predictors of outcome in 
patients with acute coronary syndromes without persistent st-segment elevation. Results from an 
international trial of 9461 patients. The pursuit investigators. Circulation. 2000;101:2557-2567 
96. Armstrong PW, Fu Y, Chang WC, Topol EJ, Granger CB, Betriu A, Van de Werf F, Lee KL, Califf RM. 
Acute coronary syndromes in the gusto-iib trial: Prognostic insights and impact of recurrent 
ischemia. The gusto-iib investigators. Circulation. 1998;98:1860-1868 
97. Lee KL, Woodlief LH, Topol EJ, Weaver WD, Betriu A, Col J, Simoons M, Aylward P, Van de Werf F, 
Califf RM. Predictors of 30-day mortality in the era of reperfusion for acute myocardial infarction. 
Results from an international trial of 41,021 patients. Gusto-i investigators. Circulation. 
1995;91:1659-1668 
98. Gurm HS, Gore JM, Anderson FA, Jr., Wyman A, Fox KA, Steg PG, Eagle KA. Comparison of acute 
coronary syndrome in patients receiving versus not receiving chronic dialysis (from the global 
registry of acute coronary events [grace] registry). The American journal of cardiology. 
2012;109:19-25 
99. Montalescot G, Sechtem U, Achenbach S, Andreotti F, Arden C, Budaj A, Bugiardini R, Crea F, 
Cuisset T, Di Mario C, Ferreira JR, Gersh BJ, Gitt AK, Hulot JS, Marx N, Opie LH, Pfisterer M, Prescott 
E, Ruschitzka F, Sabate M, Senior R, Taggart DP, van der Wall EE, Vrints CJ, Zamorano JL, 
 129 
 
Baumgartner H, Bax JJ, Bueno H, Dean V, Deaton C, Erol C, Fagard R, Ferrari R, Hasdai D, Hoes AW, 
Kirchhof P, Knuuti J, Kolh P, Lancellotti P, Linhart A, Nihoyannopoulos P, Piepoli MF, Ponikowski P, 
Sirnes PA, Tamargo JL, Tendera M, Torbicki A, Wijns W, Windecker S, Valgimigli M, Claeys MJ, 
Donner-Banzhoff N, Frank H, Funck-Brentano C, Gaemperli O, Gonzalez-Juanatey JR, Hamilos M, 
Husted S, James SK, Kervinen K, Kristensen SD, Maggioni AP, Pries AR, Romeo F, Ryden L, Simoons 
ML, Steg PG, Timmis A, Yildirir A. 2013 esc guidelines on the management of stable coronary artery 
disease: The task force on the management of stable coronary artery disease of the european 
society of cardiology. European heart journal. 2013;34:2949-3003 
100. Pierce GN, Czubryt MP. The contribution of ionic imbalance to ischemia/reperfusion-induced injury. 
Journal of molecular and cellular cardiology. 1995;27:53-63 
101. Labovitz AJ, Lewen MK, Kern M, Vandormael M, Deligonal U, Kennedy HL. Evaluation of left 
ventricular systolic and diastolic dysfunction during transient myocardial ischemia produced by 
angioplasty. Journal of the American College of Cardiology. 1987;10:748-755 
102. Crea F, Pupita G, Galassi AR, el-Tamimi H, Kaski JC, Davies G, Maseri A. Role of adenosine in 
pathogenesis of anginal pain. Circulation. 1990;81:164-172 
103. Bayturan O, Kapadia S, Nicholls SJ, Tuzcu EM, Shao M, Uno K, Shreevatsa A, Lavoie AJ, Wolski K, 
Schoenhagen P, Nissen SE. Clinical predictors of plaque progression despite very low levels of low-
density lipoprotein cholesterol. Journal of the American College of Cardiology. 2010;55:2736-2742 
104. Chhatriwalla AK, Nicholls SJ, Wang TH, Wolski K, Sipahi I, Crowe T, Schoenhagen P, Kapadia S, Tuzcu 
EM, Nissen SE. Low levels of low-density lipoprotein cholesterol and blood pressure and 
progression of coronary atherosclerosis. Journal of the American College of Cardiology. 
2009;53:1110-1115 
105. Kronmal RA, McClelland RL, Detrano R, Shea S, Lima JA, Cushman M, Bild DE, Burke GL. Risk factors 
for the progression of coronary artery calcification in asymptomatic subjects: Results from the 
multi-ethnic study of atherosclerosis (mesa). Circulation. 2007;115:2722-2730 
106. Nicholls SJ, Hsu A, Wolski K, Hu B, Bayturan O, Lavoie A, Uno K, Tuzcu EM, Nissen SE. Intravascular 
ultrasound-derived measures of coronary atherosclerotic plaque burden and clinical outcome. 
Journal of the American College of Cardiology. 2010;55:2399-2407 
107. Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA. Ten-year mortality 
from cardiovascular disease in relation to cholesterol level among men with and without 
preexisting cardiovascular disease. The New England journal of medicine. 1990;322:1700-1707 
108. Bayturan O, Tuzcu EM, Uno K, Lavoie AJ, Hu T, Shreevatsa A, Wolski K, Schoenhagen P, Kapadia S, 
Nissen SE, Nicholls SJ. Comparison of rates of progression of coronary atherosclerosis in patients 
with diabetes mellitus versus those with the metabolic syndrome. The American journal of 
cardiology. 2010;105:1735-1739 
109. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, Albus C, Benlian P, Boysen G, 
Cifkova R, Deaton C, Ebrahim S, Fisher M, Germano G, Hobbs R, Hoes A, Karadeniz S, Mezzani A, 
Prescott E, Ryden L, Scherer M, Syvanne M, Scholte op Reimer WJ, Vrints C, Wood D, Zamorano JL, 
Zannad F. European guidelines on cardiovascular disease prevention in clinical practice (version 
2012). The fifth joint task force of the european society of cardiology and other societies on 
cardiovascular disease prevention in clinical practice (constituted by representatives of nine 
societies and by invited experts). European heart journal. 2012;33:1635-1701 
110. Frey P, Waters DD, DeMicco DA, Breazna A, Samuels L, Pipe A, Wun CC, Benowitz NL. Impact of 
smoking on cardiovascular events in patients with coronary disease receiving contemporary 
medical therapy (from the treating to new targets [tnt] and the incremental decrease in end points 
through aggressive lipid lowering [ideal] trials). The American journal of cardiology. 2011;107:145-
150 
111. Otaki Y, Gransar H, Berman DS, Cheng VY, Dey D, Lin FY, Achenbach S, Al-Mallah M, Budoff MJ, 
Cademartiri F, Callister TQ, Chang HJ, Chinnaiyan K, Chow BJ, Delago A, Hadamitzky M, Hausleiter J, 
Kaufmann P, Maffei E, Raff G, Shaw LJ, Villines TC, Dunning A, Min JK. Impact of family history of 
coronary artery disease in young individuals (from the confirm registry). The American journal of 
cardiology. 2013;111:1081-1086 
 130 
 
112. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Gruppo italiano 
per lo studio della streptochinasi nell'infarto miocardico (gissi). Lancet. 1986;1:397-402 
113. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of 
suspected acute myocardial infarction: Isis-2. Isis-2 (second international study of infarct survival) 
collaborative group. Lancet. 1988;2:349-360 
114. An international randomized trial comparing four thrombolytic strategies for acute myocardial 
infarction. The gusto investigators. The New England journal of medicine. 1993;329:673-682 
115. Hachinohe D, Jeong MH, Saito S, Ahmed K, Hwang SH, Lee MG, Sim DS, Park KH, Kim JH, Hong YJ, 
Ahn Y, Kang JC, Chae SC, Kim YJ, Hur SH, Seong IW, Hong TJ, Choi D, Cho MC, Kim CJ, Seung KB, 
Chung WS, Jang YS, Rha SW, Bae JH, Park SJ. Management of non-st-segment elevation acute 
myocardial infarction in patients with chronic kidney disease (from the korea acute myocardial 
infarction registry). The American journal of cardiology. 2011;108:206-213 
116. Berger AK, Radford MJ, Krumholz HM. Cardiogenic shock complicating acute myocardial infarction 
in elderly patients: Does admission to a tertiary center improve survival? American heart journal. 
2002;143:768-776 
117. Sagripanti A, Barsotti G. Bleeding and thrombosis in chronic uremia. Nephron. 1997;75:125-139 
118. Stam F, van Guldener C, Schalkwijk CG, ter Wee PM, Donker AJ, Stehouwer CD. Impaired renal 
function is associated with markers of endothelial dysfunction and increased inflammatory activity. 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant 
Association - European Renal Association. 2003;18:892-898 
119. Best PJ, Steinhubl SR, Berger PB, Dasgupta A, Brennan DM, Szczech LA, Califf RM, Topol EJ. The 
efficacy and safety of short- and long-term dual antiplatelet therapy in patients with mild or 
moderate chronic kidney disease: Results from the clopidogrel for the reduction of events during 
observation (credo) trial. American heart journal. 2008;155:687-693 
120. James S, Budaj A, Aylward P, Buck KK, Cannon CP, Cornel JH, Harrington RA, Horrow J, Katus H, 
Keltai M, Lewis BS, Parikh K, Storey RF, Szummer K, Wojdyla D, Wallentin L. Ticagrelor versus 
clopidogrel in acute coronary syndromes in relation to renal function: Results from the platelet 
inhibition and patient outcomes (plato) trial. Circulation. 2010;122:1056-1067 
121. Boneu B, Caranobe C, Cadroy Y, Dol F, Gabaig AM, Dupouy D, Sie P. Pharmacokinetic studies of 
standard unfractionated heparin, and low molecular weight heparins in the rabbit. Seminars in 
thrombosis and hemostasis. 1988;14:18-27 
122. Goodman SG, Fitchett D, Armstrong PW, Tan M, Langer A. Randomized evaluation of the safety and 
efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-st-segment 
elevation acute coronary syndromes receiving the glycoprotein iib/iiia inhibitor eptifibatide. 
Circulation. 2003;107:238-244 
123. Petersen JL, Mahaffey KW, Hasselblad V, Antman EM, Cohen M, Goodman SG, Langer A, Blazing 
MA, Le-Moigne-Amrani A, de Lemos JA, Nessel CC, Harrington RA, Ferguson JJ, Braunwald E, Califf 
RM. Efficacy and bleeding complications among patients randomized to enoxaparin or 
unfractionated heparin for antithrombin therapy in non-st-segment elevation acute coronary 
syndromes: A systematic overview. JAMA : the journal of the American Medical Association. 
2004;292:89-96 
124. Januzzi JL, Jr., Snapinn SM, DiBattiste PM, Jang IK, Theroux P. Benefits and safety of tirofiban among 
acute coronary syndrome patients with mild to moderate renal insufficiency: Results from the 
platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs 
and symptoms (prism-plus) trial. Circulation. 2002;105:2361-2366 
125. Alexander KP, Chen AY, Roe MT, Newby LK, Gibson CM, Allen-LaPointe NM, Pollack C, Gibler WB, 
Ohman EM, Peterson ED. Excess dosing of antiplatelet and antithrombin agents in the treatment of 
non-st-segment elevation acute coronary syndromes. JAMA : the journal of the American Medical 
Association. 2005;294:3108-3116 
126. Freeman RV, Mehta RH, Al Badr W, Cooper JV, Kline-Rogers E, Eagle KA. Influence of concurrent 
renal dysfunction on outcomes of patients with acute coronary syndromes and implications of the 
 131 
 
use of glycoprotein iib/iiia inhibitors. Journal of the American College of Cardiology. 2003;41:718-
724 
127. Wison S, Foo K, Cunningham J, Cooper J, Deaner A, Knight C, Ranjadayalan K, Timmis AD. Renal 
function and risk stratification in acute coronary syndromes. The American journal of cardiology. 
2003;91:1051-1054 
128. Dumaine R, Collet JP, Tanguy ML, Mansencal N, Dubois-Rande JL, Henry P, Steg PG, Michel PL, 
Allouch P, Cohen A, Colin P, Durand E, Montalescot G. Prognostic significance of renal insufficiency 
in patients presenting with acute coronary syndrome (the prospective multicenter sycomore 
study). The American journal of cardiology. 2004;94:1543-1547 
129. Fonarow GC, Wright RS, Spencer FA, Fredrick PD, Dong W, Every N, French WJ. Effect of statin use 
within the first 24 hours of admission for acute myocardial infarction on early morbidity and 
mortality. The American journal of cardiology. 2005;96:611-616 
130. Ray KK, Cannon CP. Early time to benefit with intensive statin treatment: Could it be the pleiotropic 
effects? The American journal of cardiology. 2005;96:54F-60F 
131. Foley RN, Parfrey PS, Sarnak MJ. Epidemiology of cardiovascular disease in chronic renal disease. 
Journal of the American Society of Nephrology : JASN. 1998;9:S16-23 
132. Tonelli M, Isles C, Craven T, Tonkin A, Pfeffer MA, Shepherd J, Sacks FM, Furberg C, Cobbe SM, 
Simes J, West M, Packard C, Curhan GC. Effect of pravastatin on rate of kidney function loss in 
people with or at risk for coronary disease. Circulation. 2005;112:171-178 
133. Armitage J, Bowman L, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Peto R, Collins R. 
Intensive lowering of ldl cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors 
of myocardial infarction: A double-blind randomised trial. Lancet. 2010;376:1658-1669 
134. Ogawa M. Differentiation and proliferation of hematopoietic stem cells. Blood. 1993;81:2844-2853 
135. Ravid K, Lu J, Zimmet JM, Jones MR. Roads to polyploidy: The megakaryocyte example. Journal of 
cellular physiology. 2002;190:7-20 
136. Patel SR, Hartwig JH, Italiano JE, Jr. The biogenesis of platelets from megakaryocyte proplatelets. 
The Journal of clinical investigation. 2005;115:3348-3354 
137. Kaplan ZS, Jackson SP. The role of platelets in atherothrombosis. Hematology / the Education 
Program of the American Society of Hematology. American Society of Hematology. Education 
Program. 2011;2011:51-61 
138. Vieira-de-Abreu A, Campbell RA, Weyrich AS, Zimmerman GA. Platelets: Versatile effector cells in 
hemostasis, inflammation, and the immune continuum. Seminars in immunopathology. 2012;34:5-
30 
139. Nagareddy P, Smyth SS. Inflammation and thrombosis in cardiovascular disease. Current opinion in 
hematology. 2013;20:457-463 
140. Savage B, Saldivar E, Ruggeri ZM. Initiation of platelet adhesion by arrest onto fibrinogen or 
translocation on von willebrand factor. Cell. 1996;84:289-297 
141. Clemetson KJ. Platelets and primary haemostasis. Thrombosis research. 2012;129:220-224 
142. Smyth SS, McEver RP, Weyrich AS, Morrell CN, Hoffman MR, Arepally GM, French PA, Dauerman 
HL, Becker RC. Platelet functions beyond hemostasis. Journal of thrombosis and haemostasis : JTH. 
2009;7:1759-1766 
143. Gnatenko DV, Dunn JJ, McCorkle SR, Weissmann D, Perrotta PL, Bahou WF. Transcript profiling of 
human platelets using microarray and serial analysis of gene expression. Blood. 2003;101:2285-
2293 
144. Italiano JE, Jr., Shivdasani RA. Megakaryocytes and beyond: The birth of platelets. Journal of 
thrombosis and haemostasis : JTH. 2003;1:1174-1182 
145. Weyrich AS, Zimmerman GA. Evaluating the relevance of the platelet transcriptome. Blood. 
2003;102:1550-1551 
146. Rowley JW, Oler AJ, Tolley ND, Hunter BN, Low EN, Nix DA, Yost CC, Zimmerman GA, Weyrich AS. 
Genome-wide rna-seq analysis of human and mouse platelet transcriptomes. Blood. 
2011;118:e101-111 
 132 
 
147. Cecchetti L, Tolley ND, Michetti N, Bury L, Weyrich AS, Gresele P. Megakaryocytes differentially sort 
mrnas for matrix metalloproteinases and their inhibitors into platelets: A mechanism for regulating 
synthetic events. Blood. 2011;118:1903-1911 
148. Bugert P, Kluter H. Profiling of gene transcripts in human platelets: An update of the platelet 
transcriptome. Platelets. 2006;17:503-504 
149. Weyrich AS, Lindemann S, Tolley ND, Kraiss LW, Dixon DA, Mahoney TM, Prescott SP, McIntyre TM, 
Zimmerman GA. Change in protein phenotype without a nucleus: Translational control in platelets. 
Seminars in thrombosis and hemostasis. 2004;30:491-498 
150. Landry P, Plante I, Ouellet DL, Perron MP, Rousseau G, Provost P. Existence of a microrna pathway 
in anucleate platelets. Nature structural & molecular biology. 2009;16:961-966 
151. Kondkar AA, Bray MS, Leal SM, Nagalla S, Liu DJ, Jin Y, Dong JF, Ren Q, Whiteheart SW, Shaw C, Bray 
PF. Vamp8/endobrevin is overexpressed in hyperreactive human platelets: Suggested role for 
platelet microrna. Journal of thrombosis and haemostasis : JTH. 2010;8:369-378 
152. Viles-Gonzalez JF, Fuster V, Badimon JJ. Atherothrombosis: A widespread disease with 
unpredictable and life-threatening consequences. European heart journal. 2004;25:1197-1207 
153. Behrendt D, Ganz P. Endothelial function. From vascular biology to clinical applications. The 
American journal of cardiology. 2002;90:40L-48L 
154. Weiss N, Keller C, Hoffmann U, Loscalzo J. Endothelial dysfunction and atherothrombosis in mild 
hyperhomocysteinemia. Vasc Med. 2002;7:227-239 
155. Glagov S, Weisenberg E, Zarins CK, Stankunavicius R, Kolettis GJ. Compensatory enlargement of 
human atherosclerotic coronary arteries. The New England journal of medicine. 1987;316:1371-
1375 
156. Corti R, Fuster V, Badimon JJ. Pathogenetic concepts of acute coronary syndromes. Journal of the 
American College of Cardiology. 2003;41:7S-14S 
157. Corti R, Fuster V, Badimon JJ, Hutter R, Fayad ZA. New understanding of atherosclerosis (clinically 
and experimentally) with evolving mri technology in vivo. Annals of the New York Academy of 
Sciences. 2001;947:181-195; discussion 195-188 
158. van der Wal AC, Becker AE, van der Loos CM, Das PK. Site of intimal rupture or erosion of 
thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process 
irrespective of the dominant plaque morphology. Circulation. 1994;89:36-44 
159. Fuster V. Epidemic of cardiovascular disease and stroke: The three main challenges. Presented at 
the 71st scientific sessions of the american heart association. Dallas, texas. Circulation. 
1999;99:1132-1137 
160. Ruggeri ZM. Structure and function of von willebrand factor. Thrombosis and haemostasis. 
1999;82:576-584 
161. Siedlecki CA, Lestini BJ, Kottke-Marchant KK, Eppell SJ, Wilson DL, Marchant RE. Shear-dependent 
changes in the three-dimensional structure of human von willebrand factor. Blood. 1996;88:2939-
2950 
162. Barg A, Ossig R, Goerge T, Schneider MF, Schillers H, Oberleithner H, Schneider SW. Soluble plasma-
derived von willebrand factor assembles to a haemostatically active filamentous network. 
Thrombosis and haemostasis. 2007;97:514-526 
163. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions 
in platelet thrombus formation under flow. Cell. 1998;94:657-666 
164. Moroi M, Jung SM, Shinmyozu K, Tomiyama Y, Ordinas A, Diaz-Ricart M. Analysis of platelet 
adhesion to a collagen-coated surface under flow conditions: The involvement of glycoprotein vi in 
the platelet adhesion. Blood. 1996;88:2081-2092 
165. Nieswandt B, Watson SP. Platelet-collagen interaction: Is gpvi the central receptor? Blood. 
2003;102:449-461 
166. Santoro SA. Identification of a 160,000 dalton platelet membrane protein that mediates the initial 
divalent cation-dependent adhesion of platelets to collagen. Cell. 1986;46:913-920 
167. Ruggeri ZM. Platelet adhesion under flow. Microcirculation. 2009;16:58-83 
 133 
 
168. Ruggeri ZM, Bader R, de Marco L. Glanzmann thrombasthenia: Deficient binding of von willebrand 
factor to thrombin-stimulated platelets. Proceedings of the National Academy of Sciences of the 
United States of America. 1982;79:6038-6041 
169. Bennett JS, Vilaire G. Exposure of platelet fibrinogen receptors by adp and epinephrine. The Journal 
of clinical investigation. 1979;64:1393-1401 
170. Ni H, Denis CV, Subbarao S, Degen JL, Sato TN, Hynes RO, Wagner DD. Persistence of platelet 
thrombus formation in arterioles of mice lacking both von willebrand factor and fibrinogen. The 
Journal of clinical investigation. 2000;106:385-392 
171. Jackson SP. The growing complexity of platelet aggregation. Blood. 2007;109:5087-5095 
172. Jin J, Daniel JL, Kunapuli SP. Molecular basis for adp-induced platelet activation. Ii. The p2y1 
receptor mediates adp-induced intracellular calcium mobilization and shape change in platelets. 
The Journal of biological chemistry. 1998;273:2030-2034 
173. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, Yang RB, Nurden P, Nurden 
A, Julius D, Conley PB. Identification of the platelet adp receptor targeted by antithrombotic drugs. 
Nature. 2001;409:202-207 
174. Huang JS, Ramamurthy SK, Lin X, Le Breton GC. Cell signalling through thromboxane a2 receptors. 
Cellular signalling. 2004;16:521-533 
175. Coughlin SR. How the protease thrombin talks to cells. Proceedings of the National Academy of 
Sciences of the United States of America. 1999;96:11023-11027 
176. Ruf W, Rehemtulla A, Morrissey JH, Edgington TS. Phospholipid-independent and -dependent 
interactions required for tissue factor receptor and cofactor function. The Journal of biological 
chemistry. 1991;266:2158-2166 
177. Fiore MM, Neuenschwander PF, Morrissey JH. The biochemical basis for the apparent defect of 
soluble mutant tissue factor in enhancing the proteolytic activities of factor viia. The Journal of 
biological chemistry. 1994;269:143-149 
178. van der Wal AC, Li X, de Boer OJ. Tissue factor expression in the morphologic spectrum of 
vulnerable atherosclerotic plaques. Seminars in thrombosis and hemostasis. 2006;32:40-47 
179. Butenas S, Dee JD, Mann KG. The function of factor xi in tissue factor-initiated thrombin 
generation. Journal of thrombosis and haemostasis : JTH. 2003;1:2103-2111 
180. Walsh PN. Roles of factor xi, platelets and tissue factor-initiated blood coagulation. Journal of 
thrombosis and haemostasis : JTH. 2003;1:2081-2086 
181. Mackman N. Role of tissue factor in hemostasis, thrombosis, and vascular development. 
Arteriosclerosis, thrombosis, and vascular biology. 2004;24:1015-1022 
182. Ott I. Tissue factor in acute coronary syndromes. Seminars in vascular medicine. 2003;3:185-192 
183. Browder T, Folkman J, Pirie-Shepherd S. The hemostatic system as a regulator of angiogenesis. The 
Journal of biological chemistry. 2000;275:1521-1524 
184. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by 
antibody-directed targeting of tissue factor to tumor vasculature. Science. 1997;275:547-550 
185. Toschi V, Gallo R, Lettino M, Fallon JT, Gertz SD, Fernandez-Ortiz A, Chesebro JH, Badimon L, 
Nemerson Y, Fuster V, Badimon JJ. Tissue factor modulates the thrombogenicity of human 
atherosclerotic plaques. Circulation. 1997;95:594-599 
186. Wilcox JN, Smith KM, Schwartz SM, Gordon D. Localization of tissue factor in the normal vessel wall 
and in the atherosclerotic plaque. Proceedings of the National Academy of Sciences of the United 
States of America. 1989;86:2839-2843 
187. Annex BH, Denning SM, Channon KM, Sketch MH, Jr., Stack RS, Morrissey JH, Peters KG. Differential 
expression of tissue factor protein in directional atherectomy specimens from patients with stable 
and unstable coronary syndromes. Circulation. 1995;91:619-622 
188. Giesen PL, Rauch U, Bohrmann B, Kling D, Roque M, Fallon JT, Badimon JJ, Himber J, Riederer MA, 
Nemerson Y. Blood-borne tissue factor: Another view of thrombosis. Proceedings of the National 
Academy of Sciences of the United States of America. 1999;96:2311-2315 
189. Celi A, Cianchetti S, Dell'Omo G, Pedrinelli R. Angiotensin ii, tissue factor and the thrombotic 
paradox of hypertension. Expert review of cardiovascular therapy. 2010;8:1723-1729 
 134 
 
190. Alkistis Frentzou G, Collier ME, Seymour AM, Ettelaie C. Differential induction of cellular 
proliferation, hypertrophy and apoptosis in h9c2 cardiomyocytes by exogenous tissue factor. 
Molecular and cellular biochemistry. 2010;345:119-130 
191. Jude B, Zawadzki C, Susen S, Corseaux D. Relevance of tissue factor in cardiovascular disease. 
Archives des maladies du coeur et des vaisseaux. 2005;98:667-671 
192. Carr ME. Diabetes mellitus: A hypercoagulable state. Journal of diabetes and its complications. 
2001;15:44-54 
193. Garcia C, Feve B, Ferre P, Halimi S, Baizri H, Bordier L, Guiu G, Dupuy O, Bauduceau B, Mayaudon H. 
Diabetes and inflammation: Fundamental aspects and clinical implications. Diabetes & metabolism. 
2010;36:327-338 
194. Kim JK. Inflammation and insulin resistance: An old story with new ideas. Korean diabetes journal. 
2010;34:137-145 
195. Rauch U, Nemerson Y. Circulating tissue factor and thrombosis. Current opinion in hematology. 
2000;7:273-277 
196. Carey MJ, Rodgers GM. Disseminated intravascular coagulation: Clinical and laboratory aspects. 
American journal of hematology. 1998;59:65-73 
197. Mallat Z, Hugel B, Ohan J, Leseche G, Freyssinet JM, Tedgui A. Shed membrane microparticles with 
procoagulant potential in human atherosclerotic plaques: A role for apoptosis in plaque 
thrombogenicity. Circulation. 1999;99:348-353 
198. Rauch U, Bonderman D, Bohrmann B, Badimon JJ, Himber J, Riederer MA, Nemerson Y. Transfer of 
tissue factor from leukocytes to platelets is mediated by cd15 and tissue factor. Blood. 
2000;96:170-175 
199. Camera M, Frigerio M, Toschi V, Brambilla M, Rossi F, Cottell DC, Maderna P, Parolari A, Bonzi R, De 
Vincenti O, Tremoli E. Platelet activation induces cell-surface immunoreactive tissue factor 
expression, which is modulated differently by antiplatelet drugs. Arteriosclerosis, thrombosis, and 
vascular biology. 2003;23:1690-1696 
200. Muller I, Klocke A, Alex M, Kotzsch M, Luther T, Morgenstern E, Zieseniss S, Zahler S, Preissner K, 
Engelmann B. Intravascular tissue factor initiates coagulation via circulating microvesicles and 
platelets. FASEB journal : official publication of the Federation of American Societies for 
Experimental Biology. 2003;17:476-478 
201. Schwertz H, Tolley ND, Foulks JM, Denis MM, Risenmay BW, Buerke M, Tilley RE, Rondina MT, 
Harris EM, Kraiss LW, Mackman N, Zimmerman GA, Weyrich AS. Signal-dependent splicing of tissue 
factor pre-mrna modulates the thrombogenicity of human platelets. The Journal of experimental 
medicine. 2006;203:2433-2440 
202. Panes O, Matus V, Saez CG, Quiroga T, Pereira J, Mezzano D. Human platelets synthesize and 
express functional tissue factor. Blood. 2007;109:5242-5250 
203. Engelmann B, Luther T, Muller I. Intravascular tissue factor pathway--a model for rapid initiation of 
coagulation within the blood vessel. Thrombosis and haemostasis. 2003;89:3-8 
204. Brambilla M, Camera M, Colnago D, Marenzi G, De Metrio M, Giesen PL, Balduini A, Veglia F, 
Gertow K, Biglioli P, Tremoli E. Tissue factor in patients with acute coronary syndromes: Expression 
in platelets, leukocytes, and platelet-leukocyte aggregates. Arteriosclerosis, thrombosis, and 
vascular biology. 2008;28:947-953 
205. Colombo G, Gertow K, Marenzi G, Brambilla M, De Metrio M, Tremoli E, Camera M. Gene 
expression profiling reveals multiple differences in platelets from patients with stable angina or 
non-st elevation acute coronary syndrome. Thrombosis research. 2011;128:161-168 
206. Pabla R, Weyrich AS, Dixon DA, Bray PF, McIntyre TM, Prescott SM, Zimmerman GA. Integrin-
dependent control of translation: Engagement of integrin alphaiibbeta3 regulates synthesis of 
proteins in activated human platelets. The Journal of cell biology. 1999;144:175-184 
207. Boccardo P, Remuzzi G, Galbusera M. Platelet dysfunction in renal failure. Seminars in thrombosis 
and hemostasis. 2004;30:579-589 
208. Galbusera M, Remuzzi G, Boccardo P. Treatment of bleeding in dialysis patients. Seminars in 
dialysis. 2009;22:279-286 
 135 
 
209. Benigni A, Boccardo P, Galbusera M, Monteagudo J, De Marco L, Remuzzi G, Ruggeri ZM. Reversible 
activation defect of the platelet glycoprotein iib-iiia complex in patients with uremia. American 
journal of kidney diseases : the official journal of the National Kidney Foundation. 1993;22:668-676 
210. Gawaz MP, Dobos G, Spath M, Schollmeyer P, Gurland HJ, Mujais SK. Impaired function of platelet 
membrane glycoprotein iib-iiia in end-stage renal disease. Journal of the American Society of 
Nephrology : JASN. 1994;5:36-46 
211. Sreedhara R, Itagaki I, Hakim RM. Uremic patients have decreased shear-induced platelet 
aggregation mediated by decreased availability of glycoprotein iib-iiia receptors. American journal 
of kidney diseases : the official journal of the National Kidney Foundation. 1996;27:355-364 
212. Kozek-Langenecker SA, Masaki T, Mohammad H, Green W, Mohammad SF, Cheung AK. Fibrinogen 
fragments and platelet dysfunction in uremia. Kidney international. 1999;56:299-305 
213. Thijs A, Nanayakkara PW, Ter Wee PM, Huijgens PC, van Guldener C, Stehouwer CD. Mild-to-
moderate renal impairment is associated with platelet activation: A cross-sectional study. Clinical 
nephrology. 2008;70:325-331 
214. Bonomini M, Reale M, Santarelli P, Stuard S, Settefrati N, Albertazzi A. Serum levels of soluble 
adhesion molecules in chronic renal failure and dialysis patients. Nephron. 1998;79:399-407 
215. Breet NJ, de Jong C, Bos WJ, van Werkum JW, Bouman HJ, Kelder JC, Bergmeijer TO, Zijlstra F, 
Hackeng CM, Ten Berg JM. The impact of renal function on platelet reactivity and clinical outcome 
in patients undergoing percutaneous coronary intervention with stenting. Thrombosis and 
haemostasis. 2014;112:1174-1181 
216. Ashman N, Macey MG, Fan SL, Azam U, Yaqoob MM. Increased platelet-monocyte aggregates and 
cardiovascular disease in end-stage renal failure patients. Nephrology, dialysis, transplantation : 
official publication of the European Dialysis and Transplant Association - European Renal 
Association. 2003;18:2088-2096 
217. Surana SP, Riella LV, Keithi-Reddy SR, Charytan DM, Singh AK. Acute coronary syndrome in esrd 
patients. Kidney international. 2009;75:558-562 
218. Stigant C, Izadnegahdar M, Levin A, Buller CE, Humphries KH. Outcomes after percutaneous 
coronary interventions in patients with ckd: Improved outcome in the stenting era. American 
journal of kidney diseases : the official journal of the National Kidney Foundation. 2005;45:1002-
1009 
219. Patel UD, Ou FS, Ohman EM, Gibler WB, Pollack CV, Jr., Peterson ED, Roe MT. Hospital performance 
and differences by kidney function in the use of recommended therapies after non-st-elevation 
acute coronary syndromes. American journal of kidney diseases : the official journal of the National 
Kidney Foundation. 2009;53:426-437 
220. Angiolillo DJ, Bernardo E, Capodanno D, Vivas D, Sabate M, Ferreiro JL, Ueno M, Jimenez-Quevedo 
P, Alfonso F, Bass TA, Macaya C, Fernandez-Ortiz A. Impact of chronic kidney disease on platelet 
function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet 
therapy. Journal of the American College of Cardiology. 2010;55:1139-1146 
221. Woo JS, Kim W, Lee SR, Jung KH, Kim WS, Lew JH, Lee TW, Lim CK. Platelet reactivity in patients 
with chronic kidney disease receiving adjunctive cilostazol compared with a high-maintenance dose 
of clopidogrel: Results of the effect of platelet inhibition according to clopidogrel dose in patients 
with chronic kidney disease (piano-2 ckd) randomized study. American heart journal. 
2011;162:1018-1025 
222. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: Implications of 
aspirin resistance. Journal of the American College of Cardiology. 2008;51:1829-1843 
223. Sharma RK, Reddy HK, Singh VN, Sharma R, Voelker DJ, Bhatt G. Aspirin and clopidogrel 
hyporesponsiveness and nonresponsiveness in patients with coronary artery stenting. Vascular 
health and risk management. 2009;5:965-972 
224. Chen WH, Cheng X, Lee PY, Ng W, Kwok JY, Tse HF, Lau CP. Aspirin resistance and adverse clinical 
events in patients with coronary artery disease. The American journal of medicine. 2007;120:631-
635 
 136 
 
225. Beigel R, Hod H, Fefer P, Asher E, Novikov I, Shenkman B, Savion N, Varon D, Matetzky S. Relation of 
aspirin failure to clinical outcome and to platelet response to aspirin in patients with acute 
myocardial infarction. The American journal of cardiology. 2011;107:339-342 
226. Chen WH, Lee PY, Ng W, Kwok JY, Cheng X, Lee SW, Tse HF, Lau CP. Relation of aspirin resistance to 
coronary flow reserve in patients undergoing elective percutaneous coronary intervention. The 
American journal of cardiology. 2005;96:760-763 
227. Wenaweser P, Dorffler-Melly J, Imboden K, Windecker S, Togni M, Meier B, Haeberli A, Hess OM. 
Stent thrombosis is associated with an impaired response to antiplatelet therapy. Journal of the 
American College of Cardiology. 2005;45:1748-1752 
228. Rajendran S, Parikh D, Shugman I, French JK, Juergens CP. High on treatment platelet reactivity and 
stent thrombosis. Heart, lung & circulation. 2011;20:525-531 
229. Parmar MS. Chronic renal disease. BMJ. 2002;325:85-90 
230. Casserly LF, Dember LM. Thrombosis in end-stage renal disease. Seminars in dialysis. 2003;16:245-
256 
231. Landray MJ, Wheeler DC, Lip GY, Newman DJ, Blann AD, McGlynn FJ, Ball S, Townend JN, Baigent C. 
Inflammation, endothelial dysfunction, and platelet activation in patients with chronic kidney 
disease: The chronic renal impairment in birmingham (crib) study. American journal of kidney 
diseases : the official journal of the National Kidney Foundation. 2004;43:244-253 
232. James MT, Hemmelgarn BR, Tonelli M. Early recognition and prevention of chronic kidney disease. 
Lancet. 2010;375:1296-1309 
233. Tanrikulu AM, Ozben B, Koc M, Papila-Topal N, Ozben T, Caymaz O. Aspirin resistance in patients 
with chronic renal failure. Journal of nephrology. 2011;24:636-646 
234. Blann AD, Kuzniatsova N, Velu S, Lip GY. Renal function and aspirin resistance in patients with 
coronary artery disease. Thrombosis research. 2012;130:e103-106 
235. Breet NJ, van Werkum JW, Bouman HJ, Kelder JC, Ten Berg JM, Hackeng CM. High on-aspirin 
platelet reactivity as measured with aggregation-based, cyclooxygenase-1 inhibition sensitive 
platelet function tests is associated with the occurrence of atherothrombotic events. Journal of 
thrombosis and haemostasis : JTH. 2010;8:2140-2148 
236. Lordkipanidze M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six 
major platelet function tests to determine the prevalence of aspirin resistance in patients with 
stable coronary artery disease. European heart journal. 2007;28:1702-1708 
237. Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in 
patients with coronary artery disease. Journal of the American College of Cardiology. 2007;50:1822-
1834 
238. Blann AD, Nadar SK, Lip GY. The adhesion molecule p-selectin and cardiovascular disease. European 
heart journal. 2003;24:2166-2179 
239. Preston FE, Whipps S, Jackson CA, French AJ, Wyld PJ, Stoddard CJ. Inhibition of prostacyclin and 
platelet thromboxane a2 after low-dose aspirin. The New England journal of medicine. 
1981;304:76-79 
240. Pengo V, Boschello M, Marzari A, Baca M, Schivazappa L, Dalla Volta S. Adenosine diphosphate 
(adp)-induced alpha-granules release from platelets of native whole blood is reduced by ticlopidine 
but not by aspirin or dipyridamole. Thrombosis and haemostasis. 1986;56:147-150 
241. Rinder CS, Student LA, Bonan JL, Rinder HM, Smith BR. Aspirin does not inhibit adenosine 
diphosphate-induced platelet alpha-granule release. Blood. 1993;82:505-512 
242. Pernerstorfer T, Stohlawetz P, Stummvoll G, Kapiotis S, Szekeres T, Eichler HG, Jilma B. Low-dose 
aspirin does not lower in vivo platelet activation in healthy smokers. British journal of haematology. 
1998;102:1229-1231 
243. Dasgupta A, Steinhubl SR, Bhatt DL, Berger PB, Shao M, Mak KH, Fox KA, Montalescot G, Weber 
MA, Haffner SM, Dimas AP, Steg PG, Topol EJ. Clinical outcomes of patients with diabetic 
nephropathy randomized to clopidogrel plus aspirin versus aspirin alone (a post hoc analysis of the 
clopidogrel for high atherothrombotic risk and ischemic stabilization, management, and avoidance 
[charisma] trial). The American journal of cardiology. 2009;103:1359-1363 
 137 
 
244. Schomig M, Eisenhardt A, Ritz E. The microinflammatory state of uremia. Blood purification. 
2000;18:327-332 
245. van der Wal AC, Becker AE. Atherosclerotic plaque rupture--pathologic basis of plaque stability and 
instability. Cardiovascular research. 1999;41:334-344 
246. Furman MI, Barnard MR, Krueger LA, Fox ML, Shilale EA, Lessard DM, Marchese P, Frelinger AL, 3rd, 
Goldberg RJ, Michelson AD. Circulating monocyte-platelet aggregates are an early marker of acute 
myocardial infarction. Journal of the American College of Cardiology. 2001;38:1002-1006 
247. Bowden DW. Genetics of kidney disease. Kidney international. Supplement. 2003:S8-12 
248. Kottgen A, Glazer NL, Dehghan A, Hwang SJ, Katz R, Li M, Yang Q, Gudnason V, Launer LJ, Harris TB, 
Smith AV, Arking DE, Astor BC, Boerwinkle E, Ehret GB, Ruczinski I, Scharpf RB, Chen YD, de Boer IH, 
Haritunians T, Lumley T, Sarnak M, Siscovick D, Benjamin EJ, Levy D, Upadhyay A, Aulchenko YS, 
Hofman A, Rivadeneira F, Uitterlinden AG, van Duijn CM, Chasman DI, Pare G, Ridker PM, Kao WH, 
Witteman JC, Coresh J, Shlipak MG, Fox CS. Multiple loci associated with indices of renal function 
and chronic kidney disease. Nature genetics. 2009;41:712-717 
249. Kottgen A, Pattaro C, Boger CA, Fuchsberger C, Olden M, Glazer NL, Parsa A, Gao X, Yang Q, Smith 
AV, O'Connell JR, Li M, Schmidt H, Tanaka T, Isaacs A, Ketkar S, Hwang SJ, Johnson AD, Dehghan A, 
Teumer A, Pare G, Atkinson EJ, Zeller T, Lohman K, Cornelis MC, Probst-Hensch NM, Kronenberg F, 
Tonjes A, Hayward C, Aspelund T, Eiriksdottir G, Launer LJ, Harris TB, Rampersaud E, Mitchell BD, 
Arking DE, Boerwinkle E, Struchalin M, Cavalieri M, Singleton A, Giallauria F, Metter J, de Boer IH, 
Haritunians T, Lumley T, Siscovick D, Psaty BM, Zillikens MC, Oostra BA, Feitosa M, Province M, de 
Andrade M, Turner ST, Schillert A, Ziegler A, Wild PS, Schnabel RB, Wilde S, Munzel TF, Leak TS, Illig 
T, Klopp N, Meisinger C, Wichmann HE, Koenig W, Zgaga L, Zemunik T, Kolcic I, Minelli C, Hu FB, 
Johansson A, Igl W, Zaboli G, Wild SH, Wright AF, Campbell H, Ellinghaus D, Schreiber S, Aulchenko 
YS, Felix JF, Rivadeneira F, Uitterlinden AG, Hofman A, Imboden M, Nitsch D, Brandstatter A, 
Kollerits B, Kedenko L, Magi R, Stumvoll M, Kovacs P, Boban M, Campbell S, Endlich K, Volzke H, 
Kroemer HK, Nauck M, Volker U, Polasek O, Vitart V, Badola S, Parker AN, Ridker PM, Kardia SL, 
Blankenberg S, Liu Y, Curhan GC, Franke A, Rochat T, Paulweber B, Prokopenko I, Wang W, 
Gudnason V, Shuldiner AR, Coresh J, Schmidt R, Ferrucci L, Shlipak MG, van Duijn CM, Borecki I, 
Kramer BK, Rudan I, Gyllensten U, Wilson JF, Witteman JC, Pramstaller PP, Rettig R, Hastie N, 
Chasman DI, Kao WH, Heid IM, Fox CS. New loci associated with kidney function and chronic kidney 
disease. Nature genetics. 2010;42:376-384 
250. Friedman DJ, Pollak MR. Genetics of kidney failure and the evolving story of apol1. The Journal of 
clinical investigation. 2011;121:3367-3374 
251. Ple H, Maltais M, Corduan A, Rousseau G, Madore F, Provost P. Alteration of the platelet 
transcriptome in chronic kidney disease. Thrombosis and haemostasis. 2012;108:605-615 
252. Marques M, Sacristan D, Mateos-Caceres PJ, Herrero J, Arribas MJ, Gonzalez-Armengol JJ, Villegas 
A, Macaya C, Barrientos A, Lopez-Farre AJ. Different protein expression in normal and dysfunctional 
platelets from uremic patients. Journal of nephrology. 2010;23:90-101 
253. Vanholder R, Cornelis R, Dhondt A, Lameire N. The role of trace elements in uraemic toxicity. 
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant 
Association - European Renal Association. 2002;17 Suppl 2:2-8 
254. Tubek S, Grzanka P, Tubek I. Role of zinc in hemostasis: A review. Biological trace element research. 
2008;121:1-8 
255. Foster M, Samman S. Zinc and redox signaling: Perturbations associated with cardiovascular disease 
and diabetes mellitus. Antioxidants & redox signaling. 2010;13:1549-1573 
256. Kadota Y, Suzuki S, Ideta S, Fukinbara Y, Kawakami T, Imai H, Nakagawa Y, Sato M. Enhanced 
metallothionein gene expression induced by mitochondrial oxidative stress is reduced in 
phospholipid hydroperoxide glutathione peroxidase-overexpressed cells. European journal of 
pharmacology. 2010;626:166-170 
257. Libetta C, Sepe V, Esposito P, Galli F, Dal Canton A. Oxidative stress and inflammation: Implications 
in uremia and hemodialysis. Clinical biochemistry. 2011;44:1189-1198 
 138 
 
258. Fujii H, Nakai K, Fukagawa M. Role of oxidative stress and indoxyl sulfate in progression of 
cardiovascular disease in chronic kidney disease. Therapeutic apheresis and dialysis : official peer-
reviewed journal of the International Society for Apheresis, the Japanese Society for Apheresis, the 
Japanese Society for Dialysis Therapy. 2011;15:125-128 
259. Pamuklar Z, Lee JS, Cheng HY, Panchatcharam M, Steinhubl S, Morris AJ, Charnigo R, Smyth SS. 
Individual heterogeneity in platelet response to lysophosphatidic acid: Evidence for a novel 
inhibitory pathway. Arteriosclerosis, thrombosis, and vascular biology. 2008;28:555-561 
260. Cui MZ. Lysophosphatidic acid effects on atherosclerosis and thrombosis. Clinical lipidology. 
2011;6:413-426 
261. Di Minno G, Martinez J, McKean ML, De La Rosa J, Burke JF, Murphy S. Platelet dysfunction in 
uremia. Multifaceted defect partially corrected by dialysis. The American journal of medicine. 
1985;79:552-559 
262. Vecino AM, Teruel JL, Navarro JL, Cesar JM. Phospholipase a2 activity in platelets of patients with 
uremia. Platelets. 2002;13:415-418 
263. Bonomini M, Dottori S, Amoroso L, Arduini A, Sirolli V. Increased platelet phosphatidylserine 
exposure and caspase activation in chronic uremia. Journal of thrombosis and haemostasis : JTH. 
2004;2:1275-1281 
264. Vecino A, Navarro-Antolin J, Teruel J, Navarro J, Cesar J. Lipid composition of platelets in patients 
with uremia. Nephron. 1998;78:271-273 
265. Healy AM, Pickard MD, Pradhan AD, Wang Y, Chen Z, Croce K, Sakuma M, Shi C, Zago AC, Garasic J, 
Damokosh AI, Dowie TL, Poisson L, Lillie J, Libby P, Ridker PM, Simon DI. Platelet expression 
profiling and clinical validation of myeloid-related protein-14 as a novel determinant of 
cardiovascular events. Circulation. 2006;113:2278-2284 
266. Collins SP, Uhler MD. Characterization of pkigamma, a novel isoform of the protein kinase inhibitor 
of camp-dependent protein kinase. The Journal of biological chemistry. 1997;272:18169-18178 
267. Scita G, Confalonieri S, Lappalainen P, Suetsugu S. Irsp53: Crossing the road of membrane and actin 
dynamics in the formation of membrane protrusions. Trends in cell biology. 2008;18:52-60 
268. Vidal C, Geny B, Melle J, Jandrot-Perrus M, Fontenay-Roupie M. Cdc42/rac1-dependent activation 
of the p21-activated kinase (pak) regulates human platelet lamellipodia spreading: Implication of 
the cortical-actin binding protein cortactin. Blood. 2002;100:4462-4469 
269. Hanyaloglu AC, von Zastrow M. Regulation of gpcrs by endocytic membrane trafficking and its 
potential implications. Annual review of pharmacology and toxicology. 2008;48:537-568 
270. Stenvinkel P, Wang K, Qureshi AR, Axelsson J, Pecoits-Filho R, Gao P, Barany P, Lindholm B, 
Jogestrand T, Heimburger O, Holmes C, Schalling M, Nordfors L. Low fetuin-a levels are associated 
with cardiovascular death: Impact of variations in the gene encoding fetuin. Kidney international. 
2005;67:2383-2392 
271. Parhami F, Tintut Y, Ballard A, Fogelman AM, Demer LL. Leptin enhances the calcification of 
vascular cells: Artery wall as a target of leptin. Circulation research. 2001;88:954-960 
272. Spronk HM, Soute BA, Schurgers LJ, Cleutjens JP, Thijssen HH, De Mey JG, Vermeer C. Matrix gla 
protein accumulates at the border of regions of calcification and normal tissue in the media of the 
arterial vessel wall. Biochemical and biophysical research communications. 2001;289:485-490 
273. Tintut Y, Patel J, Parhami F, Demer LL. Tumor necrosis factor-alpha promotes in vitro calcification of 
vascular cells via the camp pathway. Circulation. 2000;102:2636-2642 
274. Davies MR, Lund RJ, Hruska KA. Bmp-7 is an efficacious treatment of vascular calcification in a 
murine model of atherosclerosis and chronic renal failure. Journal of the American Society of 
Nephrology : JASN. 2003;14:1559-1567 
275. Nitta K, Akiba T, Uchida K, Kawashima A, Yumura W, Kabaya T, Nihei H. The progression of vascular 
calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. American 
journal of kidney diseases : the official journal of the National Kidney Foundation. 2003;42:303-309 
276. Lebreton JP, Joisel F, Raoult JP, Lannuzel B, Rogez JP, Humbert G. Serum concentration of human 
alpha 2 hs glycoprotein during the inflammatory process: Evidence that alpha 2 hs glycoprotein is a 
negative acute-phase reactant. The Journal of clinical investigation. 1979;64:1118-1129 
 139 
 
277. Schinke T, Amendt C, Trindl A, Poschke O, Muller-Esterl W, Jahnen-Dechent W. The serum protein 
alpha2-hs glycoprotein/fetuin inhibits apatite formation in vitro and in mineralizing calvaria cells. A 
possible role in mineralization and calcium homeostasis. The Journal of biological chemistry. 
1996;271:20789-20796 
278. Osawa M, Yuasa I, Kitano T, Henke J, Kaneko M, Udono T, Saitou N, Umetsu K. Haplotype analysis of 
the human alpha2-hs glycoprotein (fetuin) gene. Annals of human genetics. 2001;65:27-34 
279. Luczak M, Formanowicz D, Pawliczak E, Wanic-Kossowska M, Wykretowicz A, Figlerowicz M. 
Chronic kidney disease-related atherosclerosis - proteomic studies of blood plasma. Proteome 
science. 2011;9:25 
280. Escolar G, Diaz-Ricart M, Cases A, Castillo R, Ordinas A, White JG. Abnormal cytoskeletal assembly 
in platelets from uremic patients. The American journal of pathology. 1993;143:823-831 
281. Himmelfarb J, Hakim RM. Oxidative stress in uremia. Current opinion in nephrology and 
hypertension. 2003;12:593-598 
282. Tepel M, Echelmeyer M, Orie NN, Zidek W. Increased intracellular reactive oxygen species in 
patients with end-stage renal failure: Effect of hemodialysis. Kidney international. 2000;58:867-872 
283. Zanetti M, Barazzoni R, Guarnieri G. Inflammation and insulin resistance in uremia. Journal of renal 
nutrition : the official journal of the Council on Renal Nutrition of the National Kidney Foundation. 
2008;18:70-75 
284. Radhakrishnan J, Remuzzi G, Saran R, Williams DE, Rios-Burrows N, Powe N, Bruck K, Wanner C, Stel 
VS, Venuthurupalli SK, Hoy WE, Healy HG, Salisbury A, Fassett RG, O'Donoghue D, Roderick P, 
Matsuo S, Hishida A, Imai E, Iimuro S. Taming the chronic kidney disease epidemic: A global view of 
surveillance efforts. Kidney international. 2014;86:246-250 
285. Bello AK, Levin A, Manns BJ, Feehally J, Drueke T, Faruque L, Hemmelgarn BR, Kernahan C, Mann J, 
Klarenbach S, Remuzzi G, Tonelli M. Effective ckd care in european countries: Challenges and 
opportunities for health policy. American journal of kidney diseases : the official journal of the 
National Kidney Foundation. 2015;65:15-25 
286. Weiner DE, Tighiouart H, Elsayed EF, Griffith JL, Salem DN, Levey AS, Sarnak MJ. The relationship 
between nontraditional risk factors and outcomes in individuals with stage 3 to 4 ckd. American 
journal of kidney diseases : the official journal of the National Kidney Foundation. 2008;51:212-223 
287. Anavekar NS, Pfeffer MA. Cardiovascular risk in chronic kidney disease. Kidney international. 
Supplement. 2004:S11-15 
288. Kundhal K, Lok CE. Clinical epidemiology of cardiovascular disease in chronic kidney disease. 
Nephron. Clinical practice. 2005;101:c47-52 
289. Shashar M, Francis J, Chitalia V. Thrombosis in the uremic milieu--emerging role of "thrombolome". 
Seminars in dialysis. 2015;28:198-205 
290. Zwaginga JJ, MJ IJ, de Groot PG, Vos J, de Bos Kuil RL, Sixma JJ. Defects in platelet adhesion and 
aggregate formation in uremic bleeding disorder can be attributed to factors in plasma. 
Arteriosclerosis and thrombosis : a journal of vascular biology / American Heart Association. 
1991;11:733-744 
291. Mezzano D, Tagle R, Panes O, Perez M, Downey P, Munoz B, Aranda E, Barja P, Thambo S, Gonzalez 
F, Mezzano S, Pereira J. Hemostatic disorder of uremia: The platelet defect, main determinant of 
the prolonged bleeding time, is correlated with indices of activation of coagulation and fibrinolysis. 
Thrombosis and haemostasis. 1996;76:312-321 
292. Milburn JA, Ford I, Mutch NJ, Fluck N, Brittenden J. Thrombin-anti-thrombin levels and patency of 
arterio-venous fistula in patients undergoing haemodialysis compared to healthy volunteers: A 
prospective analysis. PloS one. 2013;8:e67799 
293. Sioulis A, Malindretos P, Makedou A, Makris P, Grekas D. Coagulation factors as biological risk 
markers of endothelial dysfunction. Association with the thrombotic episodes of chronic 
hemodialysis patients. Hippokratia. 2009;13:237-241 
294. Park SH, Kim W, Park CS, Kang WY, Hwang SH. A comparison of clopidogrel responsiveness in 
patients with versus without chronic renal failure. The American journal of cardiology. 
2009;104:1292-1295 
 140 
 
295. Muller C, Caillard S, Jesel L, El Ghannudi S, Ohlmann P, Sauleau E, Hannedouche T, Gachet C, Moulin 
B, Morel O. Association of estimated gfr with platelet inhibition in patients treated with clopidogrel. 
American journal of kidney diseases : the official journal of the National Kidney Foundation. 
2012;59:777-785 
296. Chen WH, Lee PY, Ng W, Tse HF, Lau CP. Aspirin resistance is associated with a high incidence of 
myonecrosis after non-urgent percutaneous coronary intervention despite clopidogrel 
pretreatment. Journal of the American College of Cardiology. 2004;43:1122-1126 
297. Banfi C, Brioschi M, Tremoli E. [cardiovascular proteomics: Challenges and opportunities for 
cardiologists of the future]. G Ital Cardiol (Rome). 2013;14:495-503 
298. Nordfors L, Lindholm B, Stenvinkel P. End-stage renal disease--not an equal opportunity disease: 
The role of genetic polymorphisms. Journal of internal medicine. 2005;258:1-12 
299. Naseeb U, Shafqat J, Jagerbrink T, Zarina S, Alvestrand A, Jornvall H, Axelsson J. Proteome patterns 
in uremic plasma. Blood purification. 2008;26:561-568 
300. Weber C, Sigrist M, Romann A, Chiarelli G, Levin A. Novel biomarkers do not correlate with severity 
of vascular stiffness in ckd patients with severe co-morbid disease. Nephron. Clinical practice. 
2011;119:c261-268 
301. Keller TT, Squizzato A, Middeldorp S. Clopidogrel plus aspirin versus aspirin alone for preventing 
cardiovascular disease. The Cochrane database of systematic reviews. 2007:CD005158 
302. Brambilla M, Facchinetti L, Canzano P, Rossetti L, Ferri N, Balduini A, Abbonante V, Boselli D, De 
Marco L, Di Minno MN, Toschi V, Corsini A, Tremoli E, Camera M. Human megakaryocytes confer 
tissue factor to a subset of shed platelets to stimulate thrombin generation. Thrombosis and 
haemostasis. 2015;114:579-592 
303. Camera M, Toschi V, Brambilla M, Lettino M, Rossetti L, Canzano P, Di Minno A, Tremoli E. The role 
of tissue factor in atherothrombosis and coronary artery disease: Insights into platelet tissue factor. 
Seminars in thrombosis and hemostasis. 2015;41:737-746 
304. Hillmann AG, Harmon S, Park SD, O'Brien J, Shields DC, Kenny D. Comparative rna expression 
analyses from small-scale, single-donor platelet samples. Journal of thrombosis and haemostasis : 
JTH. 2006;4:349-356 
305. Gnatenko DV, Cupit LD, Huang EC, Dhundale A, Perrotta PL, Bahou WF. Platelets express 
steroidogenic 17beta-hydroxysteroid dehydrogenases. Distinct profiles predict the essential 
thrombocythemic phenotype. Thrombosis and haemostasis. 2005;94:412-421 
306. Bugert P, Dugrillon A, Gunaydin A, Eichler H, Kluter H. Messenger rna profiling of human platelets 
by microarray hybridization. Thrombosis and haemostasis. 2003;90:738-748 
307. McRedmond JP, Park SD, Reilly DF, Coppinger JA, Maguire PB, Shields DC, Fitzgerald DJ. Integration 
of proteomics and genomics in platelets: A profile of platelet proteins and platelet-specific genes. 
Molecular & cellular proteomics : MCP. 2004;3:133-144 
308. Raghavachari N, Xu X, Harris A, Villagra J, Logun C, Barb J, Solomon MA, Suffredini AF, Danner RL, 
Kato G, Munson PJ, Morris SM, Jr., Gladwin MT. Amplified expression profiling of platelet 
transcriptome reveals changes in arginine metabolic pathways in patients with sickle cell disease. 
Circulation. 2007;115:1551-1562 
309. Ho SJ, Gemmell R, Brighton TA. Platelet function testing in uraemic patients. Hematology. 
2008;13:49-58 
310. Macconi D, Vigano G, Bisogno G, Galbusera M, Orisio S, Remuzzi G, Livio M. Defective platelet 
aggregation in response to platelet-activating factor in uremia associated with low platelet 
thromboxane a2 generation. American journal of kidney diseases : the official journal of the 
National Kidney Foundation. 1992;19:318-325 
311. Sutherland M, Shankaranarayanan P, Schewe T, Nigam S. Evidence for the presence of phospholipid 
hydroperoxide glutathione peroxidase in human platelets: Implications for its involvement in the 
regulatory network of the 12-lipoxygenase pathway of arachidonic acid metabolism. The 
Biochemical journal. 2001;353:91-100 
 141 
 
312. Kimura Y, Hart A, Hirashima M, Wang C, Holmyard D, Pittman J, Pang XL, Jackson CW, Bernstein A. 
Zinc finger protein, hzf, is required for megakaryocyte development and hemostasis. The Journal of 
experimental medicine. 2002;195:941-952 
313. May F, Hagedorn I, Pleines I, Bender M, Vogtle T, Eble J, Elvers M, Nieswandt B. Clec-2 is an 
essential platelet-activating receptor in hemostasis and thrombosis. Blood. 2009;114:3464-3472 
314. Chambers G, Lawrie L, Cash P, Murray GI. Proteomics: A new approach to the study of disease. The 
Journal of pathology. 2000;192:280-288 
315. Butterfield DA, Dalle-Donne I. Redox proteomics. Antioxidants & redox signaling. 2012;17:1487-
1489 
316. Licker V, Kovari E, Hochstrasser DF, Burkhard PR. Proteomics in human parkinson's disease 
research. Journal of proteomics. 2009;73:10-29 
317. Hanash S. Disease proteomics. Nature. 2003;422:226-232 
318. Ekstrom B, Berggard I. Human alpha1-microglobulin. Purification procedure, chemical and 
physiochemical properties. The Journal of biological chemistry. 1977;252:8048-8057 
319. Akerstrom B, Gram M. A1m, an extravascular tissue cleaning and housekeeping protein. Free 
radical biology & medicine. 2014;74:274-282 
320. Penders J, Delanghe JR. Alpha 1-microglobulin: Clinical laboratory aspects and applications. Clinica 
chimica acta; international journal of clinical chemistry. 2004;346:107-118 
321. Broch M, Vendrell J, Ricart W, Richart C, Fernandez-Real JM. Circulating retinol-binding protein-4, 
insulin sensitivity, insulin secretion, and insulin disposition index in obese and nonobese subjects. 
Diabetes care. 2007;30:1802-1806 
322. Ingelsson E, Lind L. Circulating retinol-binding protein 4 and subclinical cardiovascular disease in the 
elderly. Diabetes care. 2009;32:733-735 
323. Bobbert T, Raila J, Schwarz F, Mai K, Henze A, Pfeiffer AF, Schweigert FJ, Spranger J. Relation 
between retinol, retinol-binding protein 4, transthyretin and carotid intima media thickness. 
Atherosclerosis. 2010;213:549-551 
324. Cabre A, Lazaro I, Girona J, Manzanares J, Marimon F, Plana N, Heras M, Masana L. Retinol-binding 
protein 4 as a plasma biomarker of renal dysfunction and cardiovascular disease in type 2 diabetes. 
Journal of internal medicine. 2007;262:496-503 
325. Ingelsson E, Sundstrom J, Melhus H, Michaelsson K, Berne C, Vasan RS, Riserus U, Blomhoff R, Lind 
L, Arnlov J. Circulating retinol-binding protein 4, cardiovascular risk factors and prevalent 
cardiovascular disease in elderly. Atherosclerosis. 2009;206:239-244 
326. Christou GA, Tselepis AD, Kiortsis DN. The metabolic role of retinol binding protein 4: An update. 
Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et 
metabolisme. 2012;44:6-14 
327. Etzerodt A, Kjolby M, Nielsen MJ, Maniecki M, Svendsen P, Moestrup SK. Plasma clearance of 
hemoglobin and haptoglobin in mice and effect of cd163 gene targeting disruption. Antioxidants & 
redox signaling. 2013;18:2254-2263 
328. Smith A, McCulloh RJ. Hemopexin and haptoglobin: Allies against heme toxicity from hemoglobin 
not contenders. Frontiers in physiology. 2015;6:187 
329. Wassell J. Haptoglobin: Function and polymorphism. Clinical laboratory. 2000;46:547-552 
 
 
 
 
 
 142 
 
 
 
 
 
 
 
 
 
 
 
 
PUBLICATIONS 
 
 143 
 
PUBLICATIONS 
 
M. Camera, V. Toschi, M. Brambilla, M. Lettino, L. Rossetti, P. Canzano, A. Di Minno, E. Tremoli.  
The role of tissue factor in atherothrombosis and coronary artery disease: insights into platelet 
tissue factor.  
Seminars in Thrombosis and Haemostasis 2015; 41(07): 737-746. 
 
 
Brambilla M, Facchinetti L, Canzano P, Rossetti L, Ferri N, Balduini A, Abbonante V, Boselli D, De 
Marco L, Di Minno MND, Toschi V, Corsini A, Tremoli E, Camera M. Human megakaryocytes 
express Tissue Factor and deliver it to a subset of shedded platelets where it contributes to 
thrombin generation.  
Thromb. Heamost. Thrombosis and Haemostasis 2015, 114(3):579-92; 
 
 
Camera M, Brambilla M, Boselli D, Facchinetti L, Canzano P, Rossetti L, Toschi V, Tremoli E.  
Functionally active platelets do express tissue factor.  
Blood. 2012 May 3;119(18): 4339-41. 
 
 
Camera M, Brambilla M, Facchinetti L, Canzano P, Spirito R, Rossetti L, Saccu C, Di Minno MN, 
Tremoli E.  
Tissue factor and atherosclerosis: not only vessel wall-derived TF, but also platelet-associated TF.  
Thromb Res. 2012 Mar;129(3):279-84. 
 
 
